The inactivation of Cobalamin by nitrous oxide : application in experimental chemotherapy of leukemia by Kroes, A.C.M. (Aloys)
THE INACTIVATION OF COBALAMIN BY NITROUS OXIDE: 
application in experimental chemotherapy of leukemia 

THE INACTIVATION OF COBALAMIN BY NITROUS OXIDE: 
application in experimental chemotherapy of leukemia 
HET INACTIVEREN VAN COBALAMINE DOOR LACHGAS: 
toepassing in experimentele chemotherapie van leukemie 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN DOCTOR 
AAN DE ERASMUS UNIVERSITEIT ROTTERDAM 
OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF.DR. A.H.G. RINNOOY KAN 
EN VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN. 
DE OPENBARE VERDEDIGING ZAL PLAA TSVINDEN 
OP WOENSDAG 18 NOVEMBER OM 14.00 UUR 
door 
Aloysius Comelis Maria Kroes 
geboren te Amsterdam 
PROMOTIECOMMISSIE 
PROMOTOR prof.dr. J. Abels 
LEDEN prof.dr. D.W. van Bekkum 
prof.dr. J. Bruinvels 
prof.dr. R. Willemze 
CO-PROMOTOR dr. J. Lindemans 
De publikatie van dit proefschrift werd financieel ondersteund door 
LEDERLE Nederland B.V. te Etten-Leur. 
Ter nagedachtenis aan mijn moeder 
Aan mijn vader 
Aan Christi 

Contents 
1. INTRODUCTION 
1.1. The significance of cobalamin in normal and malignant hematopoiesis 1 
1.1.1. Cobalamin, folic acid and megaloblastic anemia 1 
1.1.2. Biochemistry of cobalamin and folic acid 2 
1.1.3. The methylfolate trap hypothesis 7 
1.1.4. Cobalamin deficiency and methionine metabolism 13 
1.1.5. Alternative theories on the role of cobalamin in hematopoiesi~ 17 
1.1.6. The role of cobalamin in malignant hematopoiesis 20 
1.2. Cobalamin-antagonists: an overview 22 
1.3. The effect of nitrous oxide on cobalamin · 25 
1.4. Scope of this thesis 33 
1.5. References 34 
2. GENERAL EXPERIMENTAL PROCEDURES 51 
2.1. The Brown Norway Myeloid Leukemia 51 
2.2. Exposure of rats to nitrous oxide 55 
2.3. The deoxyuridine suppression test 57 
2.4. References 59 
3. NITROUS OXIDE AND GROWTH OF RAT LEUKEMIA 63 
3 .1. Introduction 64 
3.2. Materials and methods 65 
3.3. Results 66 
3.4. Discussion 68 
3.5. References 71 
4. NITROUS OXIDE AND CYCLOLEUCINE IN RAT LEUKEMIA 75 
4.1. Introduction 
4.2. Materials and methods 
4.3. Results 
4.4. Discussion 
4.5. References 
76 
77 
79 
82 
85 
5. NITROUS OXIDE AND METHOTREXATE IN RAT LEUKEMIA 89 
5 010 Introduction 90 
5020 Materials and methods 91 
5 03 0 Results 94 
5.40 Discussion 99 
5050 References 101 
6. NITROUS OXIDE AND 5-FLUOROURACIL 
IN RAT LEUKEMIA 105 
601. Introduction 106 
6020 Materials and methods 107 
6.30 Results 109 
6.40 Discussion 114 
6050 References 117 
7. NITROUS OXIDE AND INHIBITORS OF POLYAMINE 
SYNTHESIS IN RAT LEUKEMIA 121 
7 010 Introduction 122 
7 020 Materials and methods 124 
7 03 0 Results 125 
7.40 Discussion 128 
7050 References 130 
8. THE EFFECT OF NITROUS OXIDE 
ON HUMAN LEUKEMIA IN VITRO 135 
8010 Introduction 136 
8020 Materials and methods 137 
8030 Results 139 
8.40 Discussion 143 
8050 References 145 
9. SURVEY AND CONCLUSIONS 147 
SUMMARY 153 
SAMENV A TTING 155 
NAWOORD 159 
CURRICULUM VITAE 161 
Chapter one 
INTRODUCTION 
1.1. The significance of cobalamin in normal and malignant hemato-
poiesis. 
1.1.1. Cobalamin, folic acid and megaloblastic anemia. 
Cobalamin, also widely known as vitamin B 12, and folic acid are two con-
stituents of the diet which are essential to maintain the continuous produc-
tion of blood cells in the bone marrow. Blood cells fulfil a wide range of 
vital functions, but most types have only a limited life span, and therefore 
the lifelong process of their production, called hematopoiesis, is of great 
importance to prevent disease. 
The discovery in this century of cobalamin and folic acid as dietary fac-
tors involved in hematopoiesis has been a major medical breakthrough, 
because this has made possible the treatment and prevention of serious 
diseases caused by a lack of these vitamins. Most important in this respect 
has been the successful treatment of pernicious anemia. In this disease, 
which was already recognized by Addison in 1849 and by Ehrlich in 1880, 
hematopoiesis is severely disturbed, resulting in a serious and usually fatal 
anemia with abnormally large cells in the bone marrow, which were called 
megaloblasts. In 1926, Minot and Murphy discovered a successful therapy 
for this disorder, consisting of a diet rich in liver ( 1). This approach fitted 
well in the concept of specific nutritional deficiencies as causes of disease, 
which was just emerging at that time. The pathogenesis of pernicious 
anemia appeared to be more complex, however, when it was shown by Cas-
tle in 1929 (2), that not only this dietary (extrinsic) factor was necessary to 
prevent anemia, but also a factor present in gastric juice, which he called 
intrinsic factor. This factor appeared to facilitate specifically the absorption 
of the dietary factor. Subsequently, the extrinsic factor was purified from 
the crude liver extracts and crystallized in 1948, by Rickes et al. (3), who 
named this substance vitamin B12, and by Lester Smith (4). Finally, its 
complex structure as a porphyrin-like molecule containing cobalt, hence its 
name cobalamin, was elucidated by Hodgkin in 1956 (5). For their contri-
butions, Minot and Murphy ( 1934) and Hodgkin ( 1964) were awarded 
Nobel Prizes. Pernicious anemia, which is the consequence of the selective 
malabsorption of cobalamin, due to a lack of Castle's gastric intrinsic factor, 
had become a treatable disease. The cause of the underlying gastric disease, 
autoimmune atrophic gastritis, is still not clear, nor can it be cured, but its 
life-threatening hematologic complication is now completely prevented by 
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the parenteral administration of cobalamin. 
Some confusion resulted in the 1930s from the recogmt10n, by Wills 
( 6), of a second dietary factor which was effective in the treatment of 
megaloblastic anemia, in particular of cases occurring as a complication of 
pregnancy and tropical sprue. This factor was present in yeast (6) and 
appeared to be distinct from the liver factor (7). It turned out to be identi-
cal to an ubiquitous growth factor that was named folic acid in view of its 
isolation from plant leaves (8). The structure of this compound was 
described in 1946 (9). The existence of folate deficiency as another vitamin 
deficiency syndrome, with similar hematological consequences but separate 
from pernicious anemia, was clearly established around 1950 ( 10). 
A deficiency of either cobalamin or folic acid clinically results in the 
same, rather typical, aberration in the blood and bone marrow. The intense 
cellular proliferation, which is characteristic of hematopoiesis, is severely 
impaired in this condition and maturation of blood cells is much slower, 
resulting in reduced numbers of abnormally large cells. These clinical 
observations on the effects of deficiency states immediately suggest that the 
two vitamins are functionally closely related, and ever since their characteri-
zation, the interrelationships of cobalamin and folic acid have been the sub-
ject of intensive research. Apart from the clinical relevance of this problem, 
this interest is also explained by its obvious importance to the understanding 
of metabolic processes involved in cellular proliferation. The issue is still 
not completely settled to date, but the expansion of knowledge on this sub-
ject is apparent from the many reviews that have been published from 1951 
until recently (10-20). The subject of this introductory chapter will be a dis-
cussion of our present knowledge of the function of cobalamin and folic 
acid in normal and malignant hematopoiesis. 
1.1.2. Biochemistry of cobalamin and folic acid. 
With regard to their chemical structure, cobalamin and folic acid are entirely 
unrelated. Several forms exist of both vitamins, related to different coen-
zyme functions. Thus, the terms "cobalamin" and "folic acid" in fact both 
refer to a group of related compounds. 
Cobalamin is the parent compound of a specific subgroup of the corri-
noids (21). Corrinoids (from "core" of vitamin B12 structure) are charac-
terized by the corrin nucleus, consisting of four reduced pyrrole rings. 
Three of the links between these pyrrole rings contain a single carbon, and 
one link is direct. Corrin derivatives which contain a cobalt atom in the 
centre of the macrocyclic tetrapyrrole ring, carry a series of trivial names 
beginning with cob-. The corrinoids have a number of side chains added to 
the corrin structure as well. In the case of cobalamin, there is a specific pat-
tern of side chains, and of ligands bound to the central cobalt atom, as 
shown in Figure 1.1. This central cobalt atom has six coordinating bonds, 
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four of which are occupied by nitrogens of the corrin nucleus. Of the other 
positions, one is always occupied by the 3-N-atom of a heterocyclic base, 
5,6-dimethylbenzimidazole, an addition that is specific for cobalamin. The 
sixth position can be occupied by various ligands, as shown in Figure 1.1. 
X 
R 
-X name 
CH3 - CN cyanocobalamin (CN-Cbl) 
CH3 - OH hydroxocobalamin (OH-Cbl) 
R' 
- H20 aquocobalamin (HOH-Cbl) 
- deoxy- coenzyme B 12 (AdoCbl) adenosyl 
- CH3 methylcobalamin (MeCbl) 
R = CH 2CONH 2 
R' = CH 2CH 2CONH 2 
Figure 1.1. The structure of cobalamin, with the various ligands that can occupy the 
sixth coordinate bond of the cobalt ion in the naturally occurring forms of this vitamin. 
The cobalt-containing corrin-nucleus is synthesized by bacteria only and, like the heme-
nucleus, derived from the pathway of porphyrin synthesis. 
Four forms of cobalamin have been identified in man: cyano-, hydroxo- (or 
aquo- at lower pH), adenosyl- and methylcobalamin. Only adenosyl- and 
methylcobalamin are known to have coenzyme functions in human cells 
(22). 
Adenosylcobalamin is the coenzyme of methylmalonylcoenzyme A 
mutase, a mitochondrial enzyme converting methylmalonylCoA into succi-
nylCoA (23). This reaction involves a unique carbon skeleton rearrange-
ment, of which the exact mechanism is still controversial (24-26). Methyl-
malonic acid is formed by the degradation of odd-chain fatty acids and some 
amino acids. A deficiency of cobalamin leads to increased levels of methyl-
malonic acid in plasma and urine (27). Folic acid is not involved in this 
pathway. 
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Methylcobalamin is essential in the enzyme methionine synthetase, or 
5-methyltetrahydrofolate homocysteine methyltransferase (28-30). As is evi-
dent from the latter name, this enzyme is also involved in folate metabolism. 
Not surprisingly, therefore, explanations of the related functions of cobala-
min and folic acid in hematopoiesis focus on this enzyme. The enzyme 
catalyzes the transfer of a methyl group from 5-methyltetrahydrofolate to 
homocysteine, which results in the formation of tetrahydrofolate and 
methionine (Figure 1.2). Interestingly, no role for cobalamin has been esta-
blished in any process more directly related to cellular proliferation, like the 
synthesis of nucleic acids. 
homocysteine methionine 
5-methy ltetrahyd rofolate tetrahydrofolate 
Figure 1.2. The reaction catalyzed by the cobalamin-dependent enzyme methionine syn-
thetase (E.C. 2.1.1.13, recommended name: tetrahydropteroylglutamate methyl-
transferase). 
Regarding the chemistry of cobalamins, the oxidation state of the cobalt 
atom is also relevant to coenzyme functions. In cobalamin, cobalt can occur 
in its three usual oxidation states, which are designated cob(I)alamin, 
cob(II)alamin and cob(III)alamin, to indicate the positive charge of the 
cobalt-ion. The properties of cobalamin with regard to the binding of 
organic ligands are strictly dependent on the oxidation state (31). The 
cobalt-ion, most stable in its trivalent state in naturally occurring cobala-
mins, has to be reduced to cob(I)alamin prior to the formation of methylco-
balamin or adenosylcobalamin. Particularly in the case of methylcobalamin, 
this oxidation state is essential in the mechanism of the catalyzed reaction, 
which is based on the acceptance and transfer of the methyl-ligand by 
cob(l)alamin (32,33). The effect of nitrous oxide on cobalamin, which will 
be the subject of a separate paragraph ( 1.3), is explained by oxidation of the 
cobalt-ion, leading to the complete inactivation of the enzyme. ~ 
Other cobalamins, and other cobalamin-dependent enzymes hllVe been 
found in nature, notably in bacteria. Cobalamins are synthesized by micro-
organisms only, while plant cells do not contain cobalamin. A second 
human adenosylcobalamin-dependent enzyme, which isomerizes leucine, has 
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been described (34), but its significance is still uncertain. 
Folic acid, in a limited sense, is pteroylglutamic acid, a compound con-
sisting of a pteridine ring, connected by a single carbon atom to para-
aminobenzoic acid, which is joined by a peptide linkage to glutamic acid 
(35). This structure is shown in Figure 1.3. Folic acid, and folate, are also 
used as general terms for any member of the group of derivatives, also 
shown in Figure 1.3. Biologically active folates are reduced, compared to 
pteroylglutamic acid, and are therefore designated tetrahydrofolate (THF). 
In addition, these reduced folates can contain a single carbon unit at one of 
several levels of oxidation by covalent binding to nitrogen atoms 5 or 10, or 
both. This property is essentially the basis of all folate coenzyme functions, 
which consist of the uptake and transfer of single carbon units. Some of the 
folate-dependent enzymes are presented in Figure 1.3. These enzymes 
catalyze essential steps in the synthesis of thymidylate, with 5, 10-methylene-
THF as coenzyme, and purines, with 5,10-methenyl-THF and 10-formyl-
THF. From their involvement in these pathways, it is immediately apparent 
that reduced folates are important in DNA synthesis and cell proliferation. 
Another important folate-dependent enzyme is methionine synthetase, in 
which, as mentioned before, methylcobalamin is also necessary. This 
enzyme catalyzes not only the synthesis of the amino acid methionine, but 
also the conversion of 5-methyl-THF into THF. This step is essential in the 
metabolism of folates, because 5-methyl-THF is the reduced folate which is 
present in plasma and is taken up by cells (36,37). The conversion 
catalyzed by methionine synthetase represents the only way in which 
reduced folates, after uptake in the cell, become available for any of the 
other important folate-dependent reactions. This reaction is the single 
known point of interaction between folates and cobalamin. Considering the 
evident role of folates in nucleotide synthesis and in cellular proliferation, 
and the absence of any direct role of cobalamin in these processes, it is 
tempting to postulate that the function of cobalamin in the enzyme 
methionine synthetase should explain its importance in hematopoiesis. In 
addition, the striking similarity of the consequences of deficiencies of either 
cobalamin or folic acid, is easily explained if the hematological function of 
cobalamin conc~.:rns an essential step in folate metabolism. Based on these 
principles, more than two decades ago the "methylfolate trap hypothesis" 
was formulated to explain the metabolic consequences of cobalamin defi-
ciency, with regard to folate metabolism and hematopoiesis. This 
hypothesis, and some alternative theories, will be discussed in greater detail 
in the next paragraphs. 
More recently, the important metabolic functions were recognized of a 
particular structural property of folate coenzymes: additional glutamic acid 
residues can be coupled to the single glutamate which is part of the folate 
molecule, resulting in folylpolyglutamates (38,39). These glutamates are 
linked to each other through peptide bonds between their 1-amino and 3-
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STRUCTURE OF FOLATES 
Pteroylglutamic acid 
(folic acid) 
Tetrahydrofolate (THF) 
Substitutions: 
5-methyi-THF 
5-formyl-THF 
1 0-formyl-THF 
5-formimino-T HF 
5, 1 o-methylene-T HF 
5,1 0-methenyl-THF 
H 
at N-5: 
- CH 3 
-CHO 
-H 
-CHNH 
atN-10: 
-H 
-H 
-CHO 
-H 
between N- 5 and N-1 0: 
-CH 2 -
=CH-
FOLATE DEPENDENT ENZYMES 
Coenzyme 
5-methyi-THF 
5,1Q-methylene-THF 
5,1 0-methenyl-THF 
1Q-formyi-THF 
5,1 0-methylene-THF 
Conversion 
homocysteine .... methionine 
dUMP-dTMP 
glycinamide ribotide (GAR) .... 
formyl-GAR 
aminoimidazole carboxamide ribotide 
(AICAR) .... formyi-AICAR 
glycine .... serine 
Enzyme 
methionine synthetase 
thymidy late synthetase 
GAR formyltransferase 
AICAR formyltransferase 
serine transhydroxy-
methylase 
Figure 1.3. Structure of the folate coenzymes, all of which are reduced derivatives of 
pteroylglutamic acid (folic acid). The most important folate-dependent enzymatic 
processes are shown in the table. Not included are the folate interconverting enzymes, 
which convert one folate derivative into another, like dihydrofolate reductase. 
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carboxyl groups, in a reaction catalyzed by the enzyme folylpolyglutamate 
synthetase. Intracellular folates predominantly are polyglutamate deriva-
tives, whereas in plasma only 5-methyl-THF-monoglutamate is present 
(monoglutamate indicates folate without additional glutamates). The 
number of glutamates attached to intracellular folates is variable, but gen-
erally amounts 3 to 6. This addition of glutamates changes the properties of 
folate molecules considerably. One important consequence is the prevention 
of their transport across cellular membranes. Polyglutamation is therefore 
essential to retain folates in the cell after uptake. This was convincingly 
shown in studies of mutant CHO cells, which were extremely folate-
deficient and consequently auxotrophic for purines and pyrimidines, and in 
which the only difference from wild type cells was a lack of folylpolygluta-
mate synthetase ( 40,41). Coenzyme functions of folates are also modified 
by polyglutamation of folates. With most folate-dependent enzymes, a dis-
tinct preference is observed for a specific number of glutamates, added to 
their folate coenzymes. The affinity of these enzymes for folylmonogluta-
mates generally is much lower (39). Certain folates can also function pre-
ferentially in one of several possible reactions, depending on their polygluta-
mate chain length ( 42,43). This suggests that the level of polyglutamation 
has a function in the regulation of one-carbon metabolism ( 44). It appears 
that cobalamin also has a role in folate polyglutamation. This relates to the 
observation that 5-methyl-THF is very poorly polyglutamated by folylpo-
lyglutamate synthetase, as is evident from several metabolic studies ( 45-47), 
as well as from studies of the partially purified enzyme ( 41,48-50). There-
fore, after its uptake in the cell, 5-methyl-THF has to be demethylated by 
cobalamin-dependent methionine synthetase before it can be retained and 
function efficiently as a coenzyme. This further emphasizes the importance 
of the point of interaction between the two factors which are essential in the 
prevention of the megaloblastic disorder of hematopoiesis. 
1.1.3. The methylfolate trap hypothesis. 
Around 1960 it was recognized that the synthesis of methionine from homo-
cysteine is cobalamin-dependent, and also involves the demethylation of the 
folate coenzyme 5-methyl-THF. This reaction therefore established a meta-
bolic point of interaction between cobalamin and folic acid. The relevance 
of this reaction to cellular proliferation is not immediately apparent, how-
ever. Independently, several investigators subsequently formulated a 
hypothesis to explain the effect of cobalamin deficiency on hematopoiesis, 
based on a disturbance of the reaction, which is catalyzed by methionine 
synthetase (51 ,52). This hypothesis was called the "methylfolate trap 
hypothesis", and, at the time it was proposed, there was only limited evi-
dence to support this explanation. After 25 years of research on 
cobalamin-folate interrelationships the hypothesis still stands and, although 
some important additions appeared necessary, the explanation in fact is not 
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hypothetical anymore. Nevertheless, a few alternative theories are still 
found in the literature. The methylfolate trap hypothesis will now be con-
sidered in detail systematically. The relevant metabolic pathways are 
presented in Figure 1.4. 
The methylfolate trap hypothesis states that cobalamin deficiency causes 
reduced activity of methionine synthetase, which leads to a disturbance of 
folate metabolism because 5-methyl-THF cannot be utilized by the cell 
under these circumstances, and will become "trapped". It was expected that 
eventually the levels of all other folates would be reduced, impairing the 
important folate-dependent synthesis of nucleotides, comparable to the 
effects of folate deficiency. 
From this description some advantages of the methylfolate trap 
hypothesis are already apparent. It tries to explain the hematologic effects 
of cobalamin deficiency on the basis of the only cobalamin-dependent pro-
cess which is known to be involved in folate metabolism. This obviates the 
need for postulated additional cobalamin-dependent processes, which, up till 
now, have not been discovered. The hypothesis also simply explains the 
identical megaloblastic hematopoiesis of cobalamin and folate deficiency. 
The hypothesis can be evaluated on the basis of its four major implica-
tions, all of which have been investigated thoroughly: 
[1] the activity of methionine synthetase becomes reduced in cobalamin 
deficiency. 
[2] 5-methyl-THF cannot be utilized in any quantitatively significant process 
other than after demethylation by methionine synthetase. This implies 
that the reaction which reduces 5-methylene-THF to 5-methyl-THF, 
catalyzed by 5, 10-methylene-THF reductase, is irreversible under intra-
cellular conditions. 
[3] all reduced folates can correct the impairment of cellular proliferation in 
cobalamin deficiency, with the sole exception of 5-methyl-THF, which 
should be ineffective in this respect. 
[4] there is an accumulation of 5-methyl-THF, relative to other reduced 
folates, in cobalamin deficiency. 
Experimental evidence concerning these four points will now be considered. 
[1] Reduced activity of methionine synthetase in cobalamin-deficient cells 
has been observed invariably. This was first shown in vitamin Bl2-deficient 
rats, in which the activity of hepatic methionine synthetase was markedly 
reduced without effect on some other enzymes in folate metabolism (53). 
Subsequently, methionine synthetase activity in bone marrow from perni-
cious anemia patients was shown to be extremely low, and to be correctable 
in vitro and in vivo by vitamin B 12 addition (54). Several other studies 
confirmed these findings (55-57). In addition, the activity of methionine 
synthetase in various cultured cell lines was clearly dependent on the supply 
homocysteine methionine 
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+ jDHF reductase! 5-methyi-THF 5-methyl-THF THF ~(plasma) t ~ \ serine formate 
1 0-formyi-THF 
glycine) •ynthet'>e 
1 0-formyi-THF 
/
15, 10-methenyi-THF 
cyclohydrolase 
5, 10-methenyl-THF 
i L I -r" I I r- DHF 
~ 
dUMP synthetase dTMP 
Figure 1. 4. Outline of the intracellular interconversion of reduced folates, after the up-
take of 5-methyl-THF from plasma. The cobalamin-dependent methionine synthetase 
reaction provides the only way to enter the cellular pool of active folate coenzymes. In 
addition, 5-methyl-THF appears not to be polyglutamated by folylpolyglutamate synthe-
tase, and therefore is not retained in the cell if its metabolism is blocked. The three con-
secutive steps leading from THF and formate to 5,10-methylene-THF are catalyzed by a 
single "trifunctional" enzyme. 
1.0 
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of cobalamin ( 58-60). The relationship between megaloblastic hemato-
poiesis and reduced activity of methionine synthetase was further substan-
tiated by observations on inborn errors of cobalamin metabolism. Until 
recently four types were recognized, designated Cbl A, B, C and D mutants 
(61), and in all of these there is methylmalonic aciduria, caused by a defi-
ciency of the adenosylcobalamin-dependent mutase. In two of these types, 
Cbl C and D, there is also homocystinuria, and a reduced activity of 
methionine synthetase. Only in these cases megaloblastic anemia is found. 
Recently, the existence of an additional mutant, deficient in methionine syn-
thetase only, has been firmly established ( 62-64). This disorder is character-
ized by homocystinuria and megaloblastic anemia without methylmalonic 
aciduria. In conclusion, cobalamin deficiency leading to megaloblastic 
hematopoiesis is correlated with reduced activity of methionine synthetase in 
bone marrow cells. 
[2] Except for the cobalamin-dependent conversion catalyzed by methionine 
synthetase, there is only one other reaction in which 5-methyl-THF is 
involved. This concerns the reaction catalyzed by 5,10-methylene-THF 
reductase (indicated in Figure 1.4). However, it is not probable that in this 
reaction 5-methyl-THF is utilized as a substrate, because the reduction of 
5,10-methylene-THF appears to be irreversible. This was first found in stu-
dies of the bacterial enzyme ( 65), and was confirmed by kinetic studies of 
the mammalian enzyme ( 66,67). Some conflicting results were reported 
with regard to a possible role of 5-methyl-THF and 5,10-methylene-THF 
reductase in the methylation of biogenic amines in brain ( 68-70). When this 
pathway would indeed exist, it is probably quantitatively insignificant. The 
irreversible nature of the methylene-THF-reductase reaction under physio-
logical conditions was clearly demonstrated in cultured L1210 cells, in 
which the labelled methyl-group of 5-methyl-THF could not be recovered 
from thymidylate (71). This indicates that demethylation by methionine 
synthetase, and not oxidation by methylene-THF reductase, is the way by 
which 5-methyl-THF enters the cellular pool of reduced folates. 
[3] It is well established clinically that the hematological effect of cobalamin 
deficiency can be corrected by folic acid (72,73). In this respect, the 
demonstration of a differential effect of 5-methyl-THF compared to other 
reduced folates is of crucial importance to the methylfolate trap hypothesis, 
which postulates a selective block in the utilisation of 5-methyl-THF to be 
the fundamental defect in cobalamin deficiency. The effects of different 
folate derivatives cannot easily be studied in vivo, because reduced folates 
are readily interconverted upon administration. There is one observation 
which clearly demonstrates the ineffectiveness of parenteral 5-methyl-THF 
without cobalamin in a patient with megaloblastic anemia (74). To study 
the metabolic disturbance in cobalamin deficiency, and its correction by 
folate analogues, a specific in vitro test is usually applied. This metabolic 
test is the deoxyuridine suppression test (75, 76), which can detect a 
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disturbance of the folate-dependent synthesis of deoxythymidylate. Essen-
tially, it measures the suppression of the incorporation of labelled thymidine 
into DNA by the addition of deoxyuridine. The degree of this suppression 
will depend on the conversion of deoxyuridylate to thymidylate. Alterna-
tively, the incorporation of labelled deoxyuridine in DNA can be measured, 
which also directly depends on this folate-dependent reaction (76, 77). The 
test is described in more detail in the following chapter. Results of this test 
are abnormal in bone marrow cells and lymphocytes of cobalamin-deficient 
patients ( 56,57, 76-84). Important information is obtained by comparing the 
effects of various additives on the test values. In cobalamin deficiency the 
addition of cobalamin invariably corrects the test values, although in most 
cases only partially, compared to normal controls (57,76-84). Interestingly, 
of the different cobalamin coenzymes, methylcobalamin is always far more 
effective than adenosylcobalamin (57,79,81). In all studies, a complete 
correction of the test results was possible with the addition of folic acid or 
5-formyl-THF, whereas in all cases 5-methyl-THF appeared to be ineffective 
(56,57 ,76,77 ,81 ,82,84). 
These studies on cobalamin-deficient cells should be compared to those 
on cells from folate-deficient subjects, in which cobalamin compounds have 
no effect at all on test results (76,77,80-84), but 5-methyl-THF is as effec-
tive as all other reduced folates in stimulating the disturbed thymidylate syn-
thesis (76,77,81,82,84). The results of the deoxyuridine suppression test in 
bone marrow cells thus clearly support the methylfolate trap hypothesis by 
demonstrating a specific defect in the utilisation of 5-methyl-THF in cobala-
min deficiency. Furthermore, the possibility to completely correct the effect 
of cobalamin deficiency in this test with the addition of folates is in agree-
ment with the proposed indirect role of cobalamin in nucleotide synthesis. 
Studies on the growth of L5178Y and L1210 mouse leukemia cells in cul-
ture have confirmed the results of metabolic tests. When these cells had 
been made severely cobalamin-deficient, folic acid and 5-formyl-THF could 
restore normal growth, whereas 5-methyl-THF was totally ineffective, except 
with the simultaneous addition of cobalamin (85,86). Finally, several stu-
dies in which cobalamin was inactivated by nitrous oxide have also clearly 
demonstrated that 5-methyl-THF cannot be utilized without the methionine 
synthetase reaction. These studies will be dealt with in section 1.3. 
[4] The final implication of the methylfolate trap hypothesis concerns the 
accumulation of 5-methyl-THF in cobalamin deficiency as the ultimate cause 
of the disturbance of folate-dependent reactions. Over the past twenty years 
this point has raised serious problems, which eventually appear to have been 
solved satisfactorily. These problems were both technical, with regard to 
the difficulties in tissue determinations of folate coenzymes, and conceptual, 
relating to the unexpected central role of folylpolyglutamates in folate meta-
bolism. 
The elevation of serum levels of 5-methyl-THF in many patients with 
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cobalamin deficiency was an early observation (52), which directly contri-
buted to the development of the methylfolate trap hypothesis. This finding 
has been confirmed in other studies (87,88), although in patients with 
chronic disease or additional dietary folate deficiency, folate levels may be 
low (87). The high serum folate levels, which fall to normal following the 
supply of cobalamin, are easily explained as a consequence of methylfolate 
trapping. On the other hand, however, it was found that tissue levels of 
folate were reduced in cobalamin deficiency. This was already observed in 
1954, when folate levels in "whole blood" were measured (89), and has 
been confirmed, not only in erythrocytes (88), but also in leukocytes (90) 
and liver cells (53,91). This finding appears not to be compatible with the 
original methylfolate trap hypothesis, which implies an accumulation of 5-
methyl-THF. More recently, this cellular folate depletion has also been 
explained as direct consequence of the failure to convert 5-methyl-THF in 
cobalamin deficiency, because this will lead to severely impaired synthesis 
of folylpolyglutamates (92). The recognition of the important role of folyl-
polyglutamate synthesis has been rather slow. At first, the observations of 
increased serum levels of folate, with reduced tissue levels, have led to the 
hypothesis that the cellular uptake of folate was a cobalamin-dependent pro-
cess (93-95). Others recognized that decreased polyglutamation, resulting in 
decreased cellular retention of folates, could also explain these effects 
(53,92). This in tum has led to the suggestion that the polyglutamation of 
folates was directly cobalamin-dependent (96). It is important to notice that 
these presumed additional cobalamin-dependent processes have not been 
characterized, and in fact are not necessary. The decreased polyglutama-
tion, and the resulting decreased cellular uptake, can be explained as a 
consequence of the failure to convert 5-methyl-THF. This folate derivative 
is not used in the synthesis of polyglutamates, as is evident from several stu-
dies ( 45-50) that were discussed in the former section. Other studies have 
made it unlikely that the membrane transport of folates is cobalamin-
dependent by itself (92,97), and the enzyme activity of folylpolyglutamate 
synthetase was not affected by the absence of any form of cobalamin ( 41). 
Thus, with an expansion which includes the role of folylpolyglutamates in 
the cellular retention of folates, the methylfolate trap hypothesis can explain 
the reduction of total intracellular folate in cobalamin deficiency. 
The observed absolute reduction of tissue folates does not, however, 
exclude a relative increase of 5-methyl-THF, which would provide addi-
tional support for the methylfolate trap hypothesis. Several difficulties have 
hampered the study of folate coenzyme distribution in cobalamin deficiency. 
Reliable extraction and assay of the various intracellular folates, some of 
which are rather labile, has been difficult for a long time, so much the more 
in this case, because of: a) the low cellular folate content in cobalamin defi-
ciency; b) the abundance of 5-methyl-THF, even in cobalamin-replete cells. 
Methylated folates amount from about 83% in normal fibroblasts (98), to 
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39% in liver cells (99), and even 100% in erythrocytes (100). These high 
percentages limit the detection of a relative accumulation of 5-methyl-THF 
with regard to other folates. Nevertheless, in several studies a relative 
increase in methylated folates has been found in cobalamin deficiency, to a 
variable extent and duration. The determination of methylfolates in most 
studies has been simplified by the application of microbiological assays, 
which can differentiate between total folates (detected by Lactobacillus 
casei) and non-methylated folates (detected by Pediococcus cerevisiae or 
Streptococcus faecalis, which cannot use 5-methyl-THF). A relative 
increase of 5-methyl-THF was demonstrated in the livers of cobalamin-
deficient rats (51,101) and sheep (91,102), as well as in L1210 leukemia 
cells (103) and Euglena gracilis (104), cultured without cobalamin. In some 
of these studies ( 101-103) it was also shown that this relative increase was 
caused by a decrease of polyglutamate derivatives of other reduced folates. 
A decrease of folylpolyglutamates appeared to be the primary event in the 
development of intracellular folate deficiency resulting from cobalamin defi-
ciency. This was also shown in erythrocytes of pernicious anemia patients, 
but not of patients with primary folate deficiency ( 100, 105). With regard to 
the confirmation of the (relative) trapping of 5-methyl-THF, studies employ-
ing the nitrous oxide model of cobalamin deficiency have also been useful. 
In general, a rapid initial rise of 5-methyl-THF has been found (106-108), 
followed by severe folate loss due to decreased polyglutamation ( 47, 109). 
Thus, the postulate that cobalamin deficiency increases the proportion of tis-
sue folates in the methylated form is also supported by a large number of 
experiments. 
It can be concluded that the main implications of the methylfolate trap 
hypothesis have been confirmed experimentally. An important addition to 
the original hypothesis has been the recognition of the impairment of folyl-
polyglutamation, which explains the occurrence of intracellular folate deple-
tion in cobalamin deficiency. For this reason, it is probably not entirely 
correct to refer to methylfolate "trapping" as the ultimate cause of the meta-
bolic disturbance. Perhaps, the explanation of the effects of cobalamin defi-
ciency should be called simply methylfolate "blockade". This more 
appropriately emphasizes the mechanism responsible for the hematological 
effects of cobalamin deficiency: a secondary intracellular deficiency of 
metabolically active folates, caused by a failure to convert the methyl-form 
after its uptake from the plasma. In current literature, some alternative 
views can still be found, which will be discussed in section 1.1.5. 
1.1. 4. Cobalamin deficiency and methionine metabolism. 
Methionine is also involved in the metabolic consequences of cobalamin 
deficiency. The role of cobalamin in methionine metabolism is evident 
from its function in the enzyme methionine synthetase. In the methylfolate 
trap hypothesis the function of this enzyme in folate metabolism is 
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emphasized, but the methylation of homocysteine to methionine is also of 
great importance. In fact, as a result of the dual function of this 
cobalamin-dependent enzyme, methionine and folate metabolism are closely 
related. The folate-dependent synthesis of methionine is an essential step in 
the "methylation cycle", in which S-adenosylmethionine (SAM) serves as a 
methyldonor in a wide variety of metabolic processes. On the other hand, 
methionine has profound influence on folate metabolism as well, because 
the metabolism of one carbon-units is carefully regulated, as discussed in a 
paper by Krebs et al. ( 110). In this regulation, the intracellular concentra-
tion of SAM determines the activity of the enzyme methylene-THF-
reductase, by a strong inhibitory effect ( 66, 111). This enzyme catalyzes the 
conversion of reduced folates to 5-methyl-THF, which is the methyl donor 
in the synthesis of methionine. A low concentration of methionine, directly 
leading to reduced concentrations of SAM, therefore causes a shift of folates 
towards 5-methyl-THF at the expense of other reduced folates. High levels 
of methionine and SAM will, on the other hand, reduce 5-methyl-THF, 
favouring all other folate-dependent processes. Conceivably, in cobalamin 
deficiency, when 5-methyl-THF cannot be utilized anymore, this regulatory 
mechanism can further complicate folate metabolism. If methionine and 
SAM are low, as is to be expected in cobalamin deficiency (112), the 
increased activity of methylene-THF-reductase will further increase the pool 
of 5-methyl-THF. A large number of studies, in particular by the group of 
Stokstad, has demonstrated that methionine deficiency indeed increases the 
metabolic disturbance of folate metabolism in cobalamin deficient cells, and 
that supplementation of methionine reduces the consequences of cobalamin 
deficiency. These studies were performed in rats (53,101,113-120) or sheep 
( 102), and generally liver cells of these animals were used. In all of these 
studies methionine corrected one or more aspects of disturbed folate meta-
bolism in cobalamin-deficient animals, such as the increased proportion of 
5-methyl-THF, the intracellular depletion of folates and the impairment of 
folate-dependent processes, most often histidine degradation. Animals, 
which were methionine deficient in addition to their cobalamin deficiency, 
were more severely affected with regard to these aspects of folate metabol-
ism. These experimental results thus are in agreement with the regulatory 
effect of methionine as proposed by Kutzbach et al. ( 66) and Krebs et al. 
(110), and support the methylfolate trap hypothesis. It should be noted 
however, that although the existence of these effects in liver cells is beyond 
doubt, these results may not be directly applicable to hematopoietic cells. 
Different results were obtained when methionine was added to bone marrow 
cells of cobalamin deficient patients. In the deoxyuridine suppression test 
methionine further impaired the de novo synthesis of thymidylate ( 121, 122). 
In one study it was shown that folate metabolism of bone marrow and liver 
cells reacted differently on methionine addition. In the marrow cells, 
methionine increased the proportion of 5-methyl-THF, disturbing folate-
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dependent nucleotide synthesis ( 123). The mechanism of this was proposed 
to be the increased inhibition of methionine synthetase by excess 
methionine. This has indeed been observed in earlier studies on this 
enzyme (30,53,59). A recent study has shown that the effects of methionine 
in bone marrow cells are in fact dose-dependent ( 124). A low dose of 
methionine was able to cause a nearly complete correction of the disturbed 
deoxyuridine suppression test in cobalamin deficient bone marrow. How-
ever, higher concentrations of methionine, as used in the earlier studies, 
resulted in further disturbance of the test. With folate-deficient bone mar-
row cells there was only minimal improvement by low doses of methionine, 
while high doses again produced severe disturbance. Thus, the effects of 
methionine in cobalamin deficiency can be rather variable. The enhance-
ment of folate coenzyme functions by the low doses of methionine can be 
explained not only by the shift towards non-methylated reduced folates, 
caused by the inhibition of 5, 10-methylene-THF reductase, but possibly also 
by a catalytic action of SAM on the enzyme methionine synthetase. SAM is 
an essential cofactor in the enzyme complex (30,33, 125), and low levels of 
SAM could limit the enzyme activity. A summary of these effects is 
presented in Figure 1.5. 
The interaction of methionine with folate metabolism is apparently com-
plex and intricately regulated. Unfortunately, there are no reports of either 
a beneficial or a detrimental effect of methionine administration in perni-
cious anemia patients. It has been reported, however, that serious protein 
malnutrition (kwashiorkor), in which methionine deficiency is a prominent 
feature, may aggravate or even precipitate severe megaloblastic anemia 
( 126, 127). Scott and Weir have underlined the importance of disturbed 
methionine metabolism for the mechanism of methylfolate trapping in coba-
lamin deficiency ( 128, 129). Interestingly, these authors also presented evi-
dence that decreased synthesis of methionine is related to the occurrence of 
neurological disease (subacute combined degeneration of the spinal cord) in 
longstanding cobalamin deficiency ( 130). In this investigation, they made 
use of the nitrous oxide model for cobalamin deficiency, which will be dealt 
with in section 1.3. In several other studies employing the nitrous oxide 
effect, methionine or SAM corrected various aspects of disturbed folate 
metabolism (131-134). 
Finally, studies on inherited metabolic disorders also have provided 
insight in the way in which methionine is involved in folate metabolism. A 
recent comparison of the effects of deficiencies of either methylene-THF-
reductase or methionine synthetase is most interesting in this respect ( 135). 
In methylene-THF-reductase deficiency, there is no trapping of 5-
methylfolate, no impairment of folate coenzyme functions related to cell 
division, and consequently, no megaloblastic anemia. This may be compar-
able to the SAM-induced inhibition of this same enzyme, which in cobala-
min deficiency restores folate metabolism by preventing the formation of 
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Figure 1.5. The regulatory effects of methionine and S-adenosylmethionine (SAM) on 
folate metabolism. It should be realized that these three mechanisms are not necessarily 
active at the same time. Probably physiologically most important is the inhibition of 
5, 10-methylene-THF reductase by SAM. In cobalamin deficiency, this effect reduces 
the accumulation and subsequent loss of 5-methyl-THF, which explains the ameliorating 
influence of methionine observed in most experiments. 
methylfolate. In methylene-THF-reductase deficiency, intracellular and 
plasma levels of 5-methyl-THF are low, but total intracellular folate, mainly 
as THF, is normal. The lack of 5-methyl-THF as a cofactor in methionine 
synthesis explains the homocystinuria and low methionine levels found in 
this disease ( 136, 137), which gives rise to neurological symptoms only. 
When the activity of methionine synthetase is reduced, there is also homo-
cystinuria, low methionine and neurological disease, but in contrast, 5-
methyl-THF is high, and the total folate level is reduced. In this disease, 
folic acid coenzyme functions are severely disturbed, and there is megalob-
lastic anemia, in accordance with the methylfolate trap hypothesis. 
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It can be concluded that in the pathways of one carbon-metabolism 
methionine plays a important role, and for this reason, the involvement of 
methionine in folate metabolism is also essential to the understanding of the 
role of cobalamin in the cell. 
1.1. 5. Alternative theories on the role of cobalamin in hematopoiesis. 
Experimental results of a large number of studies have been in agreement 
with the role of cobalamin in hematopoiesis as proposed in the methylfolate 
trap hypothesis. In some instances, this hypothesis, as formulated nearly 25 
years ago, appeared to be not entirely sufficient to explain new experimental 
observations. Most prominently, this was the case with the role of folylpo-
lyglutamates in folate homeostasis. It has been possible to include this 
aspect of folate metabolism in the role of cobalamin proposed by the 
methylfolate trap hypothesis, thereby accounting for the cellular depletion of 
folates in cobalamin deficiency. The way in which methionine is involved 
in folate metabolism and cobalamin deficiency, which appeared to be rather 
complicated, is as well in agreement with the methylfolate trap hypothesis. 
Finally, results obtained with the nitrous oxide model for cobalamin defi-
ciency were in general also as predicted by this hypothesis. However, 
several other explanations of the effects of cobalamin deficiency have 
appeared in the literature. Most of these theories had to be discarded, when 
they failed to fit new experimental data. This has been the case with the 
theories that cobalamin is directly involved in the entry of folates in the cell, 
or is a cofactor in polyglutamation of folates. Some alternatives to the 
methylfolate trap hypothesis can still be found in recent literature, and will 
be described briefly now. 
1: A cobalamin function in thymidylate synthetase has been proposed by 
Haurani (138-140). He assumed a direct role of cobalamin in nucleotide 
synthesis, and this would be the induction or activation of the enzyme thy-
midylate synthetase. This theory is based on the observation that thymi-
dylate synthetase activity is low in PHA-stimulated lymphocytes obtained 
from cobalamin-deficient persons. However, this finding has never been 
confirmed. Indications of an involvement of cobalamin in the enzymatic 
activity of thymidylate synthetase are lacking in the vast literature on this 
subject. On the contrary, an increased activity of thymidylate synthetase in 
bone marrow cells from cobalamin-deficient subjects (141,142), and in mar-
row cells of nitrous oxide-treated rats ( 143) has been reported. This 
increase is easily explained as a regulatory effect, since the enzyme activity 
will be impaired by the lack of its folate coenzyme. Haurani et al. have 
reported that nitrous oxide exposure in their experiments also reduced thy-
midylate synthetase activity ( 144). It may be that either PHA -stimulated 
lymphocytes are not a useful model to study hematopoiesis, or that the 
results depend on the enzyme assay system employed by these workers. 
Their recent observation that methotrexate induces an increase in 
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thymidylate synthetase activity is also in contrast with other data (145). This 
theory is not easily compatible with the large number of observations on an 
involvement of folate metabolism in cobalamin deficiency. 
2: The "formate starvation hypothesis" was put forward by Chanarin 
and coworkers ( 146, 147). They agree that the prime defect in cobalamin 
deficiency is the reduced activity of methionine synthetase, but do not accept 
that the conversion of 5-methyl-THF to THF, catalyzed by this enzyme, is of 
functional significance. Instead, it is proposed that the impairment of 
methionine supply, another consequence of inactive methionine synthetase, 
is the ultimate cause of the effect of cobalamin deficiency on folate metabol-
ism. This is explained by suggesting a rather complicated pathway, in 
which methionine is eventually the source of formate, which subsequently is 
essential in the synthesis of formyl-THF. Finally, formyl-THF is supposed 
to be the optimal substrate for the synthesis of folylpolyglutamates. This 
would explain the fall in intracellular folate levels and the impairment of 
folate coenzyme functions, induced by cobalamin deficiency. The 
hypothesis is based on the observation that in vitro addition of formyl-THF 
more efficiently corrects the disturbance by nitrous oxide of the deoxyuri-
dine suppression test in rat bone marrow cells, if compared to the addition 
of THF ( 148). As THF was largely ineffective in this test system, it was 
concluded that the conversion of 5-methyl-THF to THF could have no 
essential function. They therefore reject the methylfolate trap hypothesis. In 
addition to their observations on the nitrous oxide model in rats, they also 
have found THF to be less effective than formyl-THF when using bone mar-
row cells of cobalamin deficient patients (149,150). These findings, how-
ever, have not been confirmed. On the contrary, in some recent studies, 
THF was quite effective in correcting the metabolic effect of cobalamin defi-
ciency, although somewhat less than formyl-THF (57,84). Furthermore, 
several authors suggested that the observed differential effect of formyl-THF 
may reflect its higher stability, and the increased capacity of cells to tran-
sport this compound ( 19,84). In addition, THF may also be more rapidly 
converted into 5-methyl-THF, and thus be lost in cobalamin deficiency. It is 
noteworthy that in the studies of Chanarin's group, like in all other studies 
discussed before, 5-methyl-THF was totally ineffective in deoxyuridine 
suppression tests of cobalamin deficient cells, leaving this essential implica-
tion of the methylfolate trap hypothesis unaffected. Chanarin and cowork-
ers have produced a large number of studies in recent years, of which they 
interpreted the results as confirming the essential role of "formate starva-
tion" in cobalamin deficiency. In most cases, they have used nitrous oxide 
exposure as a model for cobalamin deficiency. They found that methionine 
and SAM, presumed to be precursors of formate, corrected impaired folyl-
polyglutamate synthesis (109,133). This is also explained by other theories, 
as described in section 1.1.4. They also reported that formyl-THF was a 
substrate in folylpolyglutamate synthesis, while THF and 5-methyl-THF 
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were not ( 151). This pattern, however, has not been found in other studies, 
even after purification of the polyglutamate synthetase enzyme (50). Usu-
ally, THF appeared to be the preferred substrate in folylpolyglutamate syn-
thesis ( 46). According to the methylfolate trap hypothesis, any reduced 
folate, except 5-methyl-THF, may be a substrate in polyglutamate synthesis, 
and the results of Chanarin's group do not contradict this assumption. 
Furthermore, the formate starvation hypothesis implicates a fairly com-
plicated connection between methionine and the presumed production of 
formate. Cobalamin deficiency would involve reduced levels of several 
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Figure 1. 6. The pathway from methionine to formate, which according to Chanarin et 
al. is essential to prevent megaloblastic anemia. It is assumed that the reduced activity 
of methionine synthetase in cobalamin deficiency ultimately will result in decreased lev-
els of formyl-THF, supposed to be the preferred substrate for folylpolyglutamate syn-
thesis (from ref. 20 and 133). 
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important intermediates, according to the pathway described in their papers 
(20,133), and shown in Figure 1.6. Among these are methionine and SAM, 
and also decarboxylated SAM, a precursor of polyamines. Inhibition of the 
synthesis of SAM by cycloleucine, or of its decarboxylation by mitoguano-
zone (MGBG), is not known to cause megaloblastic anemia, however. 
Another difficulty with the hypothesis of Chanarin and coworkers is the 
failure of direct administration of sodium formate to correct folate metabol-
ism upon nitrous oxide treatment ( 133). For these reasons, the hypothesis 
that the hematologic consequences of cobalamin deficiency are caused by 
formate starvation, does not seem to be a likely alternative to the more 
direct involvement of folate in cobalamin deficiency, as suggested in the 
methylfolate trap hypothesis. 
An additional alternative hypothesis seems to be the recent suggestion of 
Sourial et al. (152), that the primary lesion in megaloblastic anemia is an 
inability to synthesize SAM. SAM would be required for DNA synthesis 
and hematopoiesis. It appears, however, that this suggestion only differs 
from the conventional view of methylfolate trapping by a more pronounced 
emphasis on the role of SAM in folate metabolism. In their report, based 
on the use of nitrous oxide-induced inactivation of cobalamin, Sourial et al. 
do not suggest other ways in which SAM could be required for DNA syn-
thesis than an effect on the enzyme methionine synthetase. 
Finally, it should be mentioned that controversy still exists on the 
mechanism of the neurological lesions in cobalamin deficiency. At present, 
an impairment of SAM-mediated methylation reactions in the nervous sys-
tem, as a consequence of reduced activity of methionine synthetase, seems 
to be the most probable explanation. An earlier hypothesis assumes reduced 
activity of the second cobalamin-dependent enzyme in man, methylmalonyl-
CoA mutase, to be the cause. This explanation does not fit with the well-
established occurrence of neurological lesions with long term nitrous oxide 
exposure, which only inactivates methionine synthetase ( 132,153, 154). In 
addition, a congenital deficiency of the mutase enzyme does not cause neu-
rological impairment. A detailed discussion of the active research in this 
area is beyond the scope of this chapter. 
1.1. 6. The role of cobalamin in malignant hematopoiesis. 
The importance of cobalamin in normal hematopoiesis is clearly demon-
strated by the clinical effects of cobalamin deficiency. It is the subject of 
this paragraph to describe some observations relating to the role of cobala-
min in malignant hematopoiesis, or: the growth of leukemia. This obviously 
is fundamental to the potential therapeutic application of cobalamin antagon-
ists, which will be described in the following sections. 
The cobalamin-dependent enzyme methionine synthetase, which has an 
essential function in folate metabolism, is also present in malignant 
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leukocytes ( 155-158). It appears that, in general, the activity of this enzyme 
in malignant cells is somewhat higher than in normal cells. Lymphoid 
leukemia cells have a higher activity than myeloid leukemia cells, while 
activity in the stationary phase of chronic myeloid leukemia (CML) is very 
low, in contrast to the accelerated phase. Observations on lymphoid cell 
lines (155) and (normal) CHO cells (60) have also indicated that the 
enzyme activity is highest during rapid growth of the cells. The presence of 
this enzyme in leukemic cells suggests that cobalamin is also essential to the 
growth of these malignant cells, and that methionine synthetase consequently 
is a potential target in cancer chemotherapy ( 159). Mouse leukemia cells 
effectively take up cobalamin, bound to its transport protein transcobalamin 
II (TC II) (160), and in cultures the presence of TC II-bound cobalamin is 
essential to the utilization of 5-methyl-THF and growth of these cells 
(85,86). 
Two cases have been described which demonstrate the importance of 
cobalamin for the growth of human leukemia (161,162). In these patients, 
the administration of cobalamin accelerated the growth of leukemia. In the 
first case (161), a patient with coexisting pernicious anemia and CML was 
"treated" by withholding vitamin B 12 as long as possible, because supple-
mentation appeared to cause stimulation of leukemic growth. The other 
case ( 162) also demonstrated an acceleration of leukemic blast cell prolifera-
tion on cobalamin administration. The controlling effect of cobalamin 
deprivation in this case was apparent from bone marrow cultures with and 
without the addition of cobalamin. In another report of concomitant perni-
cious anemia and leukemia ( 163), the authors speculated that vitamin B 12 
therapy had resulted in progression of the disease. On the other hand, one 
case has been reported in which maturation of leukemic blasts apparently 
resulted from cobalamin supplementation (164). 
Although the evidence is still limited at present, a role of cobalamin in 
malignant hematopoiesis seems probable, which is not surprising in view of 
the established role of folate metabolism in tumor growth. To some extent, 
the situation with regard to the application of cobalamin antagonists seems 
comparable to the introduction of folate antagonists nearly 40 years ago. 
Farber first observed the importance of folic acid to the growth of tumors, 
which was evident from an accelerated tumor growth in some cases 
(165,166), before he realized the therapeutic value of antagonists (167). 
The remainder of this introductory chapter will be devoted to a discussion of 
the present knowledge on cobalamin antagonists. 
Cobalamin and folic acid are intimately involved in the metabolism of 
malignant cells, and consequently their antagonists are of importance to the 
treatment of malignant disease. Interestingly, in malignant cells alterations 
of methionine metabolism and transmethylation reactions have been 
observed in vitro, a phenomenon which is called "methionine dependence", 
and which may be related to the process of carcinogenesis ( 168). Although 
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cobalamin and folic acid both are essential in the biosynthesis of 
methionine, it is as yet unclear whether a disturbance in the metabolism of 
these vitamins is also implicated in the development of malignant disease, as 
has been suggested (166). 
1.2. Cobalamin antagonists: an overview. 
The interest in antagonists of cobalamin started early after the elucidation of 
its chemical structure in 1956. One of the pioneers in this field has been 
Lester Smith, who has investigated several structural analogues of the vita-
min (166-171). His motivation was twofold (171): firstly, antimetabolites of 
cobalamin might provide information on the mode of action of this vitamin, 
and secondly, they might be used in the treatment of leukemia and possibly 
other malignant diseases. The same reasons still explain the current revived 
interest in cobalamin antagonists, which began in 1978 with the discovery of 
the inactivation of cobalamin by nitrous oxide. 
Several different substances have been found to interfere with cobala-
min functions, but usually their biological activity and possible application 
have not been investigated in detail. Their characterization often was lim-
ited to a single aspect of cobalamin metabolism. In fact, only the recent 
interest in nitrous oxide has resulted in extensive metabolic studies of a 
cobalamin antagonist. This does not necessarily imply, however, that 
nitrous oxide is more effective than any other antagonist. Nitrous oxide is 
probably only unique because of its easy administration by inhalation, its 
rapid action and, in particular, because of its widespread clinical use in 
anesthesia, which has necessitated the study of this side-effect. It is impor-
tant to realize that the observations on the effects of nitrous oxide may also 
apply to other antagonists that are already known, or to new ones that could 
be developed. The properties of different types of cobalamin antagonists 
will be discussed now. 
1: Structural analogues of cobalamin represent the most obvious 
approach in the search for cobalamin antagonists. The interest in these com-
pounds has been inspired by the therapeutic results obtained with folate 
analogues. Considering the complicated structure of the cobalamin 
molecule, the number of possible structural analogues is virtually unlimited. 
A large number of cobalamin analogues has been prepared, often by chemi-
cal modification of the vitamin, or by isolation from bacterial cultures. The 
systematic screening of the biological properties of these compounds has 
been very difficult, especially in the time when the metabolic functions of 
cobalamin were still ill-defined. Therefore, the rather extensive literature on 
cobalamin antimetabolites published around 1960 is nowadays of limited 
value. Some important results of these and more recent studies will be sum-
marized. 
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Chemical modification of cobalamin often started with mild acid hydro-
lysis, which converts the propionamide side chains to carboxylic acids. 
Three isomeric monocarboxylic acids may be formed, which subsequently 
may be converted into substituted amides by reactions with several different 
amines or aniline (aminobenzene). These products, called B12-amides and 
B12-anilide, were tested on biological activity mainly in bacterial systems. 
Several of these compounds, including the unsubstituted monocarboxylic 
acids, had antagonistic effects with regard to cyanocobalamin (169-175). 
Results were different dependent on the type of microorganism used in the 
test, however. Inhibition in one system did not exclude vitamin-like stimu-
lation in another. Further investigations showed that B 12-anilide produced 
megaloblast-like cells when added to human bone marrow cultures ( 173), 
and that monocarboxylic acid derivatives caused granulocytopenia in rats 
(174), but not in primates (175). In the latter study, methylmalonic acid 
excretion and serum folates were increased by the treatment with these sub-
stances. B 12-anilide failed to disturb the deoxyuridine suppression test 
(76). Treatment of malignant disease with these antagonists has not been 
encouraging ( 171) and results have not been published in detail. In one 
case of human chronic myeloid leukemia Herbert and Hoogstraten found a 
striking remission with either B 12-anilide (166) orB 12-ethylamide (176). 
In another class of structural analogues the aminopropanol moiety in the 
large side chain attached to the D-ring of cobalamin is replaced by other 
alkanolamines. These substances were produced by partial synthesis and 
some of them strongly inhibited bacterial growth, which could be corrected 
by the addition of methionine ( 177). The 2-amino-2-methylpropanol deriva-
tive (called 5102) was further tested with equivocal results (178). 
In addition, analogues have been produced with modifications in the 
nucleotide part of the cobalamin structure. In these compounds the 5,6-
dimethylbenzimidazole heterocyclic base, which is specific for cobalamin, is 
substituted or replaced by another base ( 178). These analogues in general 
were not antagonists but active coenzymes in several bacterial cobalamin-
dependent reactions. 
Antagonists of cobalamin occurring in bacterial cultures have been stu-
died ( 179), also mainly by testing their ability to inhibit the growth of 
cobalamin-requiring microorganisms. These antagonists are not necessarily 
structural analogues, although most of them were related to at least a part of 
the cobalamin molecule. However, not all were fully characterized. In cul-
tures of Bacillus cereus a substance inhibiting methionine synthetase was 
found, and from cultures of Corynebacteria compounds with a high affinity 
towards cobalamin-binding proteins were isolated. No further details on 
these and other naturally occuring antagonists have been reported. 
A wide variety of metal-substituted cobalamins has been investigated, 
like the rhodibalamins, which contain rhodium (180). These were found to 
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be weak antagonists. Manganibalamin, cupribalamin and zincobalamin have 
also been described, but appear to have no significant biological effects. 
Treatment of cobalamin with mild alkali at high temperature can result 
in an oxidative cyclization of the c-acetamide side chain at the B-ring, yield-
ing a c-lactam. Recently, the administration of hydroxocobalamin(c-lactam) 
to rats during 14 days was reported to cause inhibition of methionine synthe-
tase, comparable to nitrous oxide ( 181). 
Finally, structural analogues have been made by replacing the ligand at 
the sixth coordinating bond of the central cobalt atom. Fluoro- and 
chloroalkyl-groups, replacing methyl in methylcobalamin, yielded cobalamin 
analogues inhibiting cobalamin-dependent methane formation by bacteria 
( 182), and the synthesis of cobalamin coenzymes in human lymphocytes 
(183). A variety of nucleosides was used to prepare analogues of adenosyl-
cobalamin (184). Nearly all of these inhibited bacterial adenosylcobalamin-
dependent ribonucleotide reductase, and, moreover, all analogues effectively 
inhibited transcobalamin 11-mediated transport of cobalamin into L1210 
mouse leukemia cells. Methylcobalamin analogues were also expected to 
inhibit methionine synthetase (159), but this has not been substantiated. 
2: Complexes of cobalamins with heavy metals are readily formed in 
vitro, with platinum (185) and palladium (186), and, in the case of plati-
num, lead to transfer of the methylgroup of methylcobalamin to the metal 
( 187). The complexes of cobalamin with these heavy metals attained biolog-
ical significance when it was speculated that the serious peripheral neuro-
pathy occurring with cisplatin chemotherapy might be caused by inactivation 
of cobalamin. This neuropathy is clinically similar to the neurological 
effects of cobalamin deficiency, but in a recent study cisplatin treatment did 
not cause alterations in serum cobalamin, or in the excretion of methyl-
malonic acid or homocystine (188). A palladium-methylcobalamin complex 
was shown to inhibit the synthesis of cobalamin coenzymes in lymphocytes 
(183), and to reduce the growth of a transplanted tumor in mice (189). 
3: Nitrous oxide (N20) is an effective antagonist of the coenzyme func-
tion of methylcobalamin, causing rapid and specific inactivation of 
methionine synthetase (190-193). At present, it is the only cobalamin anta-
gonist which has been investigated in considerable detail in metabolic and 
clinical studies. The effect of nitrous oxide on the methylcobalamin coen-
zyme appears to be due to oxidation of the central cobalt ion, which disrupts 
the catalytic activity of the enzyme. This immediate action on the enzyme is 
essentially different from the effects of structural analogues, which will 
impair the synthesis of new enzyme by competition with the normal coen-
zyme. Although nitrous oxide indeed rapidly inactivates methionine synthe-
tase, the resulting disturbance of folate metabolism develops gradually. 
Nitrous oxide is a gas, and this will contribute to its effective tissue penetra-
tion. An important aspect of this cobalamin antagonist is its widespread use 
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in anesthesia and for industrial purposes, and its abuse, as a "recreational 
drug". The consequences of prolonged exposure, which are megaloblastic 
bone marrow depression and myeloneuropathy, are therefore of clinical 
importance. The effects of nitrous oxide are considered in more detail in 
the next paragraph. 
4: Alkylnitrites were recently reported to affect both methylcobalamin 
and 5-methyl-THF in vitro ( 194). It was suggested that these interactions 
were due to the oxidizing properties of the nitrites comparable to the effect 
of nitrous oxide. As yet, it is uncertain whether these effects are biologi-
cally relevant. Abuse of volatile alkylnitrites is not known to cause symp-
toms of cobalamin or folate deficiency. 
5: Other approaches in the development of cobalamin antagonists have 
been described. A variety of nucleotides was tested for antagonism towards 
the cobalamin-dependent growth of Euglena gracilis ( 195), and some indeed 
appeared to have such an effect. However, there was only little evidence of 
specificity for cobalamin. Inhibition of the enzyme methionine synthetase, 
the main objective of the application of cobalamin antagonists as inhibitors 
of cellular proliferation, may also be pursued by other means, like analo-
gues of the substrate 5-methyl-THF. Effective inhibitors of this kind are not 
known, however. It has been argued that the cobalamin coenzyme 
represents the most vulnerable and specific facet of this enzyme (159), as 
illustrated by the great care to absorb and conserve this substance in mam-
malians. 
Interestingly, another inhibitor has been described with clear clinical 
relevance. Ethanol appears to impair the activity of methionine synthetase 
(196), resulting in the accumulation of 5-methyl-THF (197). This may con-
tribute to the megaloblastic anemia frequently observed with alcoholism, but 
should not be considered to be specific enough to merit further study of the 
alcohol treatment of myeloproliferative disorders. 
1.3. The effect of nitrous oxide on cobalamin. 
Nitrous oxide, or dinitrogen monoxide (N20) is a colorless gas without 
appreciable odor or taste, which was prepared and recognized as a distinct 
gas by Joseph Priestley in 1772. The gas was extensively studied for the 
first time by Humphry Davy between 1798 and 1800 (198-200). Davy 
discovered and vividly described the particular mental effects produced by 
breathing this gas, but also noted that it could relieve pain, concluding that 
nitrous oxide "may probably be used with advantage during surgical opera-
tions" (198). Although breathing the "laughing gas" became a popular 
entertainment, it was not until 1844 before it was applied as an anesthetic by 
Colton and Wells, initially with only limited success. Nitrous oxide is not a 
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very potent anesthetic agent, and if administered alone, high concentrations 
are necessary to produce unconsciousness, with the danger of causing 
hypoxia. It appeared to be of great value, however, as an adjuvant to other 
anesthetics. In modern anesthesia, 70% nitrous oxide is commonly used to 
reduce the concentration of more potent anesthetic agents. The distinct 
analgesic properties are an additional advantage, and are the reason of its 
use in dentistry and obstetrics, which is widespread especially in the United 
States. During the long period of its application in anesthesia, nitrous oxide 
became known as a safe agent, without important side effects. Recovery 
from its effects is rapid, and ther:e is no detectable biotransformation. 
In the 1950s nitrous oxide was applied in the treatment of tetanus, to 
relieve patients from the emotional stress caused by the application of curare 
and artificial respiration. Exposure to nitrous oxide therefore lasted several 
days. It was observed that in this period severe bone marrow depression 
developed, which could even be fatal (201-203). Lassen, the first to 
describe this effect, found on examination of the bone marrow of these 
patients that "erythropoiesis was strikingly megaloblastic and the changes in 
granulocytopoiesis were so pronounced and typical that, unless one knew 
the clinical history, one would not hesitate to diagnose pernicious anaemia" 
(201). This serious megaloblastic bone marrow depression was observed 
specifically in patients who had received nitrous oxide. Thus, it appeared 
that exposure to nitrous oxide for periods longer than in ordinary surgery, 
could be very toxic. Nothing was known in these days about the possible 
mechanism of this toxicity. 
Remarkably, not much later, in two studies this unexplained side-effect 
was deliberately applied in patients with leukemia. The first report, also 
from Lassen and coworkers (204), described two patients with chronic 
myeloid leukemia (CML) in which the leukocyte counts decreased rapidly 
to about normal values on nitrous oxide exposure. This effect was rather 
quickly reversible, however, when treatment was discontinued. In addition, 
Lassen noticed a dramatic fall of serum vitamin B 12 during the treatment. 
In one case, the level was reduced from 4900 pg/ml, an increased value as 
found often in CML, to 1280 pg/ml in about 14 days, followed by a rapid 
increase after exposure had been stopped. The second publication, by East-
wood et aL (205), described nitrous oxide administration to two children 
with acute myeloid leukemia, resulting in a similar rapid fall of initially high 
leukocyte counts. In one patient, continued intermittent application of 
nitrous oxide could maintain the leukocyte counts at normal levels and 
relieve severe joint pain for more than five weeks. 
This cytotoxic effect of nitrous oxide appeared reproducible in vitro, in 
cultured embryonal mouse cells (206). Subsequently, several studies in 
rodents (207-211) have demonstrated suppression of hematopoiesis, result-
ing in a marked leukopenia. Typical megaloblastic anemia was not 
observed, but it should be noted that dietary manipulation of laboratory 
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animals also has failed to produce this, probably strictly human, 
phenomenon. Nitrous oxide was also tested in animal tumor systems. The 
growth of a transplanted fibrosarcoma in mice was reduced by nitrous oxide 
(212), and the same was found with Ehrlich ascites tumor (213). As an 
incidental finding, it was reported that nitrous oxide reduced the growth of 
lymphoma in mice (214). In another study no effect was found on a mouse 
mammary carcinoma (215,216). Another manifestation of cytotoxicity on 
chronic exposure to nitrous oxide was the inhibition of spermatogenesis in 
rats (217). 
In the meantime, inorganic chemists investigated the reactions of a 
variety of transition-metal complexes with nitrous oxide. Nitrous oxide 
appeared to be much more reactive than was previously assumed. In 1968, 
Banks et al. (218) described the rapid reaction of some cobalt(I)-complexes, 
including cob(I)alamin, with nitrous oxide, which yielded cob(II)alamin and 
nitrogen. This reaction occurred under very mild conditions, i.e. room tem-
perature, atmospheric pressure and about neutral pH. Apparently these 
chemists were not aware of the potential biological consequences of this 
reaction. Their publication escaped the attention of medical investigators, so 
this important observation with regard to the toxic effects of nitrous oxide 
remained unrecognized for a long time. Referring to the observations by 
Banks et al., Schrauzer and Stadlbauer subsequently described the oxidative 
inactivation in vitro by nitrous oxide of the bacterial cob(I)alamin-dependent 
enzyme ethanolamine ammonia-lyase (219). Other chemists further charac-
terized the reaction of cob(I)alamin and nitrous oxide in 1977 (220). These 
observations were still not connected to the fact that nitrous oxide exposure 
could disturb hematopoiesis in vivo, in a way closely similar to cobalamin 
deficiency. 
In 1978, Amess et al. reported the frequent occurrence of megaloblastic 
hematopoiesis in patients who had been treated postoperatively with nitrous 
oxide for about one day (190). This complication apparently was already a 
problem for some time (221). Searching for an explanation, these authors 
not only recovered the early reports on nitrous oxide in the treatment of 
tetanus, but also the chemical observations on nitrous oxide and cobalamin. 
With their recognition of the relation between these findings, this example 
of poor interdisciplinary communication had finally ended. Amess and 
coworkers used the deoxyuridine suppression test to demonstrate the similar-
ity between nitrous oxide exposure and cobalamin deficiency, and suggested 
that the cobalamin-dependent enzyme methionine synthetase was inactivated 
by nitrous oxide. This report was shortly afterwards followed by a confir-
mation by Deacon et al. (191), and became the start of extensive studies on 
the metabolic effects of nitrous oxide, which will now be summarized. 
With respect to the theory on the function of cobalamin in hematopoiesis, 
the research on nitrous oxide has produced important results, which have 
already been mentioned in the discussion of the methylfolate trap hypothesis 
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(1.1.3). 
First, it should be noted that in contrast to the large number of medical 
and biological studies that recently have appeared after the recognition of 
the nitrous oxide-cobalamin interaction, no further observations have been 
reported on the chemical basis of this effect. Perhaps, this is attributable to 
the cleft still existing between workers on the biological aspects of cobala-
min, and those interested in its chemistry. Not much has been added to the 
earlier reports (218,220), which demonstrated that nitrous oxide, under con-
ditions that are present intracellularly, oxidizes cob(I)alamin to 
cob(II)alamin. In view of the knowledge on the enzyme methionine synthe-
tase, as reviewed by Taylor (33), it is to be expected that the oxidation of 
cob(I)alamin results in a loss of its coenzyme function and, hence, in the 
inactivation of the enzyme. In the mechanism of its reaction, the mono-
valent cobalt-ion appears to be indispensable (222,223). However, more 
detailed information on this effect would be useful to its biomedical applica-
tion, and to the development of other cobalamin antagonists. 
To discuss the studies on the nitrous oxide effect on cobalamin in a log-
ical order, they are to be divided in the different aspects of cobalamin-
dependent metabolism. 
1: Effects on methionine synthetase are unequivocal, as all studies in 
which this fundamental aspect of cobalamin antagonism was investigated 
demonstrated the inactivation of this enzyme by nitrous oxide. Deacon et 
al. ( 191, 192) first demonstrated its reduced activity in liver cells of rats 
exposed to nitrous oxide; subsequently this was confirmed in cells from 
mouse liver (224), rat liver (97,134,225-230), brain (226) and testis (231), 
rat embryonic tissue (229,230), sheep liver, heart and brain (232), fruit bat 
liver (233), human liver (234), in cultured human lymphocytes (235), and 
also in human bone marrow cells (236). Several conclusions can be drawn 
from these studies: 
the inhibition of methionine synthetase by nitrous oxide is nearly maxi-
mal within a few hours; in most studies 4 to 6 hours exposure was used 
to study the metabolic effects of nitrous oxide. Nevertheless, in some 
studies it was shown that prolonged exposure may lead to a further 
decrease in activity of the enzyme (225,233). 
the inhibition is virtually complete, as in most studies a residual activity 
of 10% or less of control values was found. 
no recovery of enzyme activity takes place during exposure to nitrous 
oxide, as is evident from studies with exposure of up to 33 days (225) or 
even 14 weeks (233). 
cessation of exposure is followed by a slow recovery of methionine syn-
thetase activity, which does not reach control values until 3 to 4 days 
after exposure in most studies. In general, nitrous oxide was used in a 
concentration of 50%, mixed with 50% oxygen. Because this oxygen 
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concentration is higher than atmospheric, it could be argued that 
methionine synthetase is inactivated by the increased oxygen pressure. 
This was ruled out by a study (237) demonstrating that even prolonged 
exposure to hyperbaric oxygen did not affect methionine synthetase 
activity. 
The absence of an effect of nitrous oxide on the other cobalamin-
dependent enzyme, methylmalonylCoA mutase, is demonstrated by the lack 
of increased excretion of methylmalonic acid in urine (191). In one study, 
the activity of this enzyme was directly determined (225), and was found to 
be decreased after a rather extreme exposure to nitrous oxide of 16 days. 
This effect may be ascribed to a general intracellular depletion of cobalamin 
that occurs on chronic exposure to nitrous oxide, as oxidized cobalamin is 
rapidly lost from the cell, probably after the formation of cobalamin analo-
gues (238). A recent study found no significant change in methylmalonyl-
CoA mutase activity after multiple short exposures of 2 hours per day (232). 
The absence of a direct effect of nitrous oxide on the mutase enzyme may 
be related to its different mechanism, in which the oxidation state of the 
adenosylcobalamin coenzyme is not as essential as it is in the methylcobala-
min coenzyme of methionine synthetase. A study in which the levels of 
individual cobalamin coenzymes were determined (239) confirmed that, at 
least initially, only the intracellular level of methylcobalamin became 
decreased on exposure to nitrous oxide. 
2: Effects on cobalamin levels in tissue and plasma consist of a gradual 
decrease during exposure to nitrous oxide. This has been demonstrated in 
fruit bats (154), and in rats in two studies (225,238), in which in addition 
evidence was found that after oxidation by nitrous oxide analogues of coba-
lamin were formed, which were rapidly excreted. In another study a selec-
tive decrease of methylcobalamin was found in lymphocytes after nitrous 
oxide exposure (239), but in general not much work has been done on this 
subject. 
3: Effects on folate metabolism have been studied extensively, mainly in 
rats, and in general appeared to confirm the methylfolate trap hypothesis. 
The intracellular folate levels are reduced by exposure to nitrous oxide 
( 108,131 ,240). There is a decrease in net uptake of 5-methyl-THF in liver 
cells (97), and, consequently, an increase in plasma concentrations of folate 
(241 ,242). This in tum leads to an increased urinary loss of folates (243). 
Although the total intracellular folate content is reduced, there is a relative 
increase in the amount of 5-methyl-THF (107,108,240,244), which is in sup-
port of methylfolate trapping. As discussed, the impaired cellular retention 
of folates is explainable by a failure of folylpolyglutamate synthesis. This 
has also been demonstrated in nitrous oxide-treated rats ( 47,109,133, 
240,245). 
In a well-documented study (240), Lumb et al. recently showed that in 
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rat liver the ratio of 5-methyl-THF to non-methyl-THF was increased from 
0.76 to 3.60 (or, expressed in percentages, 5-methyl-THF increased from 
43% to 78%), after 10 days of exposure to nitrous oxide. Furthermore, they 
showed that the methylgroup of 5-methyl-THF was not separated from the 
THF-moiety in the first 3 days of exposure, while in non-exposed control 
rats this occurred very rapidly. After 3 days, there was some demethylation 
of 5-methyl-THF, although extremely slow as compared to the normal rate. 
They also found evidence that with longer duration there was some folylpo-
lyglutamate synthesis with 5-methyl-THF as a substrate. The mechanism of 
this potential adaptation is not clear, and its significance is uncertain, as 
folate levels continued to decrease until 10 days. In control rats, 5-methyl-
THF was not used to synthesize polyglutamates. 
Recovery of tissue folates after a period of nitrous oxide exposure has 
also been studied by Lumb et al. (246). It appeared that rat liver folate lev-
els returned to control values in about 5 days after exposure, provided that 
the diet contained adequate amounts of folate. This demonstrates that there 
is indeed a loss of folate from the body, rather than a simple redistribution 
of folates. 
It is to be expected that this disturbance of folate metabolism has con-
siderable effects on the various folate-dependent biochemical processes. 
Several of these have been studied during nitrous oxide-induced inactivation 
of cobalamin: 
the oxidation of formate is an important process in toxicology, being 
responsible for the elimination of formic acid, which accumulates in 
methanol poisoning. This reaction is dependent on the availability of 
THF as a cofactor for formyl-THF synthetase. The subsequent action of 
formyl-THF dehydrogenase oxidizes formate to C02, releasing THF 
again. Rats are normally not susceptible to methanol poisoning. Only 
in primates the rate of formate oxidation is too slow to prevent metabolic 
acidosis in this situation. Eells et al. have shown that with exposure to 
nitrous oxide rats will also develop metabolic acidosis on administration 
of methanol (244), and that in monkeys the toxicity of methanol is con-
siderably enhanced by nitrous oxide (247). It was further demonstrated 
that the decreased oxidation of formate correlated with the reduction of 
intracellular THF levels ( 132,227). The metabolism of other substances 
which lead to the formation of formic acid may also be affected (248). 
In primates, the capacity of this folate-dependent pathway is apparently 
limited, but it is not known whether this also relates to their unique sus-
ceptibility to develop megaloblastic anemia. 
the degradation of histidine is another folate-dependent catabolic path-
way. A part of the imidazole ring of histidine is transferred to THF, the 
resulting 5-formimino-THF is converted into 5, 10-methenyl-THF, and 
eventually via formyl-THF, to C02 and THF again. The excretion of 
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formiminoglutamic acid (FiGlu) is a sensitive marker of impairment of 
this pathway. Accordingly, in nitrous oxide-treated rats ( 134) and sheep 
(232) the excretion of FiGlu in urine was markedly increased, while the 
rate of histidine oxidation was substantially reduced ( 132). 
the synthesis of nucleotides: impairment of the folate-dependent steps 
in nucleotide synthesis directly affects cellular proliferation. In view of 
the special importance of this effect, it will be discussed separately. 
4: Effects on methionine metabolism are as would be expected with the 
inhibition of methionine synthesis: methionine levels are reduced, both in 
plasma (232,242,249,250) and cells (226). In addition, the intracellular con-
centration of S-adenosylmethionine (SAM) is lowered by nitrous oxide treat-
ment (132,226,251). There is some recovery of intracellular methionine in 
rat liver after 6 days of exposure (226), possibly due to the induction of 
another pathway converting homocysteine into methionine, through the reac-
tion catalyzed by betaine-homocysteine methyltransferase. Nevertheless, 
SAM levels continue to fall with exposure of up to 11 days. 
The functional significance of methionine and SAM levels with regard 
to folate metabolism, which has already been discussed, was also established 
in experiments with nitrous oxide. The addition of methionine or SAM 
restored histidine degradation ( 132, 134), formate oxidation ( 132,247), folate 
retention ( 131), folylpolyglutamate synthesis ( 133) and purine synthesis 
(252). Methionine can also correct the nitrous oxide effect on the deoxyuri-
dine suppression test ( 152), but at higher concentrations it causes further 
disturbance (236). This discrepancy was recently discussed by the authors 
of these articles (253), and has also been dealt with in 1.1.4. (Figure 1.5). 
It has also been discussed that a disturbance of SAM-mediated methylation 
reactions is implicated in the neurological effects of chronic nitrous oxide 
exposure (130,153,154). Interestingly, the conversion of methionine to 
SAM, catalyzed by methionine adenosyltransferase, appeared to be more 
active during nitrous oxide exposure (251). 
It would be expected that decreased activity of methionine synthetase 
not only leads to a low level of methionine, but also to increased homocys-
tine excretion. This was not the case in patients after nitrous oxide 
anesthesia (254), but it was in sheep (232), and in rats homocysteine in 
serum was found to be increased ( 181) . 
Although it has been found that protein and immunoglobulin synthesis 
by lymphocytes is decreased in cobalamin deficiency (255), there is no evi-
dence that protein synthesis is affected by the reduced levels of methionine 
on nitrous oxide exposure. However, this apparently has not yet been inves-
tigated in detail. 
Another metabolic process dependent on methionine and SAM supply is 
the synthesis of the polyamines spermidine and spermine. Although these 
compounds are specifically related to cell proliferation, no clear evidence of 
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their involvement in the effects of nitrous oxide or cobalamin deficiency has 
been established. In chapter 7, this will be discussed in more detail. 
5: Effects on the synthesis of nucleotides, which are fundamental to the 
influence of nitrous oxide on cellular proliferation, are a consequence of the 
effects on folate metabolism described above. Folate coenzymes are 
involved in purine synthesis and in the conversion of deoxyuridylate to thy-
midylate. Purine synthesis appears to be impaired by exposure to nitrous 
oxide in rats (252,256,257) and in human lymphoid cells (235). The signifi-
cance of these changes in purine metabolism has not been firmly established 
at present, while much more is known on the impairment of thymidylate 
synthesis by nitrous oxide exposure. The folate-dependent methylation of 
deoxyuridylate is the last step in the de novo synthesis of thymidine, which 
is essential in DNA synthesis only. Usually, the deoxyuridine (dU) 
suppression test is applied in the evaluation of this pathway. This test is 
clearly disturbed in bone marrow cells of man and animals after nitrous 
oxide exposure ( 148,152, 190,228,236,242,258-260). The dU suppression 
test can also be used to study the effect of various additives on the synthesis 
of thymidylate, as has been done in cells from cobalamin or folate deficient 
patients. In these experiments, nitrous oxide-treated cells appeared to be 
fully comparable to cobalamin-deficient cells. The results, therefore, are as 
discussed before (in 1.1.3): incomplete correction by cobalamin addition, 
and complete correction by reduced folates, but not by 5-methyl-THF 
(242,258). As described in 1.1.5, in studies of Chanarin's group on rats, 
THF did not correct the test results (148), but in one, more recent study of 
this group on human marrow cells (242), only 5-methyl-THF failed to pro-
duce correction. The results obtained with the nitrous oxide model are 
therefore, in this respect as well, in support of the methylfolate trap 
hypothesis. In a recent study in fruit bats, the dU suppression test was not 
disturbed by nitrous oxide, although methionine synthetase activity was 
reduced (233). Although fruit bats are extremely sensitive to the neurologi-
cal effects of cobalamin deficiency, they may be rather resistant towards the 
effects on folate metabolism. 
6: The effects on cellular proliferation are a logical consequence of the 
impairment of nucleotide synthesis. The bone marrow depression in 
patients after prolonged nitrous oxide anesthesia obviously is the result of 
reduced cellular proliferation. This effect was analyzed in detail by Skacel 
et al. (242), who emphasized the morphological and biochemical similari-
ties with classical cobalamin deficiency. The growth of several hemato-
poietic cell lines was shown to be inhibited by nitrous oxide exposure, with 
disturbance of the dU suppression test (261). The nature of the inhibition 
of proliferation was analyzed in a study employing DNA flow cytometry 
(262). It was found that in marrow cells of patients treated with nitrous 
oxide for 1 day, there was a significant increase of cells in the early S-phase 
of the cell cycle, and a decrease in the late S, G
2 
and M phases. This is in 
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agreement with the presumed impairment of DNA synthesis as the mechan-
ism of the effects on cellular proliferation. 
7: Clinical effects of the nitrous oxide-cobalamin interaction are of con-
siderable interest, in view of the widespread application of nitrous oxide in 
anesthesia, and the potentially serious consequences of its toxicity. The 
manifestations of this interaction, as mentioned above, can lead to unwanted 
side-effects of the use of nitrous oxide. Fortunately, the duration of ordi-
nary anesthesia is too short to give rise to serious hematological toxicity. It 
appears, however, that in some situations the interaction of nitrous oxide 
and cobalamin may lead to clinical manifestations. It has been reported that 
in seriously ill patients, who needed intensive care after surgery under 
nitrous oxide anesthesia, there was a more severe disturbance, and a slower 
recovery, of the dU suppression test compared to other patients, after opera-
tions of equal duration (263). Furthermore, the occurrence of a megaloblas-
tic bone marrow change in some of these patients correlated with a very 
high mortality. It has also been argued that repeated exposure to nitrous 
oxide in a short period may more rapidly induce megaloblastic hemato-
poiesis (264). Another problem may be the existence of unrecognized coba-
lamin or folate deficiency in some patients, because it has been shown in 
rats that the deleterious effect of cobalamin deficiency is enhanced by 
nitrous oxide exposure (265). It was recently reported that this can result in 
the precipitation of neurologic disease in patients (266). The interaction of 
nitrous oxide with folate antagonists is also a potential problem (267), as 
this may lead to a synergistic effect on folate metabolism (236). There is 
one report of unexpectedly severe toxicity of adjuvant chemotherapy includ-
ing methotrexate, which had been started immediately after surgery for 
breast cancer (268). The authors attributed this effect to a potentiation of 
the effects of methotrexate by nitrous oxide. 
A judgement on the acceptability of these risks is obviously extremely 
difficult, considering the advantages of nitrous oxide, and the toxic effects 
of alternative anesthetics. It should be noted that it is possible to avoid the 
hematological toxicity simply by the administration of folinic acid 
(257 ,269 ,270). Measurement of serum cobalamin and folic acid, and 
awareness of the existence of this interaction, are necessary to be able to 
recognize the probably rare patient, who should be protected against the 
consequences of cobalamin inactivation. 
1.4. Scope of this thesis. 
The subject of this thesis is the investigation of the role of cobalamin in 
leukemic cell proliferation. This has been studied by the application of the 
nitrous oxide-induced inactivation of the cobalamin coenzyme function in 
methionine synthetase. In most of the studies, the well-characterized 
34 
myeloid leukemia of BN rats (BNML) has been employed as a model for 
human leukemia. In some studies leukemic bone marrow cells from 
patients have been used. The intention of the studies was to provide 
answers to the following questions: 
does inactivation of the cobalamin coenzyme function by nitrous oxide 
result in reduced growth of leukemia in vivo? (chapter 3); 
are there accompanying metabolic effects, on the deoxyuridine suppres-
sion test, and on plasma cobalamin and folate levels? (chapter 3); 
is it possible to apply the inactivation of cobalamin in combination 
chemotherapy with agents active in related pathways, to achieve syn-
ergistic effects? This can be expected with combinations involving: 
1. inhibitors of the synthesis of S-adenosylmethionine (SAM), in view 
of the effects of SAM on folate metabolism, discussed in 1.1.4. 
(chapter 4); 
2. folate antagonists, because cobalamin inactivation has been shown to 
disturb folate metabolism and to cause folate depletion (chapter 5); 
3. inhibitors of thymidylate synthetase, because cobalamin inactivation 
will impair folate-dependent thymidylate synthesis (chapter 6); 
4. inhibitors of the decarboxylation of SAM, which cause impairment of 
polyamine synthesis; their action could be enhanced by a reduction 
of SAM synthesis as occurs with cobalamin inactivation (chapter 7); 
Appropriate metabolic studies are essential in the evaluation of all 
these combinations, along with the effects on leukemic growth. 
can the effects of cobalamin inactivation by nitrous oxide, alone or in 
combination with other agents, be reproduced in human leukemic cells, 
as an essential step towards the application of this approach in clinical 
chemotherapy (chapter 8)? 
The results of these studies may lead to a tentative conclusion with 
regard to the perspectives of cobalamin inactivation in antileukemic 
chemotherapy. Prior to the presentation of these studies in chapters 3 to 8, 
some essential experimental methods are described in chapter 2. This 
involves the BN rat leukemia model, the exposure of rats to nitrous oxide, 
and the deoxyuridine suppression test. 
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Chapter two 
GENERAL 
EXPERIMENTAL PROCEDURES 
2.1. The Brown Norway Myeloid Leukemia. 
In most studies presented in this thesis, the Brown Norway Myeloid 
Leukemia (BNML) has been used as a model for human myeloid leukemia. 
This leukemia, which is transplantable in BN rats, is well characterized and 
its properties appear to be very suitable for experimental chemotherapeutic 
studies. Typical advantages of the BN leukemia are: its slow growth rate, 
leading to the gradual suppression of normal hematopoiesis by bone marrow 
infiltration, and to the development of hepatosplenomegaly, quite similar to 
the pattern observed in human acute myeloid leukemia; its response to 
chemotherapy, which is very well comparable to human AML; the exact 
reproducibility of its growth chararacteristics, which facilitates the applica-
tion of this model. 
Origin of the BNML. This rat leukemia model has been developed at the 
Radiobiological Institute TNO, Rijswijk, The Netherlands, by Hagenbeek 
and Van Bekkum. The leukemia was induced in a female BN rat in 1971, 
by injections of 9,10-dimethyl-1,2-benzanthracene, 100 days earlier. It was 
introduced in 1977 (1-3). Although the leukemia can be maintained by con-
tinuous in vivo passages, this procedure has the great risk of changing 
growth properties. Therefore, it is preferable to minimize in vivo transfer 
by using cells from a large cryopreserved stock. The studies presented in 
this thesis were all c~rried out with cells from the same stock, which was 
built up after a single passage in vivo of an initial sample that was kindly 
provided by dr A. Hagenbeek. 
Characteristics of the BNML. The BN rat leukemia has morphologically and 
cytochemically been classified as an acute promyelocytic leukemia. The 
cells are large, 10-18 /Lm in diameter, and of irregular shape. Their large 
oval nucleus has a coarse chromatin pattern with a nucleolus. With May-
Grunwald-Giemsa staining, cytoplasmic granules are not observed as clearly 
as in human promyelocytes, and Auer rods are not present, but the cyto-
chemistry is almost identical. Peroxidase and Sudan black are strongly posi-
tive. The survival time of leukemic rats is strictly dependent on the number 
of the injected leukemic cells. With 107 cells, often used as a standard 
dose, rats invariably die between 20 and 24 days. A tenfold increase, or 
decrease, of this dose shortens, or prolongs, survival with 3 days. This 
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rather precise exponential dose-survival relationship can be applied in 
chemotherapeutic studies to calculate the proportional cell kill in various 
treatment groups. The growth pattern of this leukemia has been described 
in considerable detail (2-6). It has been shown that various organs are infil-
trated by the leukemic cells, notably bone marrow, liver and spleen, but also 
lungs and kidneys. The increase in spleen weight is particularly impressive: 
in terminally leukemic rats this organ can be enlarged tenfold to 4-5 g. Nor-
mal hematopoiesis gradually disappears (7, 8). The cause of death in 
leukemic rats usually is bleeding, due to severe thrombocytopenia, but 
infection may also occur. In our studies, splenic rupture was a rare, but 
occasionally observed cause of premature death in rats older than about 16 
weeks. 
Evaluation of treatment results. The effects of chemotherapy on this rat 
leukemia can be evaluated by comparing several of the characteristics of this 
disease between treatment groups. In Table 2.1, some of the techniques 
used for that purpose are listed. Most simple is the study of survival times. 
A disadvantage of this method is that it precludes metabolic or hematologic 
studies on the rats. Moreover, it generally requires large numbers of rats to 
demonstrate a difference in tumor reduction of less than tenfold, which still 
can be relevant in experimental chemotherapy. Furthermore, the extent of 
supportive care provided to the leukemic animals has a great influence on 
the results. Advanced supportive care, like blood transfusions, can make 
the model more realistic, and may also lead to more pronounced effects of 
treatment (9), but this approach is experimentally cumbersome. With most 
other methods, the duration of the disease is limited to a fixed period, usu-
ally chosen as long as possible, that is: until the untreated controls would 
die of the disease. This approach has the additional advantage of avoiding 
the terminal suffering of rats in all groups. 
Table 2.1 
EVALUATION OF TREATMENT IN THE BN RAT LEUKEMIA 
1. Survival of rats (with or without hematological supportive care) 
2. Bio-assay of leukemic clonogenic cells in bone marrow 
(LCFU-s) 
3. Leukemic infiltration of organs: liver, spleen 
4. Hematological determinations in blood and bone marrow 
5. Depression of normal hematopoiesis in vivo (CFU-s) or in vitro 
(CFU-GM, CFU-E, BFU-E) 
One of these methods is the quantification of leukemic clonogenic cells 
in a bio-assay (LCFU-s). Bone marrow contents of leukemic rats, either or 
not treated, are injected into normal BN rats. On the surface of the spleen 
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of these rats, leukemic colonies will appear after about 19 days, and can be 
counted. This is only possible within a narrow range of the injected number 
of cells. With more than 5 x 104 cells, individual colonies become confluent 
(9). The assay also has a rather large standard deviation. Although the tech-
nique has a specific advantage in measuring only those leukemic cells that 
are able to resume proliferation, its narrow range, and the large number of 
animals required, severely limit its application. 
The leukemic infiltration of organs, in particular of liver and spleen can 
be determined simply, because the weight of these organs is a direct meas-
ure of their infiltration. Spleen weight can increase about tenfold, and liver 
weight about threefold, in untreated BNML rats. This excessive splenome-
galy of leukemic rats is the reason that spleen weight is a sensitive parameter 
of leukemic growth, applicable in a wide range of tumor load. The determi-
nation of organ weights can be combined with studies of survival, by autop-
sies of rats dying spontaneously, but this appeared to be unreliable in some 
of our studies. It is likely that in terminally ill rats the infiltration of liver 
and spleen does not increase further, and may even decrease substantially, 
as is the case with their total body weight. Therefore, organ weights should 
be determined before rats tend to die spontaneously. 
Hematological parameters are essential in the evaluation of leukemia. 
The total peripheral leukocyte count is a simple and sensitive technique, 
showing a gradual increase in the course of this leukemia. The BNML does 
not give rise to excessively high leukocyte counts, except sometimes in ter-
minally ill rats. In normal rats, the leukocyte count is 3-4 x 109/1, and in 
leukemic rats this may rise to about 30 x 109/1. The differential counts 
demonstrate that the increase of leukocytes indeed is due to the appearance 
of leukemic cells (promyelocytes) in the blood. It appears that there is also 
an increase in the absolute number of normal lymphocytes in the leukemic 
rats. Differential counts of bone marrow cells provide additional informa-
tion only in the case of nearly complete remissions. Other hematological 
determinations have a limited significance in the evaluation of treatment: 
erythrocyte and hemoglobin values fall slowly during the disease (except in 
the case of bleeding), and thrombocytes are nearly always low. Finally, by 
measuring directly the residual normal hematopoiesis in vivo or in vitro, the 
destructive influence of leukemic growth can be demonstrated. Counting 
the hematopoietic colonies on the spleen of irradiated mice (CFU-s) after 
the injection of a bone marrow sample is a well-established technique. In 
bone marrow cultures, colonies of several hematopoietic precursors can be 
counted (CFU-GM: granulocytes/macrophages, CFU-E and BFU-E: colony 
and burst forming units, consisting of erythroid precursors). In general, 
depression of normal hematopoiesis will be less severe with effective treat-
ment, although the therapy is usually also toxic to the bone marrow. 
In the studies presented in this thesis, leukemic growth has been 
evaluated by the determination of spleen and liver weights, by total and 
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differential leukocyte counts, and occasionally by survival studies, without 
supportive care. In addition, it was found that the plasma level of cobala-
min gradually increased in the course of the leukemia. This may be com-
parable to the frequent occurrence of increased cobalamin levels in human 
acute promyelocytic leukemia ( 10). As will be discussed in the following 
chapters, this finding has made possible the use of plasma or serum cobala-
min levels as an additional parameter of leukemic growth. 
Relevance of this leukemia as a model for human AML. It has already been 
described that several characteristics of the BNML model are well in agree-
ment with human AML This relates to the cytology, which is very similar 
to the human AML subtype M3, the growth pattern and symptoms of the 
disease, notably the gradual suppression of normal hematopoiesis, and 
finally, its similar sensitivity to chemotherapy. This latter point has been 
substantiated by a large number of studies since the introduction of this 
leukemia (9,10-15), in which the response to chemotherapy of this rat 
leukemia appeared to be largely comparable to human AML. It has also 
been shown that its sensitivity is very different from human ALL (9). 
Thus, the BNML model may indeed be considered a releVant model with 
regard to experimental chemotherapy of AML. 
Finally, some further technical details concerning the use of this model 
will be described. 
Animals. Rats of the Brown Norway inbred strain were used, obtained from 
REPGO-TNO in Rijswijk, or CPB-TNO, Zeist, The Netherlands, who 
deliver the same strain of rats. Only male rats were used, at the age of 12 to 
16 weeks (body weight 200-275 g). In all studies, the rats received standard 
food pellets and water ad libitum. 
Transfer of leukemia. Leukemia may be transferred to rats, either by using 
cells from the frozen stock, or by preparing a cell suspension directly from 
the spleen of a leukemic rat (Figure 2.1). Rats injected with thawed cells 
were not used in experiments, however, because of rather large variations in 
growth kinetics, probably due to varying damage by freezing and thawing. 
The spleen of these rats is used exclusively to transfer leukemia to the 
experimental series. This serial transplantation was subsequently limited to 
one further generation only, to avoid a gradual change in growth properties. 
Consequently, after two experimental series, spleen cells were again 
obtained from a rat freshly inoculated with cells of the frozen stock. A 
monocellular suspension of leukemic spleen cells was prepared by cutting 
the organ into small pieces and gently pressing these fragments through a 
fine (50 J.!.m) nylon gauze, while rinsing with Hanks' balanced salt solution 
(HBSS). The cells were washed with HBSS once before use. Cells frozen 
in 10% dimethylsulfoxide and 20% fetal calf serum were kept in liquid 
nitrogen. Before use, ampoules were rapidly thawed in a water bath of 37 
°C, slowly diluted stepwise in about 30 min, and washed in HBSS. 
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frozen cells\ ./ =~~~eenn~i~~ 'io0 ~ \ 
~ 5:J 
standard dose ~ukemic spleen 
1·1 07 cells weight 3-5 g 
leads to death (normal: ± 0. 5 g) 
in 20-24 days 
Figure 2.1. Transfer of leukemic cells in the BN myeloid leukemia is possible either by 
using cells from a large frozen stock, or by direct transplantation of spleen cells from 
fully leukemic animals. The latter procedure is used in the experimental series, but is 
limited to only two serial transplantations, to prevent a gradual change in growth proper-
ties. 
Viability of the cells, checked by eosin uptake, had to be less than 50%. 
Leukemic cell suspensions were counted electronically and 10 7 cells were 
injected intravenously in rats under ether anesthesia. 
2.2. Exposure of rats to nitrous oxide. 
The investigation of the effects of nitrous oxide-induced inactivation of 
cobalamin usually requires exposure to this gas of more than about one day. 
As discussed in the former chapter, biochemical evidence of this effect can 
be found already after a few hours of exposure, but it is important to realize 
that the severe disturbance of folate metabolism, with subsequent depletion 
of cellular folates develops only gradually. If it is the objective of a study to 
examine the effects of this disturbance on the growth of a malignant tumor, 
it is likely that even longer periods of exposure will be necessary, to find a 
measurable degree of growth inhibition. This is indeed the case in the stu-
dies presented in this thesis, and for that reason an exposure system has 
been developed that allows such prolonged exposure of leukemic rats to 
nitrous oxide, for periods of one week or slightly longer. 
Chronic exposure of rats to an atmosphere containing about 50% nitrous 
oxide is surprisingly simple, as this has no appreciable effects on the cons-
ciousness of the animals. This means that exposure, after an adaptation 
period to the system of a few days, does not affect the nutritional condition 
of the rats. In the present studies, body weight of the rats did not change 
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significantly by exposure of more than one week. Parbrook ( 15) has inves-
tigated the effects of nitrous oxide exposure on food consumption and 
weight of several experimental animals, and demonstrated that rats were the 
least sensitive of the species tested. He also described an effective exposure 
system, including a cleaning circuit in which the atmosphere of the cage is 
recirculated. This circuit provides for humidity and temperature control by 
cooling, carbon dioxide absorption by soda lime and absorption of contam-
inating volatile compounds by activated charcoal. A similar recirculating 
system was described by Rupreht and Dzoljic ( 17). The system used in the 
studies of this thesis is based on the same principles, as is shown in Figure 
2.2. The main advantage of a recirculating system is that a stable atmo-
sphere can be maintained without an excessive flow of fresh gases. The 
V = 40 I 
Hp 
absorption 
CO 2 activated 
absorption charcoal 
Figure 2.2. Exposure system, designed to allow prolonged exposure of leukemic rats to 
a mixture of nitrous oxide (N 
2 
0) and oxygen ( 0 
2
) . 
flow is regulated by rotameters, which are calibrated with an oxygen 
analyzer only, because no effective method is available for the continous 
monitoring of nitrous oxide. As in most studies, an atmosphere of 50% 
nitrous oxide with 50% oxygen was chosen. This allows the use of a rela-
tively simple two cylinder system, and minimizes the risk of hypoxia. It 
also means that the partial pressure of oxygen is increased, compared to air. 
It has been shown, however, that no effect is observed even from hyperbaric 
oxygen on the cobalamin-dependent methionine synthetase ( 18). Moreover, 
oxygen transport in the circulation is hardly influenced by this increase in 
partial pressure, because hemoglobin is already saturated at normal atmos-
pheric pressure. Rats can be maintained in this system without any interrup-
tion as long as in normal cages in air, that is for 3 or 4 days if necessary. 
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The continuous flow of fresh gases, in the volume of about 40 1, can be as 
low as 500 ml/min for the mixture of the two gases, except for the first few 
hours, when 1000-1500 ml!min was blown in. Rats not exposed to nitrous 
oxide, in the same experiment, were kept in ambient air, but otherwise 
treated identically as much as possible. 
2.3. The deoxyuridine suppression test. 
The deoxyuridine ( dU) suppression test is designed to demonstrate a failure 
of the de novo synthesis of thymidylate, as occurs in cobalamin or folate 
deficiencies. The principles of this test are essentially simple, and were first 
described by Killmann in 1964 ( 19). The cells to be investigated, usually 
bone marrow cells, are first incubated with dU, and after a few hours 
labelled thymidine is added. 
The incorporation of eH]-thymidine into DNA in these cells is then com-
pared with the incorporation in the same cells, which were not incubated 
with dU. In normal cells, it appears that dU considerably suppresses this 
incorporation of [3H]-thymidine. This is explained by the conversion of dU, 
after its phosphorylation to deoxyuridylate (dUMP), to thymidylate by the 
enzyme thymidylate synthetase. An increase in thymidine nucleotides will 
then dilute the labelled exogenous thymidine, and suppress its metabolism 
through the salvage pathway. The activity of thymidylate synthetase is, as 
described previously, dependent on its folate coenzyme, 5, 10-methylene-
THF. In the case of cobalamin or folate deficiency the activity of this 
enzyme will be impaired, and consequently, there will be much less 
suppression of eH]-thymidine incorporation by dU. In Figure 2.3, the path-
ways relevant to this test are shown. 
Metz et al. (20) started to use this test in metabolic studies of cobalamin 
and folate deficient cells, and ever since this test has played an essential role 
in this field. Although the test is mainly used in research of cobalamin and 
folate metabolism, it has also been applied clinically as a diagnostic aid in 
the evaluation of megaloblastic anemia (21). In a recent report, it was sug-
gested that the dU suppression test could uncover subtle cobalamin defi-
ciency, prior to the development of anemia (22). A particular advantage of 
the test is the possibility to study the effects of different additions to the 
incubations, which can clarify the nature of a metabolic disturbance. It has 
been described (1.1.3) that in cobalamin deficiency, 5-methyl-THF cannot 
correct the abnormal test results, in contrast to folate deficiency. On the 
other hand, cobalamin addition (partially) corrects the test in cobalamin 
deficiency, and is completely ineffective in folate deficiency. These and 
similar observations have been essential in the study of cobalamin and folate 
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DEOXYURIDINE SUPPRESSION TEST 
deoxyuridine 3 H-thymidine 
"de novo" 
dUMP------------+ dTMP 
5, 10-methylene-THF DHF 
~ 
~ 
DNA 
"salvage" 
Figure 2.3. The deoxyuridine suppression test measures the effect of deoxyuridine addi-
tion on the incorporation of labelled eH]-thymidine in DNA. There will be a significant 
suppression of this incorporation if dUMP is converted into dTMP by the folate-
dependent enzyme thymidylate synthetase. There is much less suppression if folate 
metabolism is disturbed, as is the case in deficiency of either cobalamin or folate. 
deficiencies, and also in the study of cobalamin antagonists, since the intro-
duction of nitrous oxide. It is noteworthy, that these are not the only causes 
of a disturbed dU suppression test. Several cytostatic drugs, notably 5-
fluorouracil, which directly inhibits thymidylate synthetase, and methotrex-
ate, will cause abnormal test values (21). Therefore, the dU suppression 
test has also been applied in studies of combinations involving these drugs 
(23). Although the usefulness of this test is clearly beyond doubt, some of 
its principles have been challenged in recent years. It has been shown that 
there are other factors that influence [3H]-thymidine incorporation in this 
test, apart from the rate of conversion of dUMP to dTMP (24,25). These 
include the inhibition of thymidine uptake and thymidine kinase in the sal-
vage pathway of thymidine synthesis by dUMP, a certain degree of inhibi-
tion of [3H]-thymidine incorporation by other deoxynucleosides than dU, the 
inhibition of incorporation of other labelled nucleotides besides eH]-
thymidine by dU, and the stimulation of the catabolism of dUMP by some 
drugs, notably methotrexate. These mechanisms may be important with 
respect to the specificity of the dU suppression test, which is probably less 
than presumed, but do not interfere with the validity of earlier observations 
in cobalamin and folate deficiencies. Of all factors influencing this test, it 
appears that the efficacy of the de novo synthesis of thymidine is the most 
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important. 
Considerable confusion exists on the technical details of the dU 
suppression test. As described by Wickramasinghe (21), differences are 
found in the literature concerning all aspects of the test: concentrations of 
cells, dU, eH]-thymidine; incubation times; temperature during the incuba-
tions; methods to extract DNA. These variations do not lead to important 
differences in results, but they may explain that the test results generally are 
not quantitatively comparable between studies. A more basic point is the 
need for appropriate controls, if the influence of additions is investigated 
(26), which has not always been recognized. A different approach to the 
test has been described, in which eH]-dU is used instead of labelled thymi-
dine (20,27). A disadvantage of this method is that the effect of correcting 
additives is necessary to demonstrate a disturbance of the test (27 ,28). "Thy-
midine suppression" does not discriminate sufficiently between normal and 
megaloblastic cells. 
The dU suppression test as applied in the studies of this thesis was car-
ried out rather closely according to the original technique described by Metz 
et al.(20). Some modifications will be summarized now, and can also be 
found in the various chapters concerning more specific points. The dU 
suppression test was applied to fresh suspensions of leukemic spleen cells, 
which were washed once in Hanks' balanced salt solution. Incubations were 
performed in triplicate, with about 5 x 106 cells in each tube. dU (Sigma) 
was generally used in a concentration of 0.1 mmol/1, and 0.3 p,Ci of eH]-
thymidine (Amersham, specific activity of 25 Ci/mmol) was used per test. 
Incubations, at 37 °C, lasted for 4 hours (2 hours pre-incubation with or 
without dU, and 2 hours with [3H]-thymidine). DNA was extracted conven-
tionally with cold 1% trichloroacetic acid. 
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Chapter three 
NITROUS OXIDE 
AND GROWTH OF 
RAT LEUKEMIA 
This chapter has been published in Leukemia Research, 8:441-8 (1984), 
titled "Nitrous oxide reduces growth of experimental rat leukemia", by 
A.C.M. Kroes, J. Lindemans, A. Hagenbeek and J. Abels. 
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Abstract. The ability of nitrous oxide to inhibit the in vivo growth of hema-
tological neoplasms was investigated in a rat model for acute myeloid 
leukemia (BNML). Nitrous oxide, administered in a concentration of 67% 
with 33% oxygen, resulted in a reduction of spleen and liver weights of 
approx. 30%, as compared with leukemic rats kept in ambient air. Peri-
pheral white cell counts were also considerable lower in the treated rats. 
Plasma levels of vitamin B 12 were found to be elevated in untreated 
leukemia, but fell to about normal levels after nitrous oxide exposure. On 
the contrary, folic acid levels were low in untreated leukemic rats, and signi-
ficantly higher in animals exposed to nitrous oxide. The observed effects of 
nitrous oxide appeared to be. dose dependent. The deoxyuridine suppres-
sion test performed with leukemic cells became abnormal with nitrous oxide 
inhalation, in accordance with the effect on normal bone marrow. These 
results indicate that the interference of nitrous oxide with vitamin B 12-
related metabolism, which leads to impairment of de novo thymidine syn-
thesis, has the potency to reduce leukemic proliferation in vivo. 
3.1. Introduction. 
The anesthetic gas nitrous oxide (N20) has the side effect of suppressing hematopoiesis. This was first descrioed in 1956, when patients with tetanus 
who were treated with nitrous oxide anesthesia for several days developed 
pancytopenia with megaloblastic changes in the bone marrow ( 1). Subse-
quently it was found that in rats, after prolonged exposure to nitrous oxide, 
there was a marked but reversible leukopenia (2-5), while other hematologi-
cal effects were much less apparent. Preliminary trials utilizing this effect in 
the treatment of human chronic (6) and acute (7) leukemia have resulted in 
regression of leukemia upon prolonged exposure to nitrous oxide, in all four 
instances tried. 
In spite of these remarkable results, further reports on the antileukemic 
effect of nitrous oxide did not appear. 
In 1978, it was discovered that nitrous oxide oxidizes the cobalt-moiety 
of vitamin B12 (8), leading to inactivation of the methylcobalamin-requiring 
enzyme methionine synthetase or 5-methylhydrofolate homocysteine methyl-
transferase (9,10). The resulting impairment of folate-dependent do novo 
synthesis of thymidine will ultimately affect proliferation of fast dividing 
cells, like hematopoietic precursors. In recent years, the effects of nitrous 
oxide on vitamin B 12-related metabolism have been studied extensively. 
These data were recently reviewed ( 11). It appears that nitrous oxide effec-
tively can be used as an anti-cobalamin, inducing a state of functional vita-
min B12-deficiency. The present study was designed to investigate the pos-
sibility of reducing leukemic proliferation by nitrous oxide exposure. A rat 
leukemia model was used: the Brown Norway myelocytic leukemia 
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(BNML). This transplantable leukemia has been described in detail ( 12-
14). Its most important characteristics are the slow net growth rate, the gra-
dual suppression of normal hematopoiesis and the similarity with human 
acute myeloid leukemia in response to chemotherapy, which make it a suit-
able model for experimental treatment of leukemia ( 15). 
3.2. Materials and methods. 
Animals. Male rats of the Brown Norway inbred strain were used, at the age 
of 12-16 weeks (body weight 200-250 g). Food and water were supplied ad 
libitum during the experiments. 
Brown Norway myelocytic leukemia (BNMLJ. Cryopreserved leukemic cells 
were provided by the Radiobiological Institute TNO, Rijswijk, the Nether-
lands, where this transplantable rat leukemia model was developed. Origin, 
classification and proliferation kinetics were described before (12-14). 
For leukemia transfer in experimental series, spleen cells of fully 
leukemic animals were used. 107 cells were suspended in 1 ml of Hanks' 
balanced salt solution and injected i.v .. This standard dose leads to death in 
20-24 days. During this period massive infiltration of spleen liver and bone 
marrow takes place; spleen and liver weights therefore can be used as indi-
cators of tumor load. To avoid a gradual change in growth properties, serial 
transplantations were limited to only two passages in order, after which 
spleen cells were used from animals of a separate series freshly inoculated 
with cells from a cryopreserved stock. 
Exposure to nitrous oxide. Rats were exposed in a flow chamber to a mix-
ture of 67% nitrous oxide and 33% oxygen at a rate of at least 500 ml/min. 
Exposure started 7 or 8 days after inoculation with leukemia cells, and 
lasted until termination of the experiments at 17-19 days after inoculation. 
For each group treated with N20, consisting of 4-6 rats, a miltched control group, inoculated with the same cell suspension, was maintained in ambient 
air during the same period. In one experiment a separate group of four 
leukemic rats was exposed intermittently to nitrous oxide, with change from 
air to nitrous oxide/oxygen atmosphere and reverse every 2 days. In one 
nitrous oxide-treated group, normal (non-leukemic) rats were included. 
Methods of evaluation. Termination of the experiments at 17-19 days after 
inoculation of rats with leukemia is just before their expected death. Rats of 
both exposed and control groups were killed by exsanguination under deep 
ether anesthesia. Liver and spleen weights were recorded. White blood cells 
were counted electronically and routine differential blood cell counts were 
made. In some experiments, cellular contents of bone marrow were deter-
mined by flushing femurs with a constant volume of Hanks' solution and 
electronic counting of the resulting suspension. Plasma vitamin B 12 and 
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folic acid levels were determined simultaneously, essentially as described by 
Gutcho and Mans bach ( 16). Methyltetrahydrofolate was used as a folate 
standard. In one additional experiment, the orbital venous plexus was punc-
tured every 8 days to obtain 0.5 ml of blood, for regular assays of vitamin 
B12 and folic acid. This was done in 14 rats, who at 8 days after inocula-
tion were divided in a treatment and a control group, each of seven rats. 
This experiment was excluded from the studies of organ weights. Normal 
values for organ weights, as shown in the figures, were derived from earlier 
experiments with large series of the same strain of rats ( 14) . 
Deoxyuridine suppression test. This test was done in some experiments to 
evaluate the metabolic inactivation of vitamin B12. It measures the reduc-
tion of eH]-thymidine uptake (salvage pathway) by the addition of deoxy-
uridine, thus stimulating de novo synthesis of thymidine. Decreased reduc-
tion is seen as a result of folate or vitamin B 12 deficiency ( 17), as in this 
experiment, as a result of the inactivation of methylcobalamin ( 18). The 
test was carried out according to Metz (19). Leukemic spleen cells were 
used (ca. 5 x 106 per test). Incubation with deoxyuridine (Sigma Chemical 
Co., St.Louis, Missouri, USA) in various concentrations for 1 h, was fol-
lowed by addition of [3H]-thymidine (ca. 3 JLCi per test, specific activity 25 
Ci/mmol, from Amersham International, UK), and incubation for another 3 
h, after which the incorporation of labelled thymidine in DNA was deter-
mined. This incorporation is expressed as a percentage of the maximum 
incorporation, obtained by omitting deoxyuridine. 
3.3. Results. 
The results of four separate experiments in each of which 10-12 leukemic 
rats were divided in control and treatment groups are shown in Figures 3.1 
and 3.2. Figure 3.1a demonstrates a consistent reduction in spleen weights 
of the nitrous oxide-treated groups, as compared to the control groups 
breathing air. This reduction amounted to 29.4 ± 8.0% (mean ± S.D.), 
after subtraction of a normal average spleen weight of 0.6 g. Included in 
this as well as in other figures is one experiment in which a group of 
leukemic rats (n=4) was exposed intermittently to nitrous oxide; treatment 
periods of 2 days alternated with equal periods in air. In most cases, the 
results are intermediate between untreated and fully treated groups. Figure 
3.1b shows a reduction in liver weight, averaging 32.6 ± 4.1 %, as calcu-
lated after subtraction of a normal liver weight of 8 g. Figure 3.1c indicates 
a considerable decrease in peripheral white cell counts after nitrous oxide 
exposure. The differences in spleen and liver weights, and white cell 
counts, were statistically significant in each experiment, using Wilcoxon's 
non-parametric rank-serum test; p-values were less than 0.05 or 0.01, except 
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Figure 3.1. Effect of nitrous oxide (Np) on (a) spleen weight, (b) liver weight, (c) 
peripheral white cell count. Controls are untreated leukemic rats. Lines connect control 
and treatment groups of the same experiment. Standard errors of the mean are indicat-
ed. Values in comparable normal (non-leukemic) rats are shown. 
for the differences in the experiment with intermittent exposure. 
Results of a differential count of white cells can be found in Table 3.1, 
which demonstrates there is also a relative decrease in leukemic cells after 
nitrous oxide exposure. 
In one experiment, normal (non-leukemic) rats exposed to nitrous oxide 
during the same period showed no hematological abnormalities. 
Plasma levels of vitamin B 12 were found to be raised in untreated 
leukemia and about normal after nitrous oxide exposure (Figure 3.2a). 
Folic acid levels, on the contrary, were decreased in untreated leukemic rats, 
but again about normal, or slightly raised, in treated animals (Figure 3 .2b). 
In order to gain more insight in the development of the changes in vitamin 
B 12 and folic acid levels, a separate experiment was carried out with venous 
puncture at days 0, 8 and 16 after inoculation (Figures 3.3a,b). Nitrous 
oxide apparently reversed the gradual changes observed in the untreated 
leukemic animals. 
In some experiments the, purely leukemic, bone marrow cells were col-
lected from femurs of treated and control groups, and counted. Values 
obtained are (mean ± S.D.) 3.73 ± 0.42 x 107 cells/femur for the nitrous 
oxide-treated animals, and 3.14 ± 0.32 x 107 cells/femur for the controls. 
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The Wilcoxon rank-sum test of the values in these groups did not yield a 
significant difference: p = 0.05. 
Table 3.1 
DIFFERENTIATED BLOOD CELL COUNTS, EXPRESSED AS PERCENTAGES OF THE 
TOTAL NUMBER OF NUCLEATED CELLS, COUNTING .200 CELLS 
Promyelocytes Lymphocytes Neutrophils Eosinophils Monocytes 
(leukemic cells) 
Leukemic rats, 
untreated controls 
(n=6) 55.8±3.7 40.3±3.4 3.8±1.2 0 0 
Leukemic rats, 
N20-treated (n = 5) 41.6±7.0 56.0±7.1 2.3±0.4 0 0 
Normal rats (n = 4) 0 91.0 ± 1.8 5.8±2.0 0.5 2.8±0.3 
Values represent means of each group, with indication of the standard error of the mean 
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Figure 3.2. Effect of nitrous oxide (N 0) on plasma levels of (a) vitamin Bl2 and (b) 
folic acid. Controls are untreated leukemic rats. Lines connect control and treatment 
groups of the same experiment. Standard errors of the mean are indicated. Values in 
comparable normal (non-leukemic) rats are shown. 
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Figure 3.3. Effect of nitrous oxide (N 0) on plasma levels of (a) vitamin B12 and (b) 
folic acid during progression of leukefnia. The rats were inoculated with leukemia at 
day 0. Standard errors of the mean are indicated. 
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Figure 3.4. Effect of nitrous oxide (N
2
0) on deoxyuridine-induced suppression of eH]-
thymidine uptake by leukemic spleen cells. Values are expressed as a percentage of the 
maximum incorporation of eH]-thymidine, obtained by omitting deoxyuridine. Results 
of a nitrous oxide-treated rat (interrupted line) are compared with an untreated control 
(continuous line), at various concentrations of deoxyuridine. 
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A deoxyuridine suppression test was performed in some rats, using 
leukemic spleen cells. Various concentrations of deoxyuridine were used. A 
representative result is shown in Figure 3.4, which confirms the inactivation 
of methylcobalamin in the rats treated with nitrous oxide. 
Finally, total body weight was determined for all treated and untreated 
rats at the termination of each experiment. Body weight of untreated rats 
was 241.7 ± 24.5 g (mean ± S.D.), and of treated rats 232.7 ± 34.6 g, 
demonstrating that long-term exposure to nitrous oxide did not cause a signi-
ficant weight loss. 
3.4. Discussion. 
In recent years information has become available about the metabolic 
changes underlying the hematological effects of nitrous oxide. The possible 
antileukemic application of this anesthetic therefore deserves renewed atten-
tion. Recent in vitro studies (20) have demonstrated a growth inhibition by 
nitrous oxide in several cell lines derived from hematological neoplasms. 
The results of the present study indicate that nitrous oxide also has distinct 
inhibitory properties against leukemic proliferation in vivo. The relative 
decrease in spleen and liver weights in leukemic animals after nitrous oxide 
exposure is evidence of a reduced tumor load. 
The specific effect of nitrous oxide on vitamin B 12 function was veri-
fied by means of the deoxyuridine suppression test, which showed, as 
expected, abnormal values after treatment. The established mechanism of 
methylcobalamin inactivation, resulting in impaired de novo synthesis of 
thymidine, therefore remains a probable explanation of the observed effects, 
rather than less specific and weaker inhibition of mitosis that is known to 
occur with a variety of anesthetics (21). Halothane, for example, did not 
influence experimental leukemia (22), whereas nitrous oxide, in another 
study, differed from halothane in having an inhibitory effect on lymphoma 
cell proliferation (23). 
Exposing animals to nitrous oxide can cause some weight loss due to 
decreased appetite (24). In rats, at the concentrations of nitrous oxide that 
were used in this study, no influence on consciousness is evident, and their 
nutritional condition is not affected. No significant reduction in body 
weight was observed. 
The effects of nitrous oxide appeared to be dose-dependent, as indicated 
by the experiment with intermittent exposure, in accordance with earlier 
findings (5). This means that, at least from this experiment, there is no evi-
dence for adaptation to the effects in the treatment period. 
A recent report, suggesting that nitrous oxide causes impaired move-
ment of leukocytes out of extravascular bone marrow stores into circulation 
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(25), led us to investigate femur cellularity in treated and control groups. 
The small increase in femur cell content, found in the treated group, cannot 
have contributed substantially to the reduction in spleen and liver weights by 
means of a shift to the bone marrow. 
The effects on plasma folate levels are as expected: it has been observed 
in several studies that nitrous oxide-induced inactivation of vitamin B 12 
leads to a decreased cellular uptake of folates, which causes a fall in tissue 
folates (26), and, consequently, a rise in plasma and urinary folates (27-29). 
The observed low folate levels in untreated leukemic rats may be related to 
the increased demands caused by intensive cellular proliferation. The radi-
cal changes in plasma vitamin B 12 however, are not easy to explain. A rise 
in vitamin B12 levels was observed in untreated leukemia. A similar effect 
is well known in human chronic myeloid leukemia (30,31), and also occurs 
in human acute promyelocytic leukemia (31). The BNML rat model is also 
considered to be a promyelocytic leukemia ( 12). In human cases, the rise in 
vitamin B12 levels is explained by release of excessive R-type vitamin B12-
binding protein (transcobalamin I), which, however, is not found in rat 
plasma (32). The reversal of this rise by nitrous oxide seems too drastic to 
be explained just as an aspect of normalization. Inactivation of vitamin B 12 
by nitrous oxide is not known to cause deficiency of this vitamin by affect-
ing plasma levels (8). In human CML, Lassen observed in 1959 a rather 
similar decrease of vitamin B 12 levels during nitrous oxide exposure ( 6). 
The cause of these effects, however, awaits further investigations. 
The result of this study demonstrates that nitrous oxide has a growth 
reducing effect towards the BNML rat leukemia, which has generally proved 
to be a good model for the chemotherapeutic response in human AML 
(13,15). However, humans are more susceptible to deficiency and inactiva-
tion of vitamin B12 than most animals (11,33). The phenomenon of 
megaloblastic anemia, e.g. occurs only in man ( 11,34), and therefore human 
leukemia might show a different, perhaps greater, sensitivity to nitrous 
oxide. It is important to realize that the therapeutic abilities of nitrous 
oxide, albeit probably moderate when used alone, may be exploited more 
fully when combined to other agents. This is supported by the present 
knowledge of the way nitrous oxide influences vitamin B 12 and folate meta-
bolism. A synergistic effect in vitro with agents active in related pathways, 
like methotrexate, has already been reported (35). Further analysis of the 
cytostatic effect of nitrous oxide, alone or in combination, and its relevance 
to the therapy of human leukemia, seems justified. It is worth noting that 
the well-known pain-relieving and sedative effects of this easily administered 
gas might be of additional benefit when used in the treatment of cancer. 

Chapter four 
NITROUS OXIDE 
AND CYCLOLEUCINE 
IN RAT LEUKEMIA 
This chapter has been published in the British Journal of Cancer, 50:793-800 
( 1984), titled "Synergistic growth inhibiting effect of nitrous oxide and 
cycloleucine in experimental rat leukemia", by A.C.M. Kroes, J. Linde-
mans and J. Abels. 
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Abstract. Nitrous oxide (N20) inactivates the vitamin B12-dependent 
enzyme methionine synthetase with subsequent impairment of folate meta-
bolism and a reduction of cellular proliferation. Indications exist that this 
effect is antagonized by S-adenosylmethionine (SAM), and it was investi-
gated whether combination with an inhibitor of SAM synthesis, cycloleu-
cine, would result in increased inhibition of growth in rat leukemia model 
(BNML). Leukemic growth was compared in untreated rats, in rats treated 
with either nitrous oxide/oxygen (1:1) or cycloleucine (50 mg/kg i.p.), and 
in rats receiving both agents. Combined treatment resulted in the strongest 
reduction of leukemic infiltration in spleen and liver, and this reduction 
often was more than the added effects of single treatments. Peripheral leu-
kocyte counts were also lowest after combined treatment. The deoxyuridine 
suppression test, measuring folate-dependent de novo synthesis of thymidine 
was more severely disturbed with combined treatment. Levels of vitamin 
B 12 in plasma were reduced in rats receiving N 2 0, but an increase in plasma folate occurred in all treated rats. These results indicate that a 
reduction of SAM synthesis by cycloleucine can increase' the disturbance of 
folate metabolism that is caused by nitrous oxide, with a potentiation of the 
effects of leukemic growth. 
4.1. Introduction. 
The well known anesthetic gas nitrous oxide (N20) is able to suppress hematopoiesis, giving rise to megaloblastic anemia in man (1) and marked 
leukopenia in rats (2-4). This effect could be explained by a specific oxida-
tive action of nitrous oxide on the cobalt-moiety of vitamin B12 (5), which 
causes a nearly complete inactivation of the methylcobalamin-requiring 
enzyme methionine synthetase or 5-methyltetrahydrofolate homocysteine 
methyltransferase (E.C. 2.1.1.13). This results in a decreased availability of 
tetrahydrofolate coenzymes, which impairs folate dependent de novo syn-
thesis of thymidine and ultimately affects cellular proliferation. Attempts to 
utilize this hematological side effect of nitrous oxide in the treatment of 
human leukemia were already reported before its biochemical mechanism 
was revealed (6,7). These preliminary trials showed some promising results 
with a rapid, though reversible, regression of leukemia on nitrous oxide 
exposure. Recent investigations have confirmed inhibition of tumor growth 
in vitro, in several human cell lines ( 8), and in vivo, in leukemic rats ( 9) . 
The use of nitrous oxide in metabolic studies made clear that the effects 
of this agent, through a reduction of methionine supply, also involve a 
decreased synthesis of S-adenosylmethionine (SAM) (10, 11). In addition, it 
appeared that SAM antagonized the disturbance of folate metabolism which 
is caused by nitrous oxide ( 12, 13). These observations suggest that a 
further reduction of SAM might enhance the inhibiting effects of nitrous 
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oxide on cellular proliferation. 
We now report the effect of combining nitrous oxide with cycloleucine 
(NSC-1026, 1-aminocyclopentane carboxylic acid). Cycloleucine is a potent 
inhibitor of the enzyme methionine adenosyltransferase (E.C. 2.5.1.6.) (14) 
which converts methionine into SAM. The combined action of nitrous 
oxide and cycloleucine can cause a sequential blockade of SAM synthesis, 
possibly resulting in increased inhibition of tumor growth. Interestingly, 
cycloleucine by itself also has cytostatic properties ( 15, 16). However, in 
recent clinical trials this drug, in high doses, was unsuccessful mainly 
because of severe neurological and hematological toxicity ( 17, 18). 
This study describes the effects of nitrous oxide exposure, combined 
with the administration of cycloleucine, on proliferation of an experimental 
rat leukemia: the Brown Norway Myeloid Leukemia (BNML). This tran-
splantable leukemia has been described in detail (19) and is considered to 
be a suitable model for experimental chemotherapy (20). To evaluate the 
metabolic effects of vitamin B 12-inactivation by nitrous oxide, the deoxyuri-
dine suppression test is used, and plasma levels are determined of vitamin 
B 12 and folic acid. 
4.2. Materials and methods. 
Animals. Male rats of the Brown Norway inbred strain were used, at the age 
of 14-18 weeks (body weight 200-290 g). Food and water were supplied ad 
libitum during the experiments. 
Brown Norway myelocytic leukemia (BNMLJ. Cryopreserved leukemic cells 
were kindly provided by dr A. Hagenbeek from the Radiobiological Insti-
tute TNO, Rijswijk, The Netherlands, where this transplantable rat leukemia 
model was developed. Origin, classification and proliferation kinetics were 
described before ( 17). For leukemia transfer in experimental series, spleen 
cells of fully leukemic animals were used. 107 cells, suspended in 1 ml of 
Hanks balanced salt solution were injected i.v .. This standard dose leads to 
death in 20-24 days. During this period massive leukemic infiltration of 
spleen, liver and bone marrow takes place. Spleen and liver weights, there-
fore, are reliable indicators of tumor load and, along with hematological 
determinations, can be used effectively to assess the effects of chemoth-
erapy, correlating well with studies of survival time ( 19). To avoid a gra-
dual change in growth properties, serial transplantations were limited to only 
two passages in order, after which spleen cells were used from animals of a 
separate series, freshly inoculated with cells from a cryopreserved stock. 
Treatment with nitrous oxide and cycloleucine. Two sets of identical experi-
ments were carried out separately (Experiments 1 and 2). In each 4 groups 
of 4 rats were inoculated with leukemic cells at day 0. Mean body weight in 
78 
each group was nearly identical. Treatment of these leukemic rats started at 
day 7. To detect any synergistic action, one group received no treatment 
(controls), while the other 3 groups were treated with nitrous oxide, 
cycloleucine, or both. Rats were exposed to nitrous oxide in a 36 1 flow 
chamber, in which a mixture of 50% nitrous oxide and 50% oxygen was 
blown at a rate of about 1000 ml/min. Oxygen concentration was monitored 
with an oxygen analyzer (Teledyne Analytical Instruments). Exposure was 
interrupted only for short cleaning periods. Rats not exposed to N20 were kept in air, but otherwise treated identically. Cycloleucine was admmistered 
as a single i.p. injection at day 7, of 50 mg/kg cycloleucine (Sigma Chemi-
cal Co., St.Louis, USA), dissolved in water containing 0.15 mol/1 NaCl. 
Rats not receiving cycloleucine were injected with 0.15 mol/1 N aCl solution 
i.p .. 
Evaluation of treatment. To allow a simultaneous investigation of several 
parameters of leukemic growth, including metabolic tests, both experiments 
were terminated after a fixed period of 19 days of leukemia, which is just 
before the rats would die spontaneously. Rats were killed by exsanguina-
tion under either anesthesia, after recording their body weights. Liver and 
spleen were weighed. Leukocytes and thrombocytes were counted electroni-
cally. Hemoglobin concentration was measured by the hemoglobin cyanide 
spectrophotometrical assay. Plasma vitamin B 12 and folic acid were deter-
mined simultaneously, essentially as described (21). Methyltetrahydrofolate 
was used as a folate standard. Normal values for organ weights, hematolog-
ical parameters, plasma folate and vitamin B12 concentrations were derived 
from at least 12 comparable non-leukemic Brown Norway rats. 
Deoxyuridine suppression test. This test is used to evaluate the metabolic 
inactivation of vitamin B12. eH]-Thymidine incorporation in DNA is meas-
ured with and without added deoxyuridine. Deoxyuridine is able to 
suppress incorporation of [3H]-thymidine very significantly if it can be con-
verted to thymidine by folate-dependent methylation. This suppression is 
decreased in bone marrow cells as a result of folate or vitamin B 12 defi-
ciency, and as a result of the inactivation of methylcobalamin by nitrous 
oxide (22). 
In this test, leukemic spleen cells were used (ca. 5 x 106 per test) from 
rats of the various groups in Experiment 2, as described above. In addition, 
leukemic rats were included who were similarly treated for 1 day only (day 
16-17), after which they were sacrificed. In some cases, cycloleucine was 
added to the leukemic cell suspensions used in the test to compare in vitro 
and in vivo effects of this drug. The test was carried out (23) with some 
modification as described before (9). Deoxyuridine (Sigma Chemical Co., 
St.Louis, USA), was used in a concentration of 0.1 mmol/1. Incorporation 
of eH]-thymidine (ca.0.3 p.Ci per test, specific activity 25 Ci/mmol, from 
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Amersham International, UK), is expressed as a percentage of the maximum 
incorporation in each case, obtained by omitting deoxyuridine. 
4.3. Results. 
In each of the two experiments, four groups of leukemic rats were com-
pared: one untreated (controls), one treated with nitrous oxide, one treated 
with cycloleucine, and one group treated with both agents. Data on 
leukemic growth in these groups can be found in Tables 4.1 and 4.2. All 
rats survived until termination of the experiments, except for one untreated 
rat in Experiment 2, dying spontaneously a few hours before. Organ 
weights of this rat have been included in the results. 
The treated rats had reduced spleen and liver weights (Table 4.1) and 
reduced leukocyte counts (Table 4.2), compared to the untreated controls. 
With Wilcoxon's non-parametric rank sum test, applied to the values of 
individual rats in both experiments, these differences are statistically signifi-
cant (p <0.01). Combined treatment resulted in the strongest inhibition of 
leukemic growth, with an increase in organ weights of less than half of con-
trol values, as shown in Figure 4.1. The differences between groups treated 
with a single agent, and groups with combined treatment are also statistically 
significant using Wilcoxon's test (p<0.01). 
No significant difference was observed between the two groups treated 
with nitrous oxide or cycloleucine alone. In fact, after preliminary experi-
ments, the lowest dose of cycloleucine was selected which produced inhibi-
tion of growth about comparable to nitrous oxide exposure alone. This 
would facilitate recognition of a potentiating effect after combined treatment 
and minimize possible side effects of cycloleucine. With regard to the 
hematological values shown in Table 4.2, platelet counts and hemoglobin 
values do not suggest adverse effects of treatment on normal hematopoiesis. 
Although all animals remained thrombopenic, hemoglobin values showed a 
small increase with treatment and were highest after combined treatment. 
These differences were, however, not statistically significant. 
Treatment with N20, as in these experiments, is well tolerated by rats, 
without a noticeable mfluence on consciousness. A limited loss of body 
weight is observed, which is not aggravated by cycloleucine (Table 4.1). 
Plasma concentrations of vitamin B 12 and folic acid as determined in 
the various groups of both experiments, are shown in Figure 4.2. In 
untreated leukemic rats a strong increase in plasma levels of vitamin B 12 is 
found, whereas decreases are observed after treatment. A pronounced 
effect of nitrous oxide is evident, in particular when compared with the 
effect of cycloleucine. Combined treatment resulted in the lowest levels of 
vitamin B 12. Folic acid levels are low in untreated rats, with treatment 
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Table 4.1 
EFFECTS OF TREATMENT ON LEUKEMIC INFILTRATION IN SPLEEN AND LIVER, 
AND ON BODY WEIGHT 
Spleen weighta Liver weightb 
Experiment 1 Experiment 2 Experiment 1 
Treatment g±s.e. g±s.e. g±s.e. 
None (controls) 4.52 ± 0.18 4.49 ±0.15 21.38±0.60 
Cycloleucine 3.77±0.13 4.04±0.13 16.79±0.54 
Nitrous oxide 3.57±0.14 3.34±0.23 18.81 ±0.30 
Cycloleucine and 2.32±0.08 2.42 ±0.05 13.04±0.54 
nitrous oxide 
All treatment groups in both experiments consisted of 4 rats. 
s.e. =standard error of the mean in each group. 
Experiment 2 
g±s.e. 
20.54± 1.58 
16.95±0.65 
15.50 ±0.93 
13.48 ± 0.51 
Body weight 
Experiment 1 + 2 
%change 
-1.0 
+0.2 
-5.9 
-4.1 
anormal spleen weight in comparable non-leukemic Brown-Norway rats: 0.45 ± 0.07 g. 
bnormalliver weight in comparable non-leukemic Brown-Norway rats: 8.25 ± 0.99 g. 
Table 4.2 
EFFECTS OF TREATMENT ON HEMATOLOGICAL VALUES 
Leukocytesa Thrombocytesb 
Experiment 1 Experiment 2 Experiment 1 ± 2 
Treatment 1 os 1-1 ± s.e. 1 os 1-1 ± s.e. 1 os 1-1 ± s.e. 
None (controls) 32.7 ±2.3 19.2 ± 1.2 81 ± 13 
Cycloleucine 30.3±3.9 11.8 ±0.6 94±13 
Nitrous oxide 10.2±0.7 8.9 ± 1.4 60± 5 
Cycloleucine and 5.3±0.3 5.2±0.6 61 ± 8 
nitrous oxide 
All treatment groups in both experiments consisted of 4 rats. 
s.e. =standard error of the mean in each group. 
anormal value of leukocyte count in Brown Norway rats: 3.7 ± 0.3. 1 os 1-1. 
bnormal value of thrombocyte count in Brown Norway rats: 790 ± 22. 109 1-1. 
Hemoglobin 
Experiment 1 + 2 
mmol 1-1 ± s.e. 
8.0±0.2 
8.7±0.1 
8.2±0.3 
9.2 ± 0.1 
resulting in higher levels. In this case, no differences are observed between 
the various treatments. 
Results of deoxyuridine suppression test are presented in Figure 4.3. In 
this test, higher values are caused by a reduced suppressive effect of 
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Figure 4.1. The percentages of increase in weight are indicated of (a) spleen and (b) 
liver in leukemic rats, relative to normal weights of spleen: 0.45 g and liver: 8.25 g in 
comparable non-leukemic Brown Norway rats. Data of Experiments 1 and 2 are com-
bined. Each group consists of 8 rats. Standard errors of the mean are indicated. 
deoxyuridine on the incorporation of eH]-thymidine, which is indicative of 
impaired de novo synthesis of thymidine. Figure 4.3a shows suppression 
values, obtained with leukemic spleen cells from rats of the four groups in 
Experiment 2. Although the differences are small, they are suggestive of a 
limited increase in suppression values after N 2 0 or cycloleucine as single 
treatments, with a more severe disturbance after combined treatment. These 
values, however, were obtained 12 days after the initiation of treatment in 
Experiment 2. In this period, the level of cycloleucine may be appreciably 
reduced, although this agent in normal rats has a plasma half life of about 
22 days (24). Therefore, in a separate experiment leukemic spleen cells 
were used of rats 1 day after the administration of cycloleucine (Figure 
4.3b). This resulted in a more pronounced effect after combined treatment. 
About the same values were observed with in vitro addition of cycloleucine 
to leukemic cell suspensions of untreated rats and rats treated with N 2 0. At 
a concentration of 1 mmol/1, effects on the deoxyuridine suppression test are 
comparable with in vivo administration of 50 mg/kg cycloleucine. 
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Figure 4.2. Plasma levels of (a) vitamin Bl2 and (b) folic acid in leukemic rats of Ex-
periments 1 and 2. Values in normal (non-leukemic) rats are also shown. Standard er-
rors of the mean are indicated. 
4.4. Discussion. 
Exposure to N20 is known to cause a selective and virtually complete inhi-bition of the methylcobalamin-dependent enzyme methionine synthetase 
(25). This enzyme is essential both for the generation of tetrahydrofolate 
(THF) and the synthesis of methionine (see Figure 4.4). The disturbance of 
folate metabolism, and in particular of folate-dependent de novo synthesis of 
thymidine, is considered to be primarily responsible for the impairment of 
cellular proliferation caused by nitrous oxide. However, it appears that 
methionine metabolism is also involved in this effect. From metabolic stu-
dies in rats it has become evident that the disturbed folate metabolism on 
N20 exposure can be completely restored by the administration of 
methionine ( 12). An explanation for this effect is the established ability of 
methionine after its conversion to S-adenosylmethionine (SAM), to inhibit 
the enzyme 5, 10-methylene-THF reductase (26). This will prevent the detri-
mental accumulation of the substrate of methionine synthetase, 5-
methylTHF, which is caused by nitrous oxide (Figure 4.4). An alternative 
explanation is to assume direct activation of methionine synthetase by SAM 
(27). Thus, it appears that SAM antagonizes the effect of nitrous oxide on 
folate metabolism. This conclusion is supported by other reports ( 13,28), 
while it is interesting to note that methionine also protects against specific 
neurological disorders caused by nitrous oxide in some species (29,30). 
In this study, an effect is demonstrated which can be considered a direct 
83 
30 
a. after 12 days 
:::J 
"0 20 
"5 
0 
D 
-5 
D ·~ IJl 10 "' ::lro > ... 0 olo 0 
2 3 4 
<C 
z 40 
Cl 
c b. after 1 day 
c 
0 
·.;::; 
30 ro 
... 
0 
0.. 
... 
0 
u 
c 
"' 
20 
c
"0 
·e 
D D 
>-
.c 
.... 10 I 
J: 
M 
0 
2 3 4 
n c ~n ::l ::l ~n "'~n "'~n 
0 ::l t.n-< ;:;: -· 01"< 0.. --< 0.. --< 
::l ~ on 
.... 
~on ~3Q. ~3Q. ~ .... 3~ 0 Cl30 "I CD c o..3£ o..3£ 0"' lO CD IJl c lO " 0 CD 0 "' -~ 
-c "'-c ~ -c ~ -cIJl"' 
0.. A"n 0 o "n o::: n o::: n lO -· X X lO -· -~:;· w '-' 5" ~~ 0: -·~::l 0.. "' "' "' 
"' "'"' 
Figure 4.3. Deoxyuridine suppression values in leukemic cells: (a) from four groups of 
two rats each, 12 days after the administration of cycloleucine and initiation of nitrous 
oxide exposure; (b) from four rats, after treatment for I day, with cycloleucine admin-
istered in vivo (columns 2 and 4), and cycloleucine added in vitro to leukemic cell 
suspensions (columns 5 and 6). Each value is the mean of triple incubations, with a 
maximal difference between estimations of 10%. dU: deoxyuridine. 
consequence of the same interaction. The effects of nitrous oxide alone on 
leukemic growth in vivo appear to be limited to the extent which is achieved 
in this study and in previous work (9). In the present study, however, it is 
shown that the inhibitory effects on leukemia can be increased by an addi-
tional reduction of SAM synthesis, which is induced by cycloleucine. A 
combination of nitrous oxide exposure with the administration of cycloleu-
cine resulted in the strongest reduction of leukemic proliferation. With 
regard to spleen weight, the amount of this reduction seemed to be even 
more than the added effects of both agents when given separately. This is 
also reflected in the deoxyuridine suppression test, which measures the 
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Figure 4.4. Relations between the reactions discussed in the text, with indication of en-
zymes and inhibitors. N
2
0: nitrous oxide, THF: tetrahydrofolate, SAM: S-
adenosylmethionine. 
capacity of de novo synthesis of thymidine. In this test, the effect of nitrous 
oxide is enhanced by cycloleucine: this applied both to the in vivo combina-
tion of these two agents and the in vitro addition of cycloleucine to leukemic 
cells of rats treated with nitrous oxide. 
The most likely explanation of this synergistic action therefore is further 
impairment of folate metabolism. The cytostatic properties of cycloleucine 
generally are attributed to its inhibition of SAM -dependent methylation reac-
tions (31). Although it was recently shown that N 2 0 also decreases tissue levels of SAM (10,11), it remains uncertain to what extent this effect 
directly contributes to the inhibition of cellular proliferation. In this respect, 
the impairment of thymidine synthesis is an established mechanism. It 
should not be excluded that N20 and cycloleucine mutually can potentiate distinctive cytostatic effects. 
Peripheral leukocyte counts clearly are lowest with combined treatment. 
It appears that nitrous oxide more effectively reduces peripheral leukocytes, 
when compared with cycloleucine as a single agent. 
Nitrous oxide and cycloleucine also appear quite different with regard to 
their effects on plasma levels of vitamin B12. We have previously shown 
that a continuous rise of plasma vitamin B 12 is a feature of this leukemia in 
rats (9). The reduction of leukemic growth, as caused by cycloleucine, is 
not very effective in decreasing vitamin B12 levels. Nitrous oxide treat-
ment, however, with the same inhibition of leukemic growth, caused a 
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striking fall in plasma vitamin B12 to subnormal levels. This is evidence of 
a specific effect of this agent, which oxidizes the methylcobalamin coen-
zyme. Reduced vitamin B12 levels in plasma with prolonged N20 exposure 
were already reported in fruit bats (30), and, remarkably, in the first case of 
human leukemia treated with N 2 0 ( 6). Kondo et al. (32) showed that with N20 exposure analogues of cobalamin are formed which are rapidly 
excreted, resulting in a depletion of vitamin B 12. 
Folic acid levels were low in untreated leukemic rats, which is probably 
related to the increased demands of rapid cellular proliferation (33). In all 
treated groups folate levels were increased, and with regard to N2 0 treat-
ment this effect has been observed before (34). This is explained by the 
blockade in folate metabolism with a reduction of cellular uptake of folates 
and a consequent accumulation in plasma. Cycloleucine causes the same 
increase in folate levels, however, and this supports the presumed role of 
SAM in the regulation of folate metabolism, as discussed before. Finally, it 
should be noted that with a low dose of cycloleucine as used in this study, 
no adverse effects were apparent when comparing treated and untreated rats. 
It can be concluded that it is possible to achieve increased inhibition of 
leukemic proliferation when N
2
0 is combined with a low dose of cycloleu-
cine, an inhibitor of SAM synthesis. This effect supports a role of SAM in 
modulating the effects of N20, and should stimulate further research to 
establish cobalamin-dependent metabolism as an additional target in cancer 
chemotherapy. On the other hand, these results suggest that cycloleucine 
can be used more effectively, than in the toxicity limited dosages used 
before, when it is combined with N20, an agent which has the additional 
advantage of notable analgesic properties. 
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Chapter five 
NITROUS OXIDE 
AND METHOTREXATE 
IN RAT LEUKEMIA 
This chapter has been published in Cancer Chemotherapy and Pharmacol-
ogy, 17:114-20 (1986), titled "Enhanced therapeutic effect of methotrexate 
in experimental rat leukemia after inactivation of cobalamin (vitamin Bl2) 
by nitrous oxide", by A.C.M. Kroes, J. Lindemans, M. Schoester and J. 
Abels. 
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Abstract. Exposure to nitrous oxide interferes selectively with the coenzyme 
function of vitamin B 12 and causes inactivation of methionine synthetase, 
with subsequent impairment of folate metabolism and reduction of cellular 
proliferation. In a rat leukemia model (BNML) we investigated the com-
bined administration of nitrous oxide, inactivating vitamin B12, and metho-
trexate (MTX), a folate antagonist inhibiting the enzyme dihydrofolate 
reductase. Through different mechanisms, both agents decrease the availa-
bility of tetrahydrofolate, and subsequently of other reduced folates, with 
increased impairment of folate-dependent synthesis of thymidylate. Effects 
on leukemic growth and on hematological values in rats demonstrated 
enhancement of the therapeutic effect of MTX by exposure to nitrous oxide. 
With several treatment schedules, the results of combined treatment were 
seen to be better than additive when compared with the effects of single 
agents. In particular, pretreatment of leukemic rats with nitrous oxide for 3 
days before administration of MTX, concomitant exposure to nitrous oxide 
even resulted in toxic effects. These findings were in accordance with the 
results of some metabolic studies performed in leukemic rats. De novo syn-
thesis of thymidylate in leukemic cells, when studied by means of the deoxy-
uridine suppression test, showed the most severe disturbance with combined 
treatment consisting in MTX (0.5 mg/kg) and nitrous oxide pretreatment for 
3 days. Intracellular levels of folate and dTTP were lowest with 2 and 3 
days' pretreatment before MTX, respectively. It is concluded that this 
interaction of nitrous oxide and MTX can result in enhanced metabolic and 
therapeutic effects of low doses of MTX. Inactivation of vitamin B 12 
appears to be a potentially useful addition in cancer chemotherapy. 
5.1. Introduction. 
The similarity of hematological disturbances caused by deficiency of either 
folic acid or cobalamin (vitamin B12) is well established. Both vitamins are 
involved in pathways essential in the synthesis of nucleotides, and conse-
quently of DNA. The important function of folic acid in cellular prolifera-
tion is also reflected in the striking cytostatic activity of folate antagonists of 
which methotrexate (MTX) is the best known example. This antimetabolite 
is widely used in cancer chemotherapy (1). In contrast, until recently, the 
role of vitamin B12 in neoplastic growth has remained unclear, because no 
effective method was available to interfere with its coenzyme function. In 
1978, however, it was recognized that selective inactivation of vitamin B12 
could be achieved with exposure to the anesthetic gas nitrous oxide, or N20 (2,3). Megaloblastic hematopoiesis after prolonged exposure to nitrous 
oxide had ben observed much earlier ( 4), and chemical interaction of 
nitrous oxide with complexes of cobalt was also known for some time ( 5). 
It appeared that a specific oxidative action of nitrous oxide on the cobalt 
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moiety of vitamin B 12 caused a nearly complete inactivation of the 
methylcobalamin-requiring enzyme methionine synthetase, or 5-
methyltetrahydrofolate homocysteine methyltransferase (E. C .2 .1.1.13). 
Nitrous oxide effectively established a state of functional deficiency of vita-
min B12, with severely disturbed folate metabolism (6) and toxic effects on 
hematopoiesis (7). Methionine synthetase is essential in folate metabolism, 
because it provides the only pathway by which 5-methyltetrahydrofolate, the 
major extracellular folate, can be converted into tetrahydrofolate (THF). 
THF and other, subsequently formed, reduced folates can be converted into 
folylpolyglutamates, which are then retained in the cell and are important 
coenzymes in one-carbon transfer reactions. De novo synthesis of thymi-
dylate requires such folate-dependent methylation. MTX also interferes 
with folate metabolism by limiting the generation of THF, but through a dif-
ferent mechanism. Its inhibition of dihydrofolate (DHF) reductase prevents 
the reconversion of DHF to THF. 
It has been shown that the effect of nitrous oxide on vitamin B 12 can be 
utilized to reduce growth of leukemia in vitro (8) and in vivo, in rats (9). 
This effect is associated with a disturbance of folate-dependent de novo syn-
thesis of thymidylate. Therefore, it appears that nitrous oxide and MTX, 
through inhibition of different pathways, ultimately may have similar effects 
on folate metabolism. These observations suggest that the inactivation of 
vitamin B12 can modify, and possibly enhance, the efficacy of MTX. In 
vitro studies on human bone marrow have demonstrated a synergistic effect 
of MTX and nitrous oxide with regard to impairment of nucleotide synthesis 
( 10). The purpose of the present study is to investigate the influence of 
nitrous oxide on the effects of MTX in vivo, using a rat leukemia model: 
the Brown Norway myeloid leukemia (BNML). This transplantable acute 
promyelocytic leukemia has been described in detail elsewhere (11) and is 
considered to be a suitable model for chemotherapeutic studies ( 12). In 
addition to experiments intended to assess effects on leukemic growth, a 
number of metabolic studies were performed in leukemic rats, to investigate 
some effects of treatment on folate metabolism. These studies included 
deoxyuridine suppression tests, and determinations of intracellular folate 
and deoxythymidine triphosphate (dTTP) levels. 
5.2. Materials and methods. 
Animals. Male rats of the Brown Norway inbred strain were used at the age 
of 12-16 weeks (body weight 200-275 g). Food and water were supplied ad 
libitum during the experiments. 
Brown Norway myeloid leukemia (BNMLJ. Cryopreserved leukemic cells 
were kindly provided by dr A. Hagenbeek from the Radiobiological Insti-
tute (TNO), Rijswijk, the Netherlands, where this transplantable rat 
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leukemia model was developed. Origin, classification and proliferation 
kinetics were described elsewhere ( 11). For leukemia transfer in experi-
mental series, spleen cells of fully leukemic animals were used. A standard 
dose of 107 cells suspended in Hanks' balanced salt solution was injected 
i.v., which leads to progressive leukemic infiltration of bone marrow, spleen 
and liver, with death after 20-24 days. Spleen and liver weights, steadily 
increasing in the course of leukemia, are reliable indicators of tumor load 
and, along with hematological determinations, can be used effectively to 
assess effects of chemotherapy (11). To avoid a gradual change in growth 
properties, serial transplantations were limited to only two passages, after 
which spleen cells were used from rats freshly inoculated with cells from a 
cryopreserved stock. 
Treatment with nitrous oxide and MTX. Leukemic rats were treated accord-
ing to different schedules in groups of at least four. Exposure to nitrous 
oxide was carried out in a 40 1 flow chamber into which a mixture of 50% 
nitrous oxide and 50% oxygen was blown at a rate of 500 ml/min. Oxygen 
concentration was monitored with an oxygen analyzer (Teledyne Analytical 
Instruments). Carbon dioxide, water, and contaminating volatile com-
pounds were eliminated in a cleaning circuit, essentially as described by 
Rupreht and Dzoljic ( 13). Rats not exposed to nitrous oxide were kept in 
air, but otherwise treated identically. Sodium methotrexate (Ledertrexate 
SP, from Lederle) was injected i.p. Rats not receiving MTX received injec-
tions of 0.15 M NaCl i.p. instead. 
Evaluation of leukemic growth. Experiments intended to assess effects on 
leukemic growth were all evaluated by the same procedure. To allow a 
simultaneous investigation of several aspects of leukemia these experiments 
were terminated after a fixed period of 18 days (in some instances: 19 days) 
of leukemia, just before death from leukemia was to be expected. Rats 
were killed by exsanguination, after recording of body weights. Liver and 
spleen were carefully removed and weighed. Leukocytes were counted elec-
tronically, and in some experiments differential blood cell counts were 
done. Plasma levels of vitamin B12 were measured in a competitive 
radioisotope binding assay using purifiec.l intrinsic factor (14). Normal 
values for organ weights, leukocyte counts and plasma vitamin B 12 were 
derived from at least 12 comparable non-leukemic Brown Norway rats. 
Metabolic studies. In separate experiments, rats with advanced leukemia 
were treated for short periods, after which leukemic cells were used in meta-
bolic studies. Three similar experiments were carried out separately. In 
each, eight leukemic rats inoculated at day 0 were divided in four pairs. 
These pairs were treated with nitrous oxide for 3, 2, 1 or 0 days. Immedi-
ately afterwards one rat in each pair received MTX, 0.5 mg/kg i.p., the 
other rat receiving saline only. At 18 h after administration of MTX, on 
day 15 of leukemia, leukemic cells were obtained from the spleens of all 
rats, washed, and resuspended in Hanks' balanced salt solution. These cell 
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suspensions were counted electronically and used in deoxyuridine suppres-
sion tests and determinations of intracellular folate and dTTP. 
Deoxyuridine suppression test. This test demonstrates impaired de novo syn-
thesis of thymidylate. eH]-Thymidine incorporation into DNA is measured 
with and without addition of deoxyuridine. Deoxyuridine will suppress 
incorporation of eH]-thymidine in DNA if it can be converted to thymi-
dylate through folate-dependent methylation. This suppression is reduced 
by vitamin B 12 or folate deficiency ( 15), inactivation of vitamin B 12 by 
nitrous oxide ( 16), and treatment with other agents interfering with de novo 
synthesis of thymidylate ( 17). 
Leukemic spleen cells (approx. 5 x 106 per test) were used from rats of 
various groups, as described above. The test was carried out essentially 
according to Metz (18), with some modifications as described elsewhere 
(9). Deoxyuridine (Sigma, St.Louis, USA) was used in a concentration of 
0.1 mmol/1. All incubations were performed in triplicate. Incorporation of 
eH]-thymidine (0.3 JLCi per test, specific activity 25 Ci/mmol, from Amers-
ham, UK) is expressed as a percentage of the maximal incorporation, meas-
ured in each case in incubations without addition of deoxyuridine. 
Intracellular folate. In suspensions of leukemic spleen cells, intracellular 
folate content was determined. After centrifugation a pellet of approx. 108 
cells was resuspended in a total volume of 1 ml 10% ( = 1.3 mol/1) mercap-
toethanol, heated in a water bath of 100 °C for 5 min, and cooled. Hog kid-
ney polyglutamate hydrolase, prepared as described by McMartin et al. 
(19), was added and allowed to incubate at room temperature for 2 h. The 
samples were frozen at -20 °C until assayed. After thawing, the extracts 
were centrifuged ( 1500 g for 10 min at 4 °C), and aliquots of the superna-
tants were used in a folate radioisotope dilution assay, essentially as 
described by Dunn and Foster (20), with [125!]-folic acid (Becton Dickin-
son, Orangeburg, N.Y., USA), as a tracer, and f)-lactoglobulin (Sigma, 
St.Louis, USA) as a folate binder. 5-Methyl-THF was used as a standard, 
and results are expressed as picomoles of folate per 106 cells. 
Intracellular dTTP. In leukemic cells obtained from rats as described above, 
dTTP was determined using the DNA polymerase assay system originally 
developed by Solter and Handschumacher (21), with the modifications and 
corrections published by Hunting and Henderson (22). A different extrac-
tion method was used, however. After being washed once in Hanks' bal-
anced salt solution, cell suspensions were centrifuged and the supernatant 
was removed. To the pellet of about 108 cells, 1.2 JLg 
cyano[57Co]cobalamin, or 105 dpm, (Amersham, UK) was added, as an 
internal standard for cells quantities in the assay. The pellet was then 
extracted with 5 ml ice-cold 60% methanol and stored at -20 °C until 
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assayed. After centrifugation the supernatant was dried using a rotary eva-
porator at 25 °C dissolved in 50 mM potassium, cacodylate and subse-
quently used in the DNA polymerase catalyzed assay. DNA polymerase I 
from E.coli, dATP, dTTP, and poly(d(A,T)) were all obtained from Boehr-
inger Mannheim (FRG) and eH]-dATP and [3H]-dTTP were from Amers-
ham (UK). Procedures, and calculated corrections for dilution of specific 
activities by the endogenous nucleotides were carried out as described else-
where (22). Concentrations of dTTP are expressed as picomoles per 106 
cells, based upon counts of the internal standard and cell concentration of 
the initial suspension. 
5.3. Results. 
Effects of growth of leukemia in rats. In Table 5.1, results of six experi-
ments with several different treatment schedules are summarized. In all 
these experiments, one group of leukemic rats treated with MTX only is 
compared with one or more groups of rats treated with a combination of 
MTX and exposure to nitrous oxide. Most experiments included a group 
receiving nitrous oxide continuously throughout the treatment period (day 7 
to day 18 or 19 of leukemia). In other groups, nitrous oxide treatment was 
limited to either 3 days before administration of MTX (pretreatment) or 3 
days after administration of MTX (post-treatment). This is illustrated in 
Figure 5.1, which shows the treatment schedules as applied in experiment 3 
of Table 5.1. In addition, all experiments included rats receiving no treat-
ment or nitrous oxide only (days 7-19), without MTX. Cumulative results 
in these rats are also shown in Table 5.1. From the data in Table 5.1, it fol-
lows that low doses of MTX alone do not have substantial effects on 
leukemic growth. In all experiments the addition of nitrous oxide enhanced 
the therapeutic effects of MTX. The differences between rats treated with 
MTX only and rats treated with both MTX and nitrous oxide (continuously) 
are statistically significant according to Wilcoxon's non-parametric rank sum 
test. For all three parameters of leukemia, results did not overlap, yielding 
p-values of 0.05 or less, in any of the experiments 1-4. In addition, the 
results of combined treatment appeared to be better than additive in these 
experiments, with the possible exception of experiment 1, in which the 
lowest dose of MTX was administered. In other cases, the reduction of 
leukemic growth obtained with combined treatment is often greater than the 
added effects of the two single agents, which is indicative of a synergistic 
interaction. From experiments 3 and 5 it can be derived that by far the 
major part of the added effect is contributed by the period of exposure to 
nitrous oxide before administration of MTX (pretreatment schedules). In 
experiment 6 the highest dose of MTX was used ( 4 mg/kg). In this 
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Table 5.1 
NITROUS OXIDE AND METHOTREXATE 
Effects on growth of BNML in rats 
Treatment Spleen Liver Leukocytes 
(g±s.e.m.) (g ±s.e.m.) (1 os /I ± s.e.m.) 
None (controls) 3.90±0.09 17.39 ±0.45 24.8 ±2.1 
N20, continuous 2.89 ±0.09 14.33 ±0.44 11.1 ± 1.0 
MTX 1 X 0.5 mg/kg 3.64±0.10 15.60±0.69 18.1 ± 1.2 
with N20, continuous 2.34 ± 0.10 12.50±0.55 7.7±0.7 
MTX 2 X 0.5 mg/kg 3.38 ± 0.18 16.04±0.80 20.2 ± 1.4 
with N20, 2 X 3d. (after) 3.32 17.05 20.0 
with N20, 2 X 3d. (before) 2.37 ±0.11 13.08 ±0.44 8.1 ±0.6 
with N20, continuous 1.97 ±0.17 11.68 ±0.81 7.0 ± 1.1 
MTX 1 X 2 mg/kg 3.44 ± 0.14 14.00 ± 0.46 20.8±2.9 
with N20, 1 X 3d. (before) 2.58±0.24 12.59 ±0.94 7.7±1.0 
with N20, continuous 1.95 ±0.08 11.47±0.17 6.1 ±0.6 
MTX 1 X 4 mg/kg 2.85±0.32 13.30±0.74 14.9 ± 1.1 
with N20, 1 X 3d. (before) 1.47 ± 0.43 10.12 ± 0.49 4.2 ± 1.4 
with N20, continuous all rats died (without evidence of leukemia) 
7 10 13 16 19 
days of leukemia: 
N 20 before MTX 
N 20 continuous wmw&/&~41 
MTX 2x O.Smg/kg t t 
Figure 5.1. Treatment of leukemic rats with nitrous oxide (N 0) and methotrexate 
(MTX), as given in experiment 3 of Table 5 .1. Periods of exposlre to nitrous oxide are 
shaded, and arrows indicate time of administration of MTX. Rats receiving MTX or ni-
trous oxide only, and untreated rats, were also included. 
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Table 5.2 
NITROUS OXIDE AND METHOTREXATE 
Effects of treatment on differential blood cell counts (percentages± s.e.m.) 
Treatment No. of 
rats 
None (untreated controls) 8 
N20, continuous (day 7-18/19) 6 
MTX, 2x 0.5 mg/kg (day 10 and 14) 4 
+ Np, continuous (day 7-18) 4 
MTX, 1x2 mg/kg (day 10) 3 
+ N20, 1x3 d. before MTX (day 7-10) 3 
+ N20, continuous (day 7-19) 4 
MTX, 1x4 mg/kg (day 10) 4 
+ Np, 1x3 d. before MTX (day 7-10) 4 
Normal BN-rats (non-leukemic) 5 
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17.4 ± 1.9 74.4 ± 2.0 8.3 ± 1.6 
13.5 ± 3.4 83.2 ± 2.7 3.3 ± 0.8 
13.5 ± 2.2 74.5 ± 1.8 12.0 ± 1.0 
0.8 ± 0.2 98.3 ± 0.6 1.0 ± 0.4 
30.6 ± 1.5 65.0 ± 1.5 4.3 ± 1.2 
8.0 ± 6.0 90.3 ± 6.2 1.7 ± 0.3 
3.3 ± 0.9 95.5 ± 1.0 1.3 ± 0.2 
13.3 ± 3.9 81.5 ± 5.2 5.3 ± 1.6 
2.0 ± 0.7 97.5 ± 0.9 0.5 ± 0.3 
0 91.4 ± 1.4 6.0 ± 1.5 
oO 
N 20 1x0.5 2x0.5 1x2 normal 
only -----------
BN rats 
MTX (mg/kg) 
with N20 
12 5 4 4 22 
Figure 5.2. Plasma levels of vitamin Bl2 in leukemic rats treated in several experiments 
with different doses of MTX. Groups with combined treatment received nitrous oxide 
continuously (days 7-18/19 of leukemia). Values in normal (non-leukemic) BN rats are 
also shown. Bars indicate the standard error of the mean. 
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Figure 5.3. Results of metabolic experiments with leukemic spleen cells after in vivo 
treatment of rats with 0-3 days' exposure to nitrous oxide, followed or not by administra-
tion of MTX (0.5 mg/kg): (a) deoxyuridine suppression values, expressed as percen-
tages of maximal incorporation of eH]-thymidine, in incubations without deoxyuridine; 
(b) intracellular levels of folate (pmol/106 cells); (c) intracellular levels of dTTP 
(pmol/ 106 cells). Shaded columns indicate MTX treatment. The experiments were per-
formed 18 h after administration of MTX and/or exposure to nitrous oxide. 
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experiment, rats treated with both MTX and nitrous oxide (continuously) 
died prematurely at 14-16 days after inoculation, without any evidence of 
leukemia. Spleen and liver weights at autopsy were subnormal, and body 
weight was seriously reduced (77% of weight before treatment). This was 
considered to be a toxic effect of treatment. In other experiments, however, 
no toxicity was observed and nitrous oxide treatment was well tolerated by 
rats without evident effects on consciousness. Even with combined treat-
ment, loss of body weight was always less than 10%. 
In some experiments differential blood cell counts were made, which 
demonstrated that the observed reductions in peripheral leukocyte counts 
were also accompanied by a striking relative decrease of leukemic cells 
(promyelocytes), as shown in Table 5.2. 
Plasma levels of vitamin B 12, as determined in these experiments, are 
presented in Figure 5.2. Compared with normal BN rats, vitamin B12 levels 
in untreated leukemic controls, are very high. With treatment these levels 
are reduced, as is shown for three doses of MTX. Exposure to nitrous 
oxide alone has marked effects on the vitamin B 12 level in plasma, but 
much lower and even subnormal levels are found after combined treatment. 
Metabolic effects. In separate experiments, pairs of leukemic rats were 
treated with nitrous oxide for 0, 1, 2 or 3 days. One rat of each pair subse-
quently received MTX (0.5 mg/kg), and 18 h afterwards leukemic cells of 
all rats were used for deoxyuridine suppression tests and determinations of 
intracellular folate and dTTP. This experimental procedure was repeated 
twice, and results of all rats used in this study are presented together (Figure 
5.3). 
Deoxyuridine suppression tests (Figure 5.3a) show increased distur-
bance with longer duration of nitrous oxide exposure before the administra-
tion of MTX. Higher values in this test indicate a decreased ability of 
deoxyuridine to suppress the uptake of eH]-thymidine, demonstrating 
impaired de novo synthesis of thymidylate. MTX without nitrous oxide 
treatment is clearly less effective: mean values are 12% without nitrous 
oxide and 25% with 3 days of pretreatm~nt. Figure 5 .3b shows the results 
of intracellular folate determinations. Both nitrous oxide and MTX 
decreased folate levels, and the lowest levels are found with combined treat-
ment after 2 days of nitrous oxide exposure. With 3 days of nitrous oxide 
exposure it appears that folate contents recover to some extent. Figure 5.3c, 
presenting levels of intracellular dTTP, is based upon the last metabolic 
experiment only, involving eight rats, in contrast to the other results. From 
this experiment it can be concluded that dTTP levels in leukemic cells are 
lowest with combined treatment consisting in MTX and 2 or 3 days' pre-
treatment with nitrous oxide. Nitrous oxide treatment alone appears to 
cause increased levels of dTTP, but it should be emphasized that these and 
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other values were obtained 18 h after exposure and some recovery may have 
occurred. 
5.4. Discussion. 
Nitrous oxide interferes specifically with the coenzyme function of vitamin 
B 12 and thereby inactivates methionine synthetase (23). This severely 
affects folate metabolism, because methionine synthetase is required in the 
conversion of 5-methyl-THF, the predominant extracellular folate, into THF. 
This conversion is essential for folate coenzyme functions, and also for the 
cellular retention of folates. In contrast to other reduced folates, 5-methyl-
THF is not a substrate for synthesis of folylpolyglutamates, as is evident 
from metabolic studies (24,25) and from properties of the purified enzyme 
(26). The synthesis of folylpolyglutamates is decreased by nitrous oxide 
(25,27 ,28), which explains the serious cellular depletion of folates occurring 
on exposure (29). The decreased availability of reduced folates impairs 
folate-dependent synthesis of thymidylate, and subsequently reduced DNA 
synthesis and cellular proliferation. The inhibition of leukemic growth by 
nitrous oxide in vitro has been demonstrated {8), and in a previous study we 
described in vivo antileukemic effect of nitrous oxide in rats (9). We also 
showed that these effects were enhanced in combined treatment with 
cycloleucine, which inhibits the conversion of methionine into S-
adenosylmethionine and indirectly interferes with folate metabolism (30). A 
number of studies have investigated the combination of nitrous oxide, as a 
vitamin B 12-inactivating agent, and MTX, as a typical folate antagonist. 
Kano et al. ( 10) have demonstrated synergistic effects with regard to inhibi-
tion of thymidyhJ.te synthesis in normal human bone marrow. Black and 
Tephly (31) compared metabolic effects of both agents in rat liver cells. 
The inhibition of methionine synthetase by nitrous oxide considerably 
decreased the availability of THF while the inhibition of DHF reductase by 
MTX was much less effective. This difference probably can be explained 
by the low activity of thymidylate synthetase in liver cells. Dudman et al. 
(32) found increased sensitivity of leukemic cell lines to MTX with nitrous 
oxide-induced inhibition of methionine synthetase, which was further 
exploited by the use of 5-methyl-THF instead of 5-formyl-THF as a rescue 
agent. 
The present study shows effects of combined therapy with nitrous oxide 
and MTX on in vivo growth and metabolism of rat leukemia. The exposure 
of rats to nitrous oxide enhanced inhibition of leukemic growth by low 
doses of MTX. A period of exposure before the administration of MTX 
(pretreatment) appeared essential for this effect. The effects on leukemic 
infiltration in spleen and liver correlated well with hematologic results (total 
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and differential leukocyte counts) and with determinations of vitamin B12 in 
plasma. An interesting feature of this leukemia is a continuous rise of vita-
min B12 levels in the course of leukemic growth (9), which is also observed 
in human acute promyelocytic leukemia (33). Plasma vitamin B 12 can be 
used as a kind of tumor marker, and treatment leads to reduced levels. The 
particularly striking decrease caused by nitrous oxide, however, is explained 
by its specific effect on cobalamin. Analogues of cobalamin are formed 
after oxidation and a~e excreted rapidly (34). In addition to effects on 
leukemic growth, some metabolic aspects of this interaction were studied in 
leukemic cells after in vivo treatment of rats. On the basis of the results dis-
cussed before, pretreatment with nitrous oxide was administered for periods 
up to 3 days. Deoxyuridine suppression test demonstrated increased distur-
bance of de novo synthesis of thymidylate with longer duration of nitrous 
oxide pretreatment before MTX. Treatment with a single agent was clearly 
less effective. Simultaneous determination of intracellular folates, to con-
firm the presumed cellular folate depletion, indeed showed a decrease in 
folate content, particularly with combined treatment. Some comments on 
these folate measurements are warranted, however. In the radioisotope 
competitive binding assay the f)-lactoglobulin folate binder is used, and 
probably not all relevant folate derivatives show the same affinity for this 
binder. Our own observations (not included in this study) indicated that 5-
methyl-THF has slightly lower affinity than THF. As these folates are intra-
cellularly predominant (19,31), the observed decrease in total folate content 
could also be explained, at least partially, by a shift of folates from THF 
toward 5-methyl-THF. This, however, is functionally about equivalent, 
because the conversion of 5-methyl-THF is blocked on nitrous oxide expo-
sure, as discussed before. Moreover, the results of this folate radioassay in 
the measurement of tissue folates were recently found to be comparable to 
microbiological assays (35). Changes in cellular folate on nitrous oxide 
exposure in our study are similar to earlier observations (26,28), including 
an indication of recovery at more than 2 days of exposure, ad adaptive 
mechanism which is not yet understood. Finally, decreased dTTP levels 
show that the impairment of folate-dependent synthesis of thymidylate has 
noticeable effects on this direct precursor of DNA. Considered together, 
the findings in metabolic experiments are in accordance with the results of 
studies directed at inhibition of growth, showing maximum effects after 
about 3 days of pretreatment with nitrous oxide before MTX. 
Several potential mechanisms could explain the results of this interac-
tion. First, a reduction of intracellular folates by nitrous oxide pretreatment 
can obviously induce greater susceptibility to folate antagonists (36). A 
second mechanism is closely related and concerns the reduced synthesis of 
folylpolyglutamates on nitrous oxide exposure. Polyglutamation of MTX, 
leading to increased activity and cellular retention (37), occurs in competi-
tion with normal folate substrates (36,38). In cells pretreated with nitrous 
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oxide a larger proportion of MTX may be converted into polyglutamate 
forms. A third potential mechanism to explain the results relates to the 
observed marked increase in activity of thymidylate synthetase, after nitrous 
oxide exposure of up to 3 days (39). It is well established that thymidylate 
synthetase has a central role in mediating the cytotoxic effects of MTX 
(40,41), because this enzyme actually causes THF depletion by its conver-
sion of reduced folates into DHF. Increased activity of this enzyme, as a 
possible adaptation to nitrous oxide treatment, thus may result in enhanced 
effects of MTX. All these mechanisms can explain the observed importance 
of pretreatment with nitrous oxide before MTX. 
The results presented in this study demonstrate that in vivo metabolic 
manipulation of leukemic cells with nitrous oxide can enhance metabolic 
and therapeutic effect of MTX. The clinical relevance of this interaction is 
illustrated by the recent observation of increased toxicity of adjuvant 
chemotherapy involving MTX started directly post-operatively ( 42), which 
the authors attributed to inactivation of vitamin B 12 by nitrous oxide during 
anesthesia. Our findings lend support to this suggestion. In experimental 
chemotherapy, the inactivation of vitamin B12 represents a new method to 
enhance activity of MTX. The relative contributions of increased polygluta-
mation of MTX, and increased activity of thymidylate synthetase, should be 
subjects of further research. It also remains to be demonstrated that the 
effects described are applicable to human leukemia, but it is known that 
man is more susceptible to vitamin B 12 deficiency than any animal ( 6). 
Finally, these results indicate the significance of vitamin B12 in leukemic 
proliferation and the value of vitamin B 12-related metabolism as an addi-
tional target in cancer chemotherapy. 
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Chapter six 
NITROUS OXIDE 
AND 5-FLUOROURACIL 
IN RAT LEUKEMIA 
This chapter has been published in Anticancer Research, 6:737-43 (1986), 
titled "Effects of 5-fluorouracil treatment of rat leukemia with concomitant 
inactivation of cobalamin", by A.C.M. Kroes, A.A.M. Ermens, J. Linde-
marrs and J. Abels. 
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Abstract. The cytostatic activity of 5-fluorouracil (5-FU) can be modified by 
the addition of reduced folates, as well as antifolates. This is indicative of 
the complex involvement of folate metabolism in the effects of 5-FU. In the 
BN rat leukemia model, 5-FU treatment was combined with the inactivation 
of cobalamin (vitamin B 12) by nitrous oxide (N? 0). Exposure to nitrous 
oxide causes severe disturbance of folate metabolism through the inhibition 
of the cobalamin-dependent enzyme methionine synthetase, and leads to loss 
of folates from the cell. With regard to the effects on growth of leukemia, 
the addition of nitrous oxide did not antagonize 5-FU. On the contrary, 
therapeutic effects were enhanced by combined treatment, as was evident 
from a further reduction of leukemic infiltration in spleen and liver, from a 
decrease or even disappearance of leukemic cells in the peripheral blood, 
and from extended survival of rats. These findings were in accordance with 
metabolic studies in isolated leukemic cells of treated rats, in which com-
bined treatment caused further impairment of thymidylate and DNA syn-
thesis. Pretreatment with nitrous oxide, for a period of 3 days, was more 
effective than treatment after the administration of 5-FU. Folate levels, in 
plasma and intracellular, were reduced after combined treatment. It is con-
cluded that in this leukemia, unlike observations in some models of solid 
tumors, the activity of 5-FU is enhanced with a depletion of folates. This 
effect is probably comparable to the combination of methotrexate pretreat-
ment with 5-FU, and might be important to applications of 5-FU in combi-
nation chemotherapy of hematological neoplasms. 
6.1. Introduction. 
The chemotherapeutic activity of 5-fluorouracil (5-FU) is closely related to 
folic acid metabolism. Thymidylate synthetase, the target enzyme of 5-FU 
with regard to inhibition of DNA synthesis, is dependent on folate coen-
zyme function. Recently, in several ways it has been tried to combine the 
inhibition of thymidylate synthetase by 5-FU with treatment interfering with 
folate metabolism. 5-FU has been combined with antifolates, like methotrex-
ate, which, through a depletion of folate .coenzymes, also cause impairment 
of thymidylate synthesis ( 1). On the other hand, it has also been tried to 
increase the effects of 5-FU by the concomitant administration of reduced 
folates. This approach is based on biochemical evidence that the inhibitory 
complex of thymidylate synthetase and 5-FdUMP, an anabolite of 5-FU, is 
more stable in the presence of increased levels of folate coenzyme (2,3). 
Both methods are still under investigation in clinical trials, but so far vary-
ing results have been obtained ( 4-7). Clearly, the relationship between 5-
FU and folate metabolism is rather complex, and more information will be 
useful for the optimal design of these chemotherapeutic combinations. 
In this study, we present results of experiments in which 5-FU therapy 
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is combined with inactivation of cobalamin (vitamin B 12), in a rat model 
for acute myeloid leukemia (BNML, Brown Norway Myeloid Leukemia). 
Inactivation of the cobalamin coenzyme function in the enzyme methyl-
tetrahydrofolate homocysteine methyltransferase, or methionine synthetase, 
is possible by exposure to nitrous oxide, or N70, a specific side effect of 
this anesthetic gas which was recognized only recently (8-10). Methionine 
synthetase is essential in folate metabolism, and therefore exposure to 
nitrous oxide represents yet another method to interfere with folate coen-
zyme functions. The interaction of nitrous oxide with 5-FU could, theoreti-
cally, lead to increased therapeutic effects, as well as to antagonism. We 
have previously described the reduction of leukemic growth by nitrous oxide 
in the BNML model ( 11), and have also reported on the therapeutic effects 
of 5-FU in this rat leukemia ( 12). The combination of both agents in the 
present study is directed at effects on leukemic growth and survival time of 
rats, and at some metabolic changes caused by this treatment, including the 
plasma and intracellular levels of folates, and tests of thymidylate and DNA 
synthesis in leukemic cells. 
6.2. Materials and methods. 
Animals. Male rats of the Brown Norway inbred strain were used, at the 
age of 12-16 weeks (body weight 200-275 g). Food and water were sup-
plied ad libitum during the experiments. 
Brown Norway Myeloid Leukemia fBNMLJ. Properties and use of this tran-
splantable rat leukemia have been described before (11, 13). It is considered 
to be a suitable model for experimental chemotherapy (14). In this study, 
rats were injected with 107 leukemic cells i.v., which after progressive 
leukemic infiltration of bone marrow, liver and spleen leads to death after 
20-24 days. Spleen and liver weights, steadily increasing in the course of 
leukemia, are reliable indicators of leukemic growth and, along with hema-
tological determinations, can be used effectively to assess effects of 
chemotherapy ( 13). 
Treatment with nitrous oxide and 5-FU. Exposure of leukemic rats to 
nitrous oxide was carried out in a 40 1 flow chamber in which a mixture of 
50% nitrous oxide and 50% oxygen was blown at a rate of 500 ml/min. 
Oxygen concentration was monitored with an oxygen analyzer (Teledyne 
Analytical Instruments). Carbon dioxide, water and contaminating volatile 
compounds were eliminated in a cleaning circuit ( 15). Rats not exposed to 
nitrous oxide were kept in air, but otherwise treated identically. 5-FU 
(Fluorouracil Roche, from Hoffmann-La Roche) was administered i.p., at a 
dose of 15 or 25 mg/kg, according to different treatment schedules. Rats 
not receiving 5-FU were injected with 0.15 M NaCl i.p .. 
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Evaluation of therapeutic effects. In most experiments, rats from all treat-
ment groups were compared after a fixed period of leukemia of 19 days, 
which is just before untreated rats would die spontaneously. Rats were then 
killed by exsanguination, after recording their body weights. Liver and 
spleen were carefully removed and weighed. Leukocytes were counted elec-
tronically and differential blood cell counts were done. Normal values for 
organ weights and leukocyte counts were derived from 16 comparable non-
leukemic Brown Norway rats. As an alternative method, in one experiment 
the extension of survival time in the treatment groups was compared. 
Plasma vitamin B12 and folic acid. Plasma vitamin B12 and folic acid were 
determined simultaneously using a radioisotope dilution assay, essentially as 
described by Gutcho and Mans bach ( 16). 
Studies using leukemic spleen cells. In separate experiments, leukemic rats 
were examined shortly after treatment, and leukemic spleen cells were 
obtained to perform additional metabolic studies. After washing and 
resuspension in Hanks' balanced salt solution, these cell suspensions were 
counted and used in an assay of intracellular folate levels and in deoxyuri-
dine suppression tests. 
Intracellular folate. A pellet of ca. 108 cells was resuspended in a total 
volume of 1 ml 10% ( = 1.3 M) mercaptoethanol, heated for 5 min. at 100 
°C, and cooled. After incubation with hog kidney polyglutamate hydrolase 
( 17) at room temperature for 2 hours, the samples were frozen at -20 °C 
until assayed. After thawing and centrifugation (1500 g for 10 min. at 4 °C) 
aliquots of the supernatant were used in a folate radioisotope dilution assay 
( 18) with [125I]-folic acid (Becton Dickinson, Orangeburg NY, USA) as a 
tracer, and ,6-lactoglobulin (Sigma, St.Louis, USA) as a folate binder. 5-
methyltetrahydrofolate was used as a standard and results are expressed as 
pmol of folate per 106 cells. 
Deoxyuridine suppression test. This test is used to demonstrate impaired de 
novo synthesis of thymidylate. It measures the incorporation of eH]-
thymidine into DNA without and with the addition of deoxyuridine. Deoxy-
uridine will suppress eH]-thymidine incorporation if it can be converted to 
thymidylate by the enzyme thymidylate synthetase. This suppression will be 
reduced under all circumstances with impaired activity of this enzyme (19), 
and the test therefore can be used to evaluate effects of chemotherapeutic 
agents on this metabolic pathway (20). The test was carried out essentially 
as described by Metz (21), with some modification as described ( 11). All 
incubations were carried out in triplicate, in each 5 x 106 cells were used 
with and without the addition of 0.1 mM deoxyuridine (Sigma, St.Louis, 
USA). Incorporation of eH]-thymidine (0.3 p.Ci, specific activity 25 
Ci/mmol, from Amersham, UK) in incubations with deoxyuridine is 
expressed as a percentage of the incorporation in the incubations without 
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deoxyuridine. In one experiment, however, incorporation after treatment 
was too low to detect significant differences with and without deoxyuridine, 
and in this case only eH]-thymidine incorporation in dpm/106 cells is given, 
as determined in tests without deoxyuridine. 
6.3. Results. 
Inhibition of leukemic growth. Leukemic rats were treated with 5-FU, and 
the effect of concomitant exposure to nitrous oxide was investigated. After 
a fixed period of leukemia ( 19 days) several groups were compared with 
regard to leukemic infiltration in spleen and liver, and leukemic cells in the 
peripheral blood. Results of these experiments are presented together in At 
a dose of 3x15 mg/kg 5-FU (administered at days 7, 12 and 17 of leukemia) 
the addition of nitrous oxide causes a further reduction of leukemic growth, 
which is evident from all parameters that were studied. In addition, as indi-
cated in Table 6.1, most of these differences are statistically significant if 
Wilcoxon's non-parametric rank sum test is applied to values of individual 
rats. The same result is obtained with a combination of 3x25 mg/kg 5-FU 
and nitrous oxide. In this experiment the values of rats after combined 
treatment are not significantly increased compared to normal (non-leukemic) 
rats, whereas results after treatment with 5-FU alone are still significantly 
different from normal values (p < 0.05). 
In one experiment with 1x25 mg/kg 5-FU, administered at day 14 of 
leukemia, the effects were studied of timing of exposure to nitrous oxide 
relative to the administration of 5-FU. It appears that results obtained with 
4 days of nitrous oxide before 5-FU are better than with exposure only after 
5-FU. In fact, this period of exposure does not add much to the effects of 
5-FU alone, as is evident from the rats treated with nitrous oxide for both 
periods. In Figure 6.1 results are presented of determinations of plasma lev-
els of vitamin B 12 and folic acid in these experiments. It is evident that 
with treatment there is a dose-dependent normalization of the increased lev-
els of vitamin B 12 that are found in untreated controls. In all groups, how-
ever, the addition of nitrous oxide to 5-FU causes a further fall of vitamin 
B12 to subnormal levels. The determination of folic acid levels in plasma 
leads to more varying results, but it can be derived from Figure 6.1b that 
with the more effective doses of 5-FU the addition of nitrous oxide causes a 
decrease of folic acid levels to subnormal values. 
Survival of leukemic rats. Leukemic rats were treated with 25 mg/kg 5-FU 
every 5 days, either or not preceded by a period of exposure to nitrous 
oxide of 3 days. This schedule was chosen as a consequence of the results 
in the studies presented in Table 6.1, in which pretreatment with nitrous 
oxide before 5-FU was found to be most effective. Treatment was 
Table 6.1 
EFFECTS OF TREATMENT WITH 5-FU AND NITROUS OXIDE (N20) ON GROWTH OF LEUKEMIA 
Treatment No. of Spleen weight Liver weight Peripheral %Leukemic 
rats (g±s.e.m.) (g± s.e.m.) leukocytes cells 
(109/1 ± s.e.m.) (±s.e.m.) 
None (untreated controls) 9 4.10 ± 0.10 19.14 ± 0.67 23.6 ± 2.3 29±4 
N20 only (12 days) 6 2.87 ±0.14 13.57 ±0.83 13.5 ± 1.4 23±4 
5-FU 3 X 15 mg/kg 10 2.91 ±0.20 12.52±0.69 15.6 ± 1.6 16 ±3 
5-FU 3 X 15 mg/kg + N20 (12 days) 9 1.87 ± 0.74** 11.15±0.81 7.0±1.6* 8±4* 
5-FU 1 X 25 mg/kg 3 0.85 ±0.03 8.19±0.67 5.3 ± 1.0 0 
5-FU 1 X 25 mg/kg + N20 (4 d. after 5-FU) 3 0.83 ±0.06 8.20±0.25 7.2 ±0.9 0 
5-FU 1 X 25 mg/kg + N20 (4 d. before 5-FU) 4 0.46±0.04 8.49±0.26 3.3±0.6 0 
5-FU 1 X 25 mg/kg + N20 (8 days) 5 0.43 ±0.01 7.28 ± 0.18 2.7 ±0.3 0 
5-FU 3 X 25 mg/kg 9 0.90±0.19 9.02±0.92 5.7 ± 0.8 1 ± 1 
5-FU 3 X 25 mg/kg + N20 (12 days) 9 0.49 ± 0.07** 7.48 ± 0.16** 2.7 ±0.6** 0 
Normal BN rats 16 0.45 ±0.02 8.25±0.24 3.9 ± 0.4 0 
* Significantly different from results without N20 with p < 0.-025 
** Significantly different from results without N20 with p < 0.01 
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Figure 6.1. Plasma levels of (a) vitamin B12 and (b) folic acid, in leukemic rats after 
various treatment schedules. Shaded columns indicate results with exposure to nitrous 
oxide during the treatment period. Values in normal (non-leukemic) BN rats are shown 
in the last columns. Standard error of the mean is indicated in each column. 
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Figure 6.2. Survival of leukemic rats without treatment (controls), with 5-fluorouracil 
(FU) only, and with the combination of 5-fluorouracil and nitrous oxide (FU + N
2
0). 
5-FU (25 mg/kg i.p.) was administered every 5 days. With combined therapy, rats were 
exposed to nitrous oxide 3 days before each administration of 5-FU. 
continued until death of the rats. Results of this experiment are presented in 
Figure 6.2. It appears that with addition of nitrous oxide survival of 
leukemic rats is extended to 40.2 ± 1.5 days (mean ± s.e.m.) compared to 
22.0 ± 0.5 days for untreated rats, and 34.3 ± 0.5 days for rats treated with 
5-FU alone. The results of combined treatment are significantly different 
from treatment with 5-FU only, with p < 0.005 (Wilcoxon's rank sum test). 
Survival after combined treatment is increased by 18.2 days compared to 
untreated rats ( 183%). In this leukemia m,odel, 3 days of increased survival 
are equivalent to a 10-fold reduction in tumor load ( 13), which in this case 
would mean a reduction by a factor 106. All rats were examined after death 
and without exception, leukemia was considered to be the cause of death, in 
view of increased spleen and liver weights. No evidence for toxicity was 
found. 
Deoxyuridine suppression tests. Treatment of leukemic rats with a single 
dose of 25 mg/kg 5-FU, was combined with 3 days of exposure to nitrous 
oxide, either before or after 5-FU, or both. Rats treated with 5-FU or 
nitrous oxide only, and untreated rats were also included. Leukemic spleen 
cells of all rats were used in deoxyuridine suppression tests, 3 days after 
administration of 5-FU, at day 16 of leukemia. Results of these tests are 
presented in Table 6.2. It appears that there is an enhanced effect of 
Table 6.2 
DEOXYURIDINE SUPPRESSION TESTS IN LEUKEMIC CELLS AFTER 
TREATMENT OF RATS WITH 5-FU AND NITROUS OXIDE (N2 0) 
5-FU: 1 X 25 mg/kg i.p. at 3 days before examination 
Treatment No. of o/o Suppression 
rats 
None 4 12.6 (± 1.7) 
5-FU only 4 12.8 (± 0.6) 
N20 only (3 days) 4 15.5 (± 2.1) 
5-FU + N20 (3 d., after 5-FU) 2 14.5 (13, 16) 
5-FU + N20 (3 d., before 5-FU) 2 24.0 (22,26) 
5-FU + N20 (6 days) 2 35.5 (33,38) 
Mean values of each group are given, with indication of s.e.m. in groups of 
4 rats, and of individual results in groups of 2 rats. The result of each rat is 
the mean of triple incubations. 
113 
combined treatment, indicated by a higher percentage of suppression, with 
nitrous oxide pretreatment and with continuous treatment for 6 days, but not 
with nitrous oxide exposure after 5-FU. 5-FU alone, after 3 days, does not 
cause a disturbance of this test. 
DNA synthesis in leukemiC cells. In a similar experiment, rats were exam-
ined 1 day after administration of 25 mg/kg 5-FU. In this case, only pre-
treatment with nitrous oxide for 3 days is possible. In Table 6.3, results are 
included of tumor growth in various groups, examined at day 16 of 
leukemia. As in other experiments, combined treatment is most effective in 
reducing leukemic growth. In addition, in this table results are given of 
eH]-thymidine incorporation in isolated leukemic cells of these rats. DNA 
synthesis in both groups treated with 5-FU was impaired to such an extent 
that it was not possible to perform a deoxyuridine suppression test. A small 
additional effect of nitrous oxide exposure is still detectable, however. 
Intracellular folate. In leukemic cell suspensions of rats treated in vivo with 
25 mg/kg 5-FU, 1 or 3 days before examination and with or without 3 days 
of exposure to nitrous oxide prior to the the administration of 5-FU, the 
intracellular levels of folate were determined. Results can be found in Fig-
ure 6.3. For comparison, values in untreated rats and rats treated with 3 
days of nitrous oxide only, are also given. With 5-FU treatment there is 
some decrease of folate content, more apparent at the first day after 
administration, but with the addition of nitrous oxide folate loss becomes 
much more severe. 
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Table 6.3 
EFFECTS OF TREATMENT WITH 5·FU AND NITROUS OXIDE (N2 0) ON GROWTH OF 
LEUKEMIA AND ON DNA SYNTHESIS IN LEUKEMIC CELLS 
5-FU: 1 X 25 mg/kg i.p. at day 1 before examination 
Examination at day i 6 of leukemia 
Treatment No. of Spleen weight Peripheral 3H-thymidine 
rats (g±s.e.m.) leukocytes incorporation 
(109/1 ± s.e.m.) (dpm/1 os cells± s.e.m.) 
None 3 2.65 ±0.18 10.8±0.7 3522±942 
N20 only (3 days) 3 1.83±0.06 8.8± 1.6 2135±536 
5-FU only 3 1.01 ± 0.06 5.1 ±0.1 243± 71 
5-FU + N20 (3 d., before 5-FU) 3 0.68±0.04 4.2±0.2 173± 17 
Value of 3H·thymidine incorporation in leukemic cells of each rat is the mean of triple incubations. 
For normal values of spleen weight and leukocyte count in BN rats, see Table 6.1. 
6.4. Discussion. 
Nitrous oxide disturbs folate metabolism because of its specific interference 
with the coenzyme function of cobalamin, which causes inactivation of the 
enzyme methionine synthetase (22). This prevents the conversion of 5-
methyltetrahydrofolate into tetrahydrofolate, which is essential for folate 
coenzyme functions. The effects of nitrous oxide develop rapidly, in a few 
hours after exposure is started, and remain remarkably constant even with 
prolonged exposure of one week or more (23). 
In this report exposure to nitrous oxide has been used to study the 
effects of impaired availability of folate coenzyme forms on the activity of 
5-FU towards the the BN rat leukemia. It appeared that the therapeutic 
effects of 5-FU were increased with the addition of nitrous oxide, with 
regard to the reduction of leukemic infiltration in spleen and liver, as well 
as with regard to leukocyte counts. In addition, compared to treatment with 
5-FU alone, there was a significantly increased survival of leukemic rats 
after combined treatment. In none of the treatment schedules there was any 
indication of antagonism, and no evidence of increased toxicity was found. 
Plasma levels of vitamin B12 in this study are interesting for two rea-
sons. First, in this leukemia vitamin B 12 steadily increases with progression 
of disease (11), an effect which is also often observed in human promyelo-
cytic leukemia (24). Treatment of leukemia will reduce vitamin B12 to 
about normal levels. Separately, however, the specific effect of nitrous 
oxide on vitamin B 12 will cause an additional fall of plasma levels ( 11 ,25). 
These effects explain both the dose-dependent reduction of plasma vitamin 
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Figure 6.3. Intracellular folate levels in isolated leukemic cells after in vivo treatment of 
rats. 5-FU (25 mg/kg) was administered at 1 day and 3 days before examination, respec-
tively, either or not preceded by 3 days of exposure to nitrous oxide (shaded columns). 
Standard error of the mean is indicated in each column. 
B12 with treatment, and the occurrence of the lowest, subnormal, levels in 
rats with combined therapy. 
The disturbance of folic acid metabolism by nitrous oxide is evident 
from the striking decrease of intracellular folates in leukemic cells after 3 
days of exposure. Folate depletion with nitrous oxide exposure has often 
been observed (26), and is explained by a decreased synthesis of folate 
polyglutamates (27), as these forms are essential for cellular retention. 
Interestingly, 5-FU by itself also caused a, less pronounced, fall in intracel-
lular folates, compared to untreated rats. This is evidence of a blockade in 
folate metabolism, as will indeed occur with inhibition of thymidylate syn-
thetase, but the precise mechanism of this effect remains unclear. As would 
be expected, intracellular folate is lowest with combined treatment, one day 
after the administration of 5-FU. 
The intracellular depletion of folates will ultimately also lead to reduced 
plasma levels of folate, as is demonstrated by the subnormal levels found 
after combined treatment with nitrous oxide and higher doses of 5-FU. 
Temporarily, however, loss of folates from the tissues can give rise to 
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increased concentrations of folate in plasma, as has been observed before 
with nitrous oxide exposure ( 11 ,28). This can explain the observations in 
this study of increased folate levels in rats after nitrous oxide alone and after 
low doses of 5-FU. 
With regard to the mechanism of the interaction described in this study, 
an important observation is the significance of pretreatment with nitrous 
oxide. With nitrous oxide exposure after 5-FU, there was no enhancement 
of the effects of 5-FU on leukemic growth, and even some indication of a 
reduced effect in the deoxyuridine suppression test. A similar schedule-
dependency of combination therapy is found with methotrexate and 5-FU 
(29,30). In that combination, methotrexate pretreatment is essential to 
achieve synergistic effects. If 5-FU precedes methotrexate, antagonism will 
result (1). Several mechanisms have been proposed to explain these effects 
(31). Probably, the inhibition of purine synthesis by methotrexate is impor-
tant, because this can lead to increased formation of 5-FU-nucleotides, 
interfering with both thymidylate (DNA) and RNA synthesis (32). This 
effect could also occur with nitrous oxide treatment, which can impair 
purine synthesis as well (33,34). Other mechanisms may be involved how-
ever. Unlike methotrexate, nitrous oxide treatment for up to 3 days increases 
the activity of thymidylate synthetase (35), probably as an adaptive mechan-
ism. Subsequent inhibition of this enzyme by 5-FU could render cells more 
vulnerable to the effects of nitrous oxide. This would also explain the 
necessity of pretreatment to achieve increased effects. Finally, it has been 
reported (2) that the addition of vitamin B 12 and 5-methyltetrahydrofolate 
decreased the stability of the binding of 5-FdUMP to thymidylate synthetase. 
Prolonged exposure to nitrous oxide will decrease both these factors, and 
could therefore stabilize the inhibitory complex. 
An important result of this study is the observation that some degree of 
folate depletion does not necessarily antagonize the effects of 5-FU. This 
conclusion obviously only applies to the leukemia model used in this study, 
but, interestingly, in another experimental leukemia it has been found that 
the addition of reduced folates to 5-FU did not increase therapeutic effects 
(36). Furthermore, no increased cytoxicity resulted from folate addition to 
cultured leukemic cells treated with methotrexate and 5-FU (37). In that 
study, it was also concluded that the interactions of 5-FU and folates were 
more complex and variable than was previously understood. The synergistic 
effect of folates and 5-FU as observed in xenografts of colon carcinomas 
might well be tissue specific to some degree. As discussed in another study 
( 12), 5-FU is not used clinically in the treatment of leukemia. Recently 
however, sequential methotrexate/5-FU therapy has been applied to human 
leukemia with favourable results (38). This report further adds to the 
potential importance of 5-FU, alone or in combination with other agents 
interfering with folate-dependent nucleotide synthesis, in the treatment of 
leukemia. 
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Chapter seven 
NITROUS OXIDE 
AND INHIBITORS OF 
POLY AMINE SYNTHESIS 
IN RAT LEUKEMIA 
This chapter has been submitted for publication, titled "The reduction of 
intracellular polyamines by sequential inhibition of the synthesis of decar-
boxylated S-adenosylmethionine: effects on rat leukemia", by A.C .M. 
Kroes, A.A.M. Ermens, J. Lindemans, M. Schoester, and J. Abels. 
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Abstract. Decarboxylated S-adenosylmethionine (SAM) is an aminopropyl-
donor in the synthesis of the polyamines spermidine and spermine. The 
decarboxylation of SAM is inhibited by the toxic cytostatic drug MGBG. 
To achieve more specific and less toxic effects of MGBG, this drug was 
combined with cycloleucine, which inhibits SAM synthesis, and with nitrous 
oxide, which inhibits methionine synthetase. This treatment thus aimed at 
sequential inhibition of the synthesis of decorboxylated SAM, and was stu-
died in a rat leukemia model (BNML). Combined treatment further 
decreased the level of spermine, but not of spermidine, in leukemic cells, 
compared to the effects of MGBG alone. The therapeutic effects of this 
combination were additive or less than additive, however. MGBG was not 
very effective in reducing leukemic growth and severely toxic, although less 
with combined treatment. Another inhibitor of SAM decarboxylase, 
berenil, was also used, and although this drug was about equally active in 
inhibition of leukemic growth, alterations in intracellular polyamines were 
not observed. The combination of nitrous oxide and cycloleucine, which 
effectively reduced leukemic growth at non-toxic dosages, selectively inhi-
bited spermine synthesis, and therefore may be applied to interfere with 
polyamine metabolism. The relevance of this polyamine deprivation to the 
treatment of leukemia could not be demonstrated. 
7 .1. Introduction. 
The polyamines spermidine and spermine have essential functions in cellular 
proliferation ( 1 ,2), and the biosynthesis of these compounds is therefore 
considered a target in cancer chemotherapy (3). In the pathway of polyam-
ine synthesis putrescine is converted into spermidine by the addition of an 
aminopropyl group, derived from decarboxylated S-adenosylmethionine 
(SAM), and the subsequent synthesis of spermine requires a second ami-
nopropyl donation. From this pathway, it is evident that decarboxylated 
SAM is an essential intermediate, and interference with the enzymatic decar-
boxylation of SAM is an obvious approach to the inhibition of polyamine 
synthesis (4). Methylglyoxalbis(guanylhydrazone) or MGBG, also known 
as methyl-GAG and mitoguazone, is a cytostatic agent which is known to 
inhibit the decarboxylation of SAM ( 5 ,6). As the impairment of cellular 
proliferation caused by this drug can be prevented by the addition of sper-
midine (7 ,8), the inhibition of polyamine synthesis is indeed considered to 
be its mechanism of action. The application of MGBG in the treatment of 
cancer is limited by its severe toxicity, which probably relates to other meta-
bolic effects of this drug, notably its ability to cause severe mitochondrial 
damage (9). This action appeared to be independent of the effects on 
polyamines ( 10). 
In this study, it is attempted to enhance the specificity of the inhibition 
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Figure 7.1. Three sequential steps in the synthesis of decarboxylated S-
adenosylmethionine, with indication of the inhibitors applied in this study. The role of 
decarboxylated S-adenosylmethionine in the synthesis of the polyamines spermidine and 
spermine is shown. 
of decarboxylated SAM synthesis by MGBG through concomitant interfer-
ence with two preceding steps in this pathway. As outlined in Figure 7.1, 
these steps involve the synthesis of methionine and SAM, catalyzed by 
methionine synthetase and methionine adenosyltransferase, respectively. 
Methionine synthetase can be inhibited by exposure to nitrous oxide (N20), 
which inactivates its cobalamin coenzyme (11), and the inhibition of 
methionine adenosyltransferase is accomplished by the amino acid analogue 
cycloleucine, or 1-aminocyclopentane carboxylic acid ( 12). The combined 
use of nitrous oxide, cycloleucine and MGBG thus represents a sequential 
inhibition of the synthesis of decarboxylated SAM, which may enhance the 
selectivity of the effects of MGBG on this pathway. The modulation of 
polyamine synthesis by interference with the role of SAM was extensively 
reviewed recently (3). 
Nitrous oxide inhibits cellular proliferation in vitro ( 13) and in vivo 
(14), and is known to decrease the intracellular levels of methionine and 
SAM (15,16). Cycloleucine has cytostatic properties as well (17), and in a 
previous study it was shown that the combination of these two agents 
resulted in a synergistic inhibition of leukemic growth ( 18). 
We now report on the effects of nitrous oxide and cycloleucine, com-
bined with MGBG in an experimental rat leukemia, the Brown Norway 
Myeloid Leukemia (BNML). ~.LGBG has been considered a promising 
124 
CH HN:--._ 1 3 ...-:NH 
'e-N H-N=C-CH=N-NH-C"' 
H N/ 'NH 
2 2 
spermidine MGBG 
berenil cycloleucine 
Figure 7.2. Structures of spermidine, MGBG (mitoguazone, methyl-GAG), berenil and 
cycloleucine. 
agent in the treatment of leukemia (6, 19-21). Along with treatment results 
of various combinations, polyamine levels were determined in isolated 
leukemic cells, after in vivo treatment of rats. In addition to MGBG, the 
antiparasitic drug berenil was used in some experiments, since it was 
recently reported that this drug is an inhibitor of SAM decarboxylase as well 
(22). The structural formulas of these drugs and of spermidine are shown 
in Figure 7.2. 
7 .2. Materials and methods. 
Animals. Male rats of the Brown Norway inbred strain were used, at the age 
of 12-16 weeks (body weight 200-275 g). Food and water were supplied ad 
libitum during the experiments. 
Brown Norway Myeloid Leukemia (BNMLJ. Properties and use of this tran-
splantable rat leukemia have been described before ( 14,23). It is considered 
to be a suitable model for experimental chemotherapy (24). In this study, 
rats were injected with 107 leukemic cells i.v., which after progressive 
leukemic infiltration of bone marrow, liver and spleen leads to death in 20-
24 days. Spleen and liver weights, steadily increasing in the course of 
leukemia, are reliable indicators of leukemic growth and, along with hema-
tological determinations, can be used effectively to assess effects of 
chemotherapy ( 14). 
Treatment of rats. MGBG was administered at doses of 20 to 80 mg/kg by 
i.p. injection of MGBG dihydrochloride (Aldrich, Milwaukee, USA) dis-
solved in water containing 0.15 mol/1 NaCL Treatment started at day 8 of 
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leukemia, and was repeated every 3 days until day 17. Exposure of rats to 
nitrous oxide was carried out in a 40 1 flow chamber in which a mixture of 
50% nitrous oxide and 50% oxygen was blown at a rate of 500 ml/min. 
Oxygen concentration was monitored with an oxygen analyzer (Teledyne 
Analytical Instruments). Carbon dioxide, water and contaminating volatile 
compounds were absorbed in a cleaning circuit (25). Exposure started at 
day 7 of leukemia and was continued until the end of the experiments at day 
18. Rats not exposed to nitrous oxide were kept in air, but otherwise 
treated identically. Cycloleucine was administered at day 7 of leukemia, as 
a single i.p. injection of 50 mg/kg cycloleucine (Sigma, St.Louis, USA), 
dissolved in water containing 0.15 mol/1 NaCl. Berenil or diminazene 
aceturate (Sigma, St.Louis, USA) was administered at doses of 12.5 to 75 
mg/kg, dissolved in water containing 0.15 mol/1 NaCl, by the same schedule 
as described for MGBG. 
Evaluation of therapeutic effects. In all experiments, rats from the various 
treatment groups were compared after a fixed period of 18 days, which is 
just before untreated rats would die spontaneously. Rats were killed by 
exsanguination, after recording their body weight. Liver and spleen were 
carefully removed and weighed. Leukocytes were counted electronically. 
Normal values for organ weights and leukocyte counts were derived from 16 
comparable non-leukemic Brown Norway rats. 
Intracellular polyamines. Leukemic spleen cells were washed, resuspended 
in Hanks' solution and counted. Intracellular polyamines were separated 
and quantified as their dansylated derivatives by HPLC as described (26). 
Modifications were the use of a Hypersil ODS ( 4.6 mm ID x 150 mm) 
column (Chrompack, Middelburg, The Netherlands), and a methanol gra-
dient of 75 to 100% in 14 min. Retention times were: internal standard 
1,6-diaminohexane 9.5 min, putrescine 8.2 min, spermidine 11.8 min and 
spermine 13.2 min. Interference of polyamine peaks with MGBG or 
Berenil was excluded. Polyamine values are the mean of duplicate determi-
nations, and are expressed in nmol/106 cells. 
DNA and protein content of leukemic cells. In one experiment, DNA and 
protein content of leukemic cells were determined in addition to the assay of 
polyamines. A DNA assay based on the colorimetric diphenylamine method 
was used (27), and protein was measured by the Folin-Ciocalteu method 
(28). 
7 .3. Results. 
Effects of treatment on leukemia. The results are presented in Table 7.1, 
with indication of the spleen and liver weights, and the leukocytes counts in 
each treatment group, as determined after 18 days of leukemia. In addition 
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the number of rats dying prematurely, that is before 18 days, is indicated. 
As premature death was rare in untreated rats, this result 
Table 7.1 
THERAPEUTIC EFFECTS IN LEUKEMIC RATS OF MGBG, NITROUS OXIDE, 
CYCLOLEUCINE AND BERENIL. 
Treatment a Initial Premature Spleen Liver Peripheral 
number or toxic weight weight leukocytes 
of rats deaths (g±s.d.} (g±s.d.) (1 09/1 ± s.d.) 
None (controls) 18 2 4.23 ±0.48 17.81 ± 2.24 19.6± 6.4 
Nitrous oxide 10 0 2.88±0.53 14.44 ± 1.99 9.0± 5.7 
Nitrous oxide + cycloleucine 12 0 2.22±0.39 12.13± 1.78 6.7± 3.7 
MGBG20 3 0 4.00±0.50 15.92 ± 1.38 21.0± 1.7 
+nitrous oxide+ cycloleucine 3 0 1.97±0.46 11.92 ± 1.52 5.7± 1.8 
MGBG40 15 2 3.46±0.32 15.37 ± 1.55 16.6± 6.7 
+ cycloleucine 5 0 3.25±0.23 13.36± 1.32 11.3± 1.7 
+ nitrous oxide 4 0 2.59±0.60 12.67± 1.32 4.1 ± 1.7 
+ nitrous oxide + cycloleucine 7 0 2.13 ± 0.35 11.91 ± 1.07 6.7± 2.4 
MGBG50 5 3 2.35 15.71 32.5 
+ nitrous oxide+ cycloleucine 5 0 2.73±0.32 15.06±1.79 10.2± 2.1 
MGBG60 6 5 1.69 10.57 15.2 
+ nitrous oxide+ cycloleucine 6 6 
MGBG80 3 3 
Berenil12.5 4 1 3.46±0.50 15.24± 1.74 10.6± 5.0 
+nitrous oxide+ cycloleucine 4 0 2.42±0.26 11.74±0.51 3.2± 0.6 
Berenil25 9 4 3.18±0.27 15.72 ±2.93 14.2± 3.9 
+ nitrous oxide+ cycloleucine 5 0 1.97 ±0.11 11.15 ± 0.49 2.3± 0.2 
Berenil50 4 4 
+ nitrous oxide+ cycloleucine 4 1 1.94±0.42 11.70±0.86 2.3± 0.8 
Berenil75 3 3 
Berenill2.5 + MGBG 20 4 0 2.96±0.38 13.21 ± 2.18 21.1 ± 10.0 
+ nitrous oxide+ cycloleucine 4 0 1.82±0.09 11.85±0.89 2.8± 1.6 
Normal (non-leukemic) rats 16 0.45±0.07 8.25±0.99 3.9± 1.3 
a Dose of MGBG and Berenil is indicated in mg/kg (q 3d.) 
represents an estimation of the toxicity of treatment. From the data in Table 
7.1, it appears that MGBG is severely toxic at doses of 50 mg/kg and 
higher. Rats receiving 80 mg/kg died 1 or 2 days after the first injection. 
Most experiments were done with 40 mg/kg MGBG (q.3 d.), since this dose 
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was only moderately toxic, with still measurable therapeutic effects. The 
addition of nitrous oxide and/or cycloleucine to this dose of MGBG more 
effectively inhibited leukemic growth. The results are about additive, if 
compared with the effects of nitrous oxide and cycloleucine alone. Toxicity 
with combined treatment was less in rats receiving 50 mg/kg MGBG, but 
was not different at 60 mg/kg. 
Results of treatment with berenil, also summarized in Table 7. .1, are not 
much different from the results obtained with MGBG. Combined treatment 
with nitrous oxide/ cycloleucine and berenil, 25 or 50 mg/kg, was most 
effective, with apparently very little toxicity. Berenil, administered alone, 
was increasingly toxic at doses from 12.5 mg/kg. 
The simultaneous administration of low doses of MGBG and berenil, 
combined with nitrous oxide and cycloleucine, resulted in pronounced inhi-
bition of leukemia, without causing toxicity. 
Effects on intracellular polyamine levels. Putrescine could be determined 
reliably in leukemic cells after MGBG treatment only. In all other cases, 
putrescine was less than 0.08 nmol/106 cells. MGBG at a dose of 40 mg/kg 
resulted in a putrescine level of 0.52±0.08 nmol/106 cells (n=7). There 
was no further elevation with the addition of nitrous oxide, cycloleucine or 
berenil. Spermidine was highest in cells obtained from untreated rats (mean 
level: 0.74±0.10 nmol/106 cells, n= ~6), and reduced by treatment with 40 
mg/kg MGBG to 0.56±0.08 nmol/10 cells (n= 11), but was not influenced 
by nitrous oxide/cycloleucine treatment, with a mean level of 0.74±0.12 
nmoll 106 cells (n = 8). The most interesting results were obtained with the 
determination of intracellular spermine levels, which are shown in Figure 
7.3. With MGBG treatment, there is a dose-dependent reduction of sper-
mine. Nitrous oxide alone, and nitrous oxide combined with cycloleucine 
also lead to reduced levels. In addition, if these agents are combined with 
MGBG there is a further reduction at all doses of MGBG. Surprisingly, 
berenil alone was not able to cause reduction of spermine or spermidine lev-
els. Neither did this drug have synergistic effects with nitrous oxide and 
cycloleucine in this respect, and combinations of berenil with these drugs 
and MGBG result in the same spermine values as found without berenil. 
DNA and protein content of leukemic cells. In one experiment, leukemic 
cells were obtained from four groups of 3 leukemic rats each, which were 
untreated, or treated with either nitrous oxide/cycloleucine, MGBG 1x60 
mg/kg, or a combination of both. The mean DNA content, expressed per 
cellular protein, was lowest in the controls, 0.126 mg DNA/mg protein, and 
increased with treatment: 0.151 after nitrous oxide/cycloleucine, 0.167 after 
MGBG and 0.162 after MGBG with nitrous oxide/cycloleucine. 
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Figure 7.3. Spermine concentrations in leukemic cells after in vivo treatment of rats. In-
dividual results of rats are indicated by dots, and columns indicate the mean of each 
group. Values are expressed in nmol/106 cells. Dose of MGBG and berenil is indicated 
in mg/kg ( q. 3 days). Controls are untreated leukemic rats. 
7 .4. Discussion. 
Cellular polyamine deprivation is a potentially valuable approach in cancer 
chemotherapy, although it is not easily achieved in vivo. One of the agents 
most widely applied for this purpose is MGBG, a drug inhibiting SAM 
decarboxylase but with other biochemical effects as well, which probably 
cause its severe toxicity. As the particular toxic effect of MGBG on mito-
chondria appears unrelated to its effect on polyamines ( 10), an obvious 
approach in the reduction of toxicity would be a combination with other 
agents impairing the synthesis of decarboxylated SAM. 
In this study, it has been tried to increase the specificity of MGBG by 
aiming at a sequential inhibition of the biosynthesis of decarboxylated SAM. 
The addition of nitrous oxide and cycloleucine will reduce SAM synthesis. 
This could enhance the inhibition of SAM decarboxylase by MGBG, which 
is known to be competitive with the substrate SAM ( 5). 
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The inhibition of leukemic growth by MGBG was unimpressive, com-
pared with results obtained with nitrous oxide and cycloleucine, or with 5-
fluorouracil in a previous study, employing the same leukemia model (29). 
This is remarkable in view of some early clinical studies reporting promising 
effects in human acute myeloid leukemia ( 19-21), although not all studies 
were positive (30). Severe toxicity has limited its use, and was also 
observed in our experiments. The combination of MGBG with nitrous 
oxide and cycloleucine further inhibited leukemic growth, but results were 
about additive, with only slightly reduced toxicity. The results obtained 
with berenil in leukemic rats were essentially the same as with MGBG. Nei-
ther drug was able to improve the results of nitrous oxide and cycloleucine 
substantially. In the experiment combining low doses of MGBG and 
berenil, there was an additional effect on leukemia without increased toxi-
city. Interestingly, the antifungal agent stilbamidine, which is structurally 
nearly identical to berenil, has been reported to potentiate the effect of 
MGBG on mouse leukemia in early studies (31). 
These observations on the effects on leukemic growth in rats should be 
interpreted together with the results of the simultaneous determinations of 
intracellular polyamines in leukemic cells. The alterations of polyamine lev-
els caused by MGBG treatment were as expected: an increase in putrescine, 
with a decrease of spermidine and spermine. Nitrous oxide, and nitrous 
oxide with cycloleucine, caused a decrease of spermine levels only, and 
could further decrease spermine levels if combined with MGBG. This 
selective effect on spermine may be explained by the fact that the synthesis 
of this polyamine requires a twofold aminopropyl donation from decarboxy-
lated SAM. With other inhibitors of polyamine synthesis, the reduction of 
spermine levels often is only limited (32). As spermine is the main polyam-
ine in the nucleus (33), it is expected to be functionally important. 
Although with combined treatment spermine levels were clearly further 
reduced, even to 35% of normal values, the accompanying enhancement of 
therapeutic results was additive at best. Similar absence of growth inhibition 
by selective spermine depletion has been reported before (34), and in a 
leukemic cell line only a weak correlation between spermine depletion and 
growth control was found (35). In spite of its therapeutic effect, which was 
about equal to MGBG, berenil did not have any measurable influence on 
polyamine levels. 
These results therefore raise some questions concerning the use of 
polyamine deprivation in cancer chemotherapy. There appears to be no 
direct correlation between the therapeutic results and the intracellular 
polyamine levels with a number of metabolic inhibitors. Berenil, although 
an active inhibitor of SAM decarboxylase in vivo in rats (22), did not have 
effects on polyamines. Its therapeutic, and toxic, properties thus may as 
well be the result of some other effect of this drug. This has been suggested 
before with regard to MGBG (36,37). Furthermore, the rat leukemia 
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employed in this study, which has been shown to be a reliable model for 
human acute myeloid leukemia (24), was only minimally sensitive to 
polyamine deprivation, in contrast to expectations based on clinical observa-
tions on the use of MGBG. 
An interesting result of this study is the observation of reduced sper-
mine levels with inactivation of the cobalamin coezyme of methionine syn-
thetase by nitrous oxide. This suggests that to some extent the biosynthesis 
of polyamines is dependent on cobalamin (vitamin B 12). A role of cobala-
min in polyamine synthesis has not been observed before. In a recent report 
on the effects of polyamine deprivation in CHO cells (38), it was noticed 
that these cells became closely resemblant to megaloblastic cells, as observed 
in cobalamin deficiency. Although it is well established that cobalamin defi-
ciency leads to a disturbance of folate metabolism, it might be that reduced 
polyamine synthesis contributes to the impairment of cellular proliferation. 
The cellular DNA contents after treatment indicated a blockade in the S 
or G2 phase rather than earlier in the cell cycle. This differs from the 
results of a recent study, in which depletion of polyamines reduced DNA 
contents of cultured BHK cells (39). Similar variations between cell types 
in this respect have been described before, however ( 40). 
It can be concluded that sequential inhibition of the synthesis of decar-
boxylated SAM further reduces the intracellular level of spermine in the 
treatment of leukemic rats with MGBG, but that this does not lead to syn-
ergistic effects on leukemic growth. The rat leukemia model used in this 
study was not as sensitive to polyamine depletion as was expected, and both 
inhibitors of SAM decarboxylase proved very toxic. Nitrous oxide alone, 
and combined with cycloleucine, effectively can decrease spermine levels, 
which may be applied in the study of polyamine synthesis, and also supports 
a potential function of cobalamin in this pathway. 
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Abstract Prolonged exposure to the anesthetic gas nitrous oxide (N20) decreases cellular proliferation and causes megaloblastic bone marrow 
depression. This effect is the result of oxidation, by nitrous oxide, of the 
cobalamin coenzyme of methionine synthetase, an essential enzyme in folate 
metabolism. This oxidation completely inactivates the enzyme and leads to 
a severe cellular depletion of folic acid coenzymes, resulting in impaired 
folate-dependent synthesis of thymidylate ( dTMP). As hematopoietic cells 
are specifically dependent on the function of cobalamin, the effect of nitrous 
oxide is potentially valuable in the treatment of leukemia. In this study, 
leukemic cells we~;e used, obtained from bone marrow aspirates and peri-
pheral blood of patients with acute leukemia. Nucleated cells were 
suspended in culture flasks and exposed to nitrous oxide by gassing the 
flasks, alone or combined with methotrexate (MTX) dissolved in the culture 
medium. After a fixed period of 20 hrs, the cultured cells were used in the 
deoxyuridine (dU) suppression test, which measures the disturbance of 
folate-dependent dTMP synthesis. In 15 of 16 bone marrow samples, and 6 
of 9 peripheral blood samples, exposure to nitrous oxide increased the dU 
suppression value by about 150%, indicating disturbed de novo synthesis of 
dTMP. Suppression values obtained with MTX alone were further 
increased by nitrous oxide exposure. In addition, two human hematopoietic 
cell lines, HL60 and U937, were also tested. A consistent disturbance of 
the dU suppression test on exposure to nitrous oxide was found with U937 
cells only, as HL60 cells appeared to grow largely independent of cobalamin 
supply. It is concluded that human leukemic cells usually are sensitive 
towards the effect of cobalamin inactivation in vitro, as evident from a dis-
turbed folate-dependent thymidylate synthesis, which is in accordance with 
previous in vivo results in a rat leukemia model. Cobalamin-antagonists 
thus may reduce leukemic proliferation, or enhance the therapeutic effects 
of related drugs, like MTX, in vivo as well as in vitro. 
8.1. Introduction. 
Cobalamin, or vitamin B 12, is a nutritional factor indispensable for the 
maintenance of normal hematopoiesis. This is explained by its role as a 
coenzyme in the enzyme methionine synthetase, or 5-methyltetrahydrofolate 
homocysteine methyltransferase. This enzyme is essential in the metabolism 
of reduced folates, and, as several steps in the biosynthesis of nucleotides 
are dependent on the function of folate coenzymes, this provides the link 
between cobalamin deficiency and a disturbance of hematopoietic prolifera-
tion. This immediate importance to proliferating cells makes the metabolism 
of reduced folates a potential target in the chemotherapy of malignant 
tumors. Structural analogues of reduced folates, notably methotrexate, have 
demonstrated the validity of this approach. It has been attempted to find 
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similar antagonists of the essential function of cobalamin in folate metabol-
ism, but early efforts, mainly with structural analogues, were largely unsuc-
cessful (1-3). No effective antagonist of cobalamin was known until the 
recognition of a peculiar side effect of the anesthetic gas nitrous oxide in 
1978 ( 4), which already was known to cause megaloblastic hematopoiesis on 
prolonged exposure (5). Nitrous oxide inactivates the methylcobalamin 
coenzyme of methionine synthetase, resulting in a virtually complete inhibi-1 
tion of this enzyme ( 6). This has been explained by an oxidative effect of 
nitrous oxide on the cobalt moiety of cobalamin (7). The availability of a 
genuine cobalamin antagonist has revived the interest in possible applica-
tions in chemotherapy. In addition, the demonstration of the cobalamin 
dependence of malignant proliferation is of more general interest. We have 
shown previously that nitrous oxide reduces the growth of leukemia in rats 
(8), and renders the leukemic rats more susceptible to subsequent metho-
trexate therapy (9). Kano et al. (10) have demonstrated that nitrous oxide 
inhibits nucleotide synthesis and proliferation in a number of h.uman hema-
topoietic cell lines. In this study, we have investigated the effects of nitrous 
oxide in vitro on human leukemic bone marrow and peripheral blood cells, 
of patients with different types of acute leukemia. The assessment of the 
sensitivity of human leukemia to nitrous oxide should be considered an 
essential step towards the application of cobalamin inactivation in clinical 
chemotherapy. The effects on two human leukemic cell lines, HL60 and 
U937, were studied for comparison. The deoxyuridine suppression test, 
being an established method to demonstrate the metabolic consequences of 
cobalamin deficiency or inactivation, was used to evaluate the effects of 
nitrous oxide. 
8.2. Materials and methods. 
Leukemic bone marrow and blood cells. Bone marrow aspirates and peri-
pheral blood samples were obtained from consenting patients with a diag-
nosis of acute leukemia. The patients were untreated, or, in some cases, in 
early relapse of their disease. Each marrow aspirate, usually 5-10 ml, was 
collected in a sterile bottle containing 0.4 ml (2000 IU) heparin. Peripheral 
blood was collected in heparinized tubes. Each case of acute myeloid 
leukemia (AML) was morphologically and cytochemically classified accord-
ing to the FAB classification (11,12), and cases of acute lymphoid leukemia 
(ALL) were classified according to immunological phenotype. The percen-
tage of leukemic blasts in each sample was determined in a differential 
count of 500 cells. Marrow cells from one case of a myelodysplastic syn-
drome, and from four normal aspirates were also studied. 
Isolation of nucleated cells from marrow and blood. Nucleated cells from 
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bone marrow aspirates, diluted with an equal volume of Hanks' balanced 
salt solution (HBBS), and from peripheral blood samples, were isolated by 
sedimentation through 2% methylcellulose at an angle of 45° in about 10 
min. The cells were washed in HBBS, counted and diluted to a concentra-
tion of 106/ml with McCoy's medium 5A, modified by replacement of folic 
acid by 400 nmol/1 methyltetrahydrofolate (Sigma, St.Louis, USA), limita-
tion of methionine to 25 p,mol/1, and omission of cobalamin. Viability of 
the cells was checked by trypan blue exclusion. 
Exposure of cells to nitrous oxide. Cell suspensions (5 ml in flasks of 50 
ml) were exposed to nitrous oxide by gassing the culture flasks during 30 
min with a filtered mixture of 50% nitrous oxide, 20% oxygen, 25% nitro-
gen and 5% carbon dioxide, released from a premixed cylinder (Hoekloos, 
Schiedam, The Netherlands). After this period, the flasks were closed and 
incubated overnight for about 20 h at 37 °C. Control suspensions were 
exposed to a mixture of air with 5% carbon dioxide, and otherwise treated 
identically. After incubation, cell viability was checked again by trypan 
blue exclusion. 
Addition of methotrexate. Methotrexate (Ledertrexate SP, from Lederle) was 
added in a negligible volume to the culture flasks in some experiments, to a 
final concentration of 50 nmol/1. 
Deoxyuridine suppression test. This test was used to evaluate the impairment 
of the de novo synthesis of thymidylate as a consequence of the disturbance 
of folate metabolism by nitrous oxide or methotrexate. [3H]-Thymidine 
incorporation into DNA is measured with and without the pre-incubation of 
cells with deoxyuridine. Deoxyuridine suppresses the incorporation of 
eH]-thymidine if it can be converted to thymidylate by folate-dependent 
methylation. If this conversion is impaired, the suppression by deoxyuri-
dine will be reduced. The test values are expressed as the percentage ratio 
of the eH]-thymidine incorporation with and without deoxyuridine in the 
same cell suspension. The test was carried out essentially as described by 
Metz et al. (13), with some modifications. The concentration of deoxyuri-
dine was 0.1 mmol/1. The duration of pre-incubation, either with or without 
deoxyuridine, as well as of incubation with eH]-thymidine was 2 hours. 0.3 
p,Ci of eH]-thymidine with a specific activity of 25 Ci/mmol (Amersham, 
UK) was used per test, with about 106 cells. All results are the mean of tri-
ple incubations. 
Culture of leukemic cell lines. Two cell lines, HL60 and U937, were also 
tested. The HL60 cell line originated from a human acute promyelocytic 
leukemia and has been described extensively ( 14). U937 is a hematopoietic 
cell line derived from a patient with true histiocytic lymphoma ( 15), consist-
ing of monocyte-like cells. A comparative review of the two cell lines was 
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published recently ( 16). Samples of these cell lines were kindly provided 
by dr N. de Both (Dept. of Pathology, Erasmus University Rotterdam). 
The cells were cultured in suspension, in McCoy's medium with 10% fetal 
calf serum (Gibco), prepared without the addition of folic acid, cobalamin 
or methionine, as these constituents have to be carefully controlled in stu~ 
dies on cobalamin and folic acid metabolism. 5-Methyltetrahydrofolate 
(Sigma) was added to replace folic acid (pteroylglutamic acid). In most 
experiments, conditions and concentrations were as described by Kano et 
al., with 200 nmol/1 of 5-methyltetrahydrofolate ( 10). After each series of 
experiments, the cultures were replaced by fresh cells from the same frozen 
stock. Experiments were carried out with cells in a logarithmic growth 
phase. Exposure to nitrous oxide and subsequent incubations were per-
formed as described for bone marrow cells. 
8.3. Results. 
Patient characteristics are summarized in Table 8.1. In all of 16 cases, the 
normal bone marrow was largely replaced by leukemic cells, with a mean of 
73.1% (± s.d. 24.1) of leukemic blasts. 
Table 8.1 
CHARACTERISTICS OF PATIENTS 
Number of patients 
male 
female 
Mean age 
Diagnosis 
acute myeloid leukemia 
FABtype M1 
M2 
M4 
M5 
acute lymphoid leukemia 
null-ALL 
c-ALL 
B-ALL 
T-ALL 
myelodysplastic syndrome 
16 
11 
5 
37.7y. 
9 
1 
2 
4 
2 
6 
1 
2 
1 
2 
1 
The results of deoxyuridine suppression tests after nitrous oxide exposure of 
the leukemic marrow cells, compared to the same cells exposed to air, are 
shown in Figure 8.1a. In 15 of the 16 cases, the exposure to nitrous oxide 
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caused a marked increase of the test value, indicating an impaired ability to 
use deoxyuridine as a substrate in the de novo synthesis of thymidine. The 
suppression values are presented on a logarithmic scale, because it is likely 
that the ratios of the values obtained in air and in nitrous oxide are more 
relevant than their absolute differences. There is a wide variation of 
suppression values after exposure to air, from 5.4 to 45%, with a mean of 
17.9, probably related to the heterogeneity of cell types in different forms of 
leukemia. After nitrous oxide exposure of these same cells, the test values 
range from 8.4 to 58%, with a mean of 30.0. The only non-responding cells 
were from a case of T-ALL. Figure 8.1b shows that normal bone marrow 
cells are also sensitive to the inactivation of cobalamin. Results obtained 
with blood cells of 9 leukemic patients, who all had a high number of peri-
pheral blasts cells, are presented in Figure 8.1c. The increase in mean 
suppression values, from 20.4 to 31.1 %, is comparable to the result 
obtained with the marrow cells. However, as apparent from the figure, the 
pattern is somewhat less consistent, as of the 9 cell samples 3 were found to 
be unresponsive to nitrous oxide, all from cases of ALL. 
Methotrexate was added, prior to the incubation, to 8 of the leukemic 
and 2 of the normal marrow cell suspensions. The results are shown in Fig-
ure 8.1d. The addition of methotrexate alone to the marrow cells increased 
the suppression value in all cases, resulting in a mean value of 47.0%, with 
a range of 19 to 69%. If the cells were, in addition, exposed to nitrous 
oxide, this resulted in a further increase of the mean suppression value to 
55.1 %, with a range of 37 to 74%. In some cases, however, in which 
methotrexate was already very effective, no substantial further increase was 
observed; this applies to values of 60% and higher. It should be 
emphasized that these values indicate a rather extreme disturbance of the 
test, and that in this range the deoxyuridine suppression test is probably not 
sensitive anymore. In all of the other 5 cases, nitrous oxide enhanced the 
effect of methotrexate. 
Finally, results obtained with the cell lines HL60 and U937, with culture 
conditions as described by Kana et al. (10), are presented in Tables 8.2 and 
8.3. Only U937 cells appeared to be consistently sensitive towards nitrous 
oxide exposure, as is evident from results. in three consecutive experiments 
in Table 8.2. The test values appear rather variable quantitatively, between 
experiments, and in the same experiment on successive days, but there 
remains a clear difference between the cultures in air and nitrous oxide. 
The cultures exposed to air were always in the normal range of the test. In 
contrast, cultures of HL60 cells only showed a clearly increased dU suppres-
sion value on nitrous oxide exposure after 1 day, but this difference largely 
disappeared with continuation of the experiment, when all cells became 
about equally disturbed (Table 8.3). This cell line therefore appears not 
suitable for this kind of experiments, as illustrated by the experiment shown 
in Figure 8.2. In this experiment, the growth of HL60 cells was compared 
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Figure 8.1. Results of in vitro exposure to nitrous oxide on deoxyuridine suppression 
tests in fresh human marrow or peripheral blood nucleated cells: (a) leukemic marrow 
cells (b) normal marrow cells (c) peripheral blood cells of leukemia patients (d) marrow 
cells, either leukemic (continuous line) or normal (interrupted line), treated previously 
in vitro with methotrexate (MTX). Mean suppression values of groups without and with 
nitrous oxide exposure are indicated. 
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Table 8.2 
DEOXYURIDINE SUPPRESSION TESTS IN U937 CELLS AFTER 
EXPOSURE TO NITROUS OXIDE 
Days of Percentage of suppression by deoxyuridine 
culture 
Experiment 1 Experiment 2 Experiment 3 
Air N20 Air N20 Air N20 
0 18 18 8 8 15 15 
1 3 5 6 34 11 11 
2 8 24 2 9 10 14 
3 9 91 3 27 6 16 
Table 8.3 
DEOXYURIDINE SUPPRESSION TESTS IN HL60 CELLS AFTER EXPOSURE 
TO NITROUS OXIDE 
Culture conditions according to Kano et al. (1 0) 
Days of culture 
0 
1 
3 
4 
7 
Percentage of suppression by 
deoxyuridine 
Air Nitrous oxide 
8.6 8.3 
7.1 17.5 
37.1 39.9 
39.6 46.6 
33.2 66.2 
in fully supplemented medium, and in medium deprived of methyltetrahy-
drofolate and/or cobalamin, to study the degree of dependence on this con-
stituents. It appears that after 24 days of culture, there still is a minimal 
difference in growth between the supplemented and deprived cultures. 
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Figure 8.2. Culture of HL60 cells in four different media for 24 days. The cumulative 
cell number of each culture is shown. All cultures started with 4.5 x 109 cells. In all 
groups McCoy's Medium SA was used with 10% fetal calf serum, 25 mol/1 L-
methionine and mmol/1 glutamine, with: (a) 400 nmol/1 5-methyl-THF and 40 nmol/1 
hydroxocobalamin; (b) 200 nmol!l 5-methyl-THF only; (c) 40 nmol/1 5-methyl-THF hy-
droxocobalamin only; (d) no additions. 
8.4. Discussion. 
At present, there is only limited evidence for the cobalamin-dependence of 
malignant hematopoiesis in human leukemia, which is an essential require-
ment for the possible application of cobalamin antagonists in chemotherapy. 
Nitrous oxide, the only available effective antagonist of the metabolic func-
tion of cobalamin, has been shown to inhibit rat leukemia in vivo (8), and 
human leukemic cell lines in vitro ( 1 0). There are also two early observa-
tions of a distinct antileukemic effect of nitrous oxide exposure in patients 
(17,18), dating from the time before this agent was known to inactivate 
cobalamin. Two cases have been described of patients with leukemia, in 
which the administration of cobalamin was considered to enhance leukemic 
proliferation ( 19 ,20). A disturbance of the deoxyuridine suppression test in 
normal bone marrow cells after nitrous oxide exposure of about 24 hours is 
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well established (21), and this effect was also found to be enhanced by 
methotrexate addition (22). 
The results of the present study provide evidence that in nearly all cases 
of acute leukemia the leukemic cells are sensitive to cobalamin inactivation, 
as is apparent from a disturbance of the deoxyuridine suppression test. This 
in vitro metabolic effect of cobalamin inactivation on malignant blood cells 
is fully comparable to the consequences of cobalamin deficiency on normal 
marrow cells. It may therefore be expected that the application of nitrous 
oxide will result in the same inhibition of cellular proliferation as is 
observed in cobalamin deficient normal marrow cells. 
The synergistic effect of nitrous oxide and methotrexate, with regard to 
the disturbance of deoxyuridine suppression in leukemic cells in vitro, is in 
accordance with the results obtained before in leukemic rats (9) and normal 
human bone marrow (22). 
As nearly all cases of leukemias were responsive to cobalamin inactiva-
tion, it is difficult to draw conclusions on the differential sensitivity of par-
ticular types. It may be relevant, however, that the single marrow cell 
suspension, and the three blood cell samples, that were found to be 
unresponsive, were all cases of ALL. 
With regard to the results obtained with cultured leukemic cell lines, it 
is remarkable that for HL60 cells, the conditions as described by Kano et al. 
(10) were not suitable to perform reliable experiments. In addition, it 
appeared that, in contrast to results obtained by these authors, there was no 
indication of growth inhibition of the cells by nitrous oxide, and neither was 
complete deprivation of cobalamin and folate sufficient to cause a signifi-
cant effect on proliferation. Not included in the results are the similar 
effects of several modifications of the culture conditions. The HL60 cell 
line therefore probably is not a useful model in the study of cobalamin-
dependent metabolism. The U937 cell line also appeared to be sensitive 
towards minor variations in culture conditions, but after nitrous oxide expo-
sure the deoxyuridine suppression test was more consistently disturbed in 
these cells. 
In conclusion, the results of this study demonstrate that the metabolic 
consequences of cobalamin inactivation by nitrous oxide can be observed in 
malignant hematopoietic cells, in a way comparable to normal marrow cells. 
The deoxyuridine suppression test may well be predictive for the clinical 
sensitivity of acute leukemias to nitrous oxide, as results obtained with 
nitrous oxide in vitro are in agreement with those obtained treating rat 
leukemia in vivo. These findings encourage further investigations, eventu-
ally directed at the administration of nitrous oxide to selected patients with 
leukemia. 
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Chapter nine 
SURVEY AND CONCLUSIONS 
Cobalamin, historically known as vitamin B 12, is indispensable in nor-
mal hematopoiesis. Its metabolic role has been the subject of intensive 
study in the past thirty years, and is fairly well understood now, as reviewed 
in the first chapter of this thesis. The inactivation of cobalamin by nitrous 
oxide has provided a valuable new method to investigate the function of this 
vitamin in hematopoiesis. At the same time, this particular side-effect of the 
widely-used anesthetic agent can be used to study the role of cobalamin in 
the growth of malignant hematopoietic cells, and to evaluate the value of 
cobalamin-dependent metabolism as a target in tumor chemotherapy. The 
purpose of the investigations presented in this thesis is to study the applica-
tion of the nitrous oxide effect on cobalamin in the treatment of leukemia, 
in a systematic and orienting way. In each of the preceding chapters only a 
single aspect of the results obtained with nitrous oxide has been discussed, 
and in this chapter it will be tried to formulate more general conclusions on 
the perspectives of cobalamin inactivation in the therapy of leukemia. 
In most experiments, a realistic rat model for acute myeloid leukemia, 
the Brown Norway Myeloid Leukemia (BNML) has been used. The results 
of experimental chemotherapy in this leukemia can be evaluated by a 
number of methods, which are discussed in Chapter 2. The main subject of 
the studies described in the previous chapters has been the search for an 
influence of cobalamin inactivation on leukemic growth, and its correlation 
with biochemical alterations. Therefore, the method that was usually chosen 
to evaluate the effects of treatment consisted of the simultaneous analysis of 
the rats of all treatment groups, after a fixed period of leukemic growth. 
This method of evaluation correlated well with the established technique of 
measurement of survival. The latter method, however, does not permit 
metabolic studies in the same experiment. 
Referring to the scope of this thesis, as outlined in section 1.4, the most 
essential results of the investigations will be reviewed. 
In the first studies, a significant retardation of the growth of the 
leukemia resulted from exposure of the rats to nitrous oxide alone. This 
was accompanied by metabolic effects, suggesting that the inactivation of 
cobalamin was indeed responsible for the therapeutic result. The deoxyuri-
dine suppression test was disturbed in leukemic cells of treated rats, plasma 
cobalamin was decreased, and plasma folate was elevated. The effect on 
leukemic growth in this model was readily measurable and appeared very 
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well reproducible, but a complete remission of the leukemia was not 
observed. In the following studies, it was tried to impair cobalamin-
dependent metabolism more effectively by combining nitrous oxide expo-
sure with the administration of selected other agents. Agents with poten-
tially synergistic actions were chosen on the basis of the present knowledge 
on the metabolic role of cobalamin. The results have been presented of 
experiments combining nitrous oxide with cycloleucine, methotrexate, 5-
fluorouracil and inhibitors of polyamine biosynthesis. With the first three 
of these agents, it is assumed that a depletion of intracellular folates, as 
brought about by nitrous oxide, will result in enhanced activity. On the 
other hand, with polyamine inhibitors, an interaction is expected based on 
the reduced synthesis of methionine, which is as well a consequence of the 
inactivation of methionine synthetase. 
The synergistic growth inhibiting effect of nitrous oxide and cycloleu-
cine demonstrates the importance of S-adenosylmethionine as a regulatory 
intermediate in one-carbon metabolism, as cycloleucine is a selective inhibi-
tor of the synthesis of this compound. Cycloleucine was considered to be a 
promising cytostatic agent in the early sixties, and even in some recent trials, 
but has been discarded mainly because of severe side-effects. The increased 
inhibition of leukemic growth in rats apparently does not lead to more pro-
nounced side-effects. The addition of nitrous oxide to cycloleucine, or one 
of the other inhibitors of S-adenosylmethionine synthesis, appears to be a 
promising example of metabolic manipulation. Decreased levels of S-
adenosylmethionine enhance the disturbance of folate metabolism, but in 
addition, the effects of cycloleucine could also be enhanced by the inhibition 
of methionine synthesis by nitrous oxide. 
Considering the essential role of cobalamin in folate metabolism, it is 
not surprising that a significant enhancement of the therapeutic efficacy of 
methotrexate can be produced by exposure to nitrous oxide. It is important, 
however, to study the mechanism of this interaction, to be able to apply the 
most effective treatment schedules in further experiments. It appears that 
the intracellular folate depletion, produced by exposure to nitrous oxide of 
up to three days, correlates well with the .therapeutic results of the combina-
tion. This is in accordance with the finding that exposure to nitrous oxide 
before methotrexate is necessary to result in increased therapeutic effects. 
The development of severe folate depletion probably takes one or two days. 
In this respect, the pretreatment with nitrous oxide can be considered the 
reverse of folinic acid rescue after methotrexate therapy. Likewise, nitrous 
oxide can possibly be applied to modulate the cytotoxicity of methotrexate. 
It has not been investigated so far whether this combination also increases 
polyglutamation of methotrexate. Polyglutamation of this antifolate, which 
considerably enhances its therapeutic effects, is known to occur in competi-
tion with normal folate derivatives, and could therefore be stimulated by the 
induced folate depletion. 
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The results of the nitrous oxide/5-fluorouracil combination appear to be 
important to the actual problem of the involvement of folate metabolism in 
the mechanism of 5-fluorouracil cytotoxicity. The increase in therapeutic 
effects, brought about by nitrous oxide pretreatment before 5-fluorouracil 
administration, is rather small compared to the interaction of nitrous oxide 
with methotrexate. However, as it has been suggested that an increase of 
intracellular folates with 5-fluorouracil therapy is essential to obtain an 
optimal therapeutic effect, even the small enhancement of its effect by 
nitrous oxide addition demonstrates that this hypothesis is, at least, not 
always true. A depletion of cellular folates clearly can result in increased 
activity of 5-fluorouracil. Furthermore, these experiments have demon-
strated an unexpectedly high activity of fluorouracil towards the rat 
leukemia, emphasizing the need for further evaluation of this drug in the 
treatment of human leukemia. 
Thus, all three combinations that were based on interference with folate 
metabolism or folate dependent nucleotide synthesis resulted in an enhance-
ment of antitumor activity. The final combination that has been tested is 
involved in the other part of the reaction catalyzed by the cobalamin-
dependent methionine synthetase: the conversion of homocysteine to 
methionine. In cobalamin-deficient or nitrous oxide treated cells methionine 
is low, and this in tum results in low S-adenosylmethionine (SAM) levels. 
SAM is involved in a wide variety of metabolic processes, but only one of 
these is definitely related to cell proliferation. This is the synthesis of the 
polyamines spermidine and spermine, requmng decarboxylated S-
adenosylmethionine as a donor of aminopropyl groups. The cytostatic drug 
mitoguazone, or MGBG, inhibits the decarboxylation of SAM, but appeared 
to be little specific, resulting in severe toxicity in clinical trials. Nitrous 
oxide can limit the supply of methionine, and thereby impair the synthesis 
of spermidine and spermine. Cycloleucine, inhibiting the conversion of 
methionine to SAM, could increase this effect. It appeared that this 
approach to the inhibition of polyamine synthesis, consisting of nitrous 
oxide, cycloleucine and mitoguazone, was indeed effective with regard to 
the reduction of intracellular levels of one of these polyamines, spermine. 
There appeared to be no synergistic effect on tumor growth, however, as the 
therapeutic result of the combination was about additive, compared to the 
results of individual drugs. For this reason, there was neither much reduc-
tion in the toxicity of mitoguazone. These experiments illustrate the diffi-
culties frequently encountered when polyamine biosynthesis is used as a tar-
get in cancer chemotherapy. Although this study has demonstrated that 
cobalamin may have a role in the synthesis of spermine, it was not yet possi-
ble to increase substantially the therapeutic value of nitrous oxide by aiming 
at a reduction of polyamine synthesis. 
From these experiments in leukemic rats, it can be concluded that the 
inactivation of cobalamin, as a new approach in chemotherapy, is able to 
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reduce leukemic growth, and to modify significantly the response of 
leukemic cells to certain cytostatic drugs, without evidence of increased toxi-
city. It would be of interest to compare the results obtained with nitrous 
oxide with those of more established cytostatic drugs. In the studies 
described in this thesis, the results of methotrexate treatment were not much 
different from those with nitrous oxide, while 5-fluorouracil appeared, 
surprisingly, more effective. Differences in evaluation techniques make 
comparisons with other studies rather difficult. From a number of extensive 
chemotherapeutic studies in this rat leukemia, the impression would be that 
the extent of growth inhibition by exposure to nitrous oxide, as evident from 
spleen and liver weights, is about comparable to the effect of low or 
moderate doses of cytarabine and adriamycine (Colly LP. Chemotherapy in 
a transplantable leukaemia in Brown Norway rats. Thesis, Erasmus Univer-
sity Rotterdam. Delft: Meinema, 1980). It has appeared from several stu-
dies that results obtained with the BNML model agree well with clinical 
effects, but still the results of these animal studies may only be cautiously 
applied to predict the value of nitrous oxide in humans. Man appears to be 
rather vulnerable with regard to the consequences of cobalamin deficiency. 
If nitrous oxide is combined with other agents, its strong enhancement 
of the effects of the antifolate methotrexate is most conspicuous. Further 
analysis of this interaction seems warranted, in particular with regard to its 
mechanism. In addition, the combination of nitrous oxide with other anti-
folates could be investigated. It is also interesting to study the influence of 
nitrous oxide on the development of resistance towards methotrexate. 
Nitrous oxide exposure appears to result in enhanced enzyme activity of thy-
midylate synthetase. Depression of the activity of this enzyme is one of the 
ways in which cells may become resistant to methotrexate. 
In order to obtain information on the sensitivity of human leukemia to 
the metabolic effects of nitrous oxide, experiments were carried out with 
bone marrow cells from patients, and with human leukemic cell lines. In 
nearly all cases, the deoxyuridine suppression test was clearly disturbed 
after exposure to nitrous oxide, demonstrating the sensitivity of these human 
malignant cells. The application of nitrous oxide to selected patients with 
leukemia, under carefully controlled conditions, logically should be the next 
step. Nitrous oxide is in fact already a well known and widely used drug, 
but this radically different application, with a longer duration of administra-
tion, and involving other clinical departments, requires a cautious approach. 
The results of the experiments with human leukemic cells can be considered 
an essential step in this direction. 
The practical application of nitrous oxide in chemotherapy is obviously 
hampered by its gaseous state. "Breathing" a drug is rather uneasy, com-
pared to oral and parenteral administrations. However, some early trials 
have demonstrated the feasibility of this way of administration. Neverthe-
less, it seems worthwhile to search for a solid or liquid alternative for 
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nitrous oxide, and some candidates in fact exist, like the alkylnitrites. The 
importance of the studies presented in this thesis also lies in the demonstra-
tion of the dependence of tumor growth on the metabolic function of cobala-
min, and of the increased vulnerability towards other drugs after inactivation 
of cobalamin. These findings may as well apply to other cobalamin anta-
gonists. 
The application of nitrous oxide in this series of investigations has 
demonstrated once again that toxicity, from a pharmacological point of 
view, is only a relative phenomenon. Effects of a drug that are not desired 
in a certain clinical situation are designated toxic, which does not preclude 
that the same effect may be useful in another clinical situation. Unwanted, 
toxic effects of several substances have found an application in medicine. 
Side-effects tum into desired effects, if drugs are administered to patients 
with a different disease. Some examples are the antithrombotic effects of 
acetylsalicylic acid, the use of the vasodilator diazoxide to inhibit insulin 
secretion, the interference with ADH effects by the antibiotic demeclocy-
cline, the enzyme induction in neonates by the anti-epileptic phenobarbital, 
or recently, the introduction of the antihypertensive minoxidil as the long-
awaited drug promoting hair growth. The nitrous oxide/ cobalamin interac-
tion can also serve to illustrate this concept. Nitrous oxide causes severe 
impairment of blood cell proliferation, which can result in a megaloblastic 
bone marrow depression. This effect is obviously unwanted in surgical 
patients receiving nitrous oxide during anesthesia. On the other hand, the 
selective suppression of the growth of blood cells is of great interest in 
hematology. Therefore, this interaction has been studied extensively both in 
anesthesiology and hematology, although for different reasons. In this 
thesis, the interaction of nitrous oxide and cobalamin has been studied from 
the hematological point of view. The toxic effect has been applied deli-
berately, as a new method to influence the growth of malignant blood cells. 
Cobalamin, an essential constituent of food for all animals, is intimately 
involved in the metabolic pathways concerned with the transfer of single 
carbons. These metabolic steps are in particular important in the synthesis 
of the various nucleotides. This is the reason that cobalamin, and the func-
tionally closely related vitamin folic acid, appear essential to the rapidly 
proliferating hematopoietic cells. It also explains that antagonists of both 
these vitamins may be used to impair the process of cellular proliferation. 
In contrast to the folate antagonists, probably the most widely used class of 
chemotherapeutic agents, cobalamin antagonists have not yet contributed to 
the treatment of malignant growth. The studies presented in this thesis 
could stimulate the development of this new class of metabolic inhibitors 
applicable in the fight against cancer. 

Summary 
The essential role of cobalamin (vitamin B12) in the metabolism of folates is 
based on its coenzyme function in the enzyme methionine synthetase. 
Exposure to the anesthetic gas nitrous oxide leads to oxidation of the cobala-
min coenzyme, and thereby to a virtually complete inactivation of this 
enzyme. The consequences of this interaction are fully comparable to a 
severe deficiency of cobalamin, with a disturbance of folic acid metabolism, 
resulting in a pronounced impairment of hematopoiesis. 
The subject of this thesis is the investigation of the applicability of this 
specific side-effect of nitrous oxide in chemotherapy of hematologic malig-
nancies. In contrast to the well-known antagonists of folic acid, up till now 
no effective antagonist of cobalamin is available. 
The introductory Chapter 1 contains a review on the biochemistry of 
cobalamin and folic acid and their interrelationships, with emphasis on the 
"methylfolate trap hypothesis". In addition, an overview is presented of 
cobalamin antagonists in general, and of the the nitrous oxide-cobalamin 
interaction in particular. 
Chapter 2 describes the most essential experimental methods employed 
in the investigations presented in this thesis: the Brown Norway rat myeloid 
leukemia, the system used for nitrous oxide exposure and the deoxyuridine 
suppression test. 
In Chapter 3 experiments are discussed in which leukemic rats were 
exposed to nitrous oxide. Results included a retardation of leukemic proli-
feration, as measured by organ infiltration and leukocyte counts, accom-
panied by a fall of plasma cobalamin, a rise of plasma folate and a distur-
bance of the deoxyuridine suppression test in leukemic cells. 
Chapter 4 discusses the first of a series of investigations in which it was 
tried to exploit the effects of nitrous oxide by combined treatment with 
chemotherapeutic agents active in the same or related pathways. In this 
chapter, experiments involving cycloleucine are described which resulted in 
a synergistic inhibition of leukemic growth and an additional disturbance of 
the deoxyuridine suppression test. It seems probable that cycloleucine 
further disturbs folate metabolism, and the pathways involved in this effect 
are described. 
In Chapter 5 the results of nitrous oxide exposure combined with 
methotrexate treatment are discussed. Substantially enhanced therapeutic 
activity towards the rat leukemia was observed, along with an additional 
reduction of intracellular folates and of deoxythymidylate, and with a 
further disturbance of the deoxyuridine suppression test. From these 
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experiments it appeared that pretreatment with nitrous oxide before metho-
trexate was essential for an optimal therapeutic interaction. 
Chapter 6 contains observations on the combination of nitrous oxide 
with 5-fluorouracil. 5-Fluorouracil appeared to be an effective treatment of 
the rat leukemia, which effect still could be enhanced by the addition of 
nitrous oxide. This was accompanied by intracellular folate depletion, 
demonstrating that, in this leukemia, the effect of 5-fluorouracil was not 
dependent on high levels of intracellular folate, as observed with some other 
tumors. 
Chapter 7 deals with the experiments aimed at a reduction of polyamine 
synthesis, by means of combined treatment consisting of nitrous oxide, 
cycloleucine and mitoguazone (MGBG). It was found that treatment 
directed at polyamine deprivation was toxic and only minimally active in the 
rat leukemia, and that there was at best an additive effect when MGBG was 
combined with nitrous oxide and cycloleucine. On the other hand, it was 
possible to cause a further, selective, reduction of the intracellular level of 
spermine by nitrous oxide and cycloleucine. This could mean that cobala-
min has a role in polyamine synthesis. 
In Chapter 8, in vitro experiments are described in which nitrous oxide 
was applied to human leukemic cells, from bone marrow and peripheral 
blood of patients with leukemia. For comparison, cells from human con-
tinuous leukemia cell lines (U937 and HL60) were also used. These experi-
ments demonstrated that the results obtained by in vivo treatment of 
leukemic rats were applicable to the human leukemic cells, with regard to 
nitrous oxide exposure as well as to the combinations involving methotrex-
ate. 
Finally, in Chapter 9 the results are discussed in coherence with more 
general conclusions on the perspectives of cobalamin inactivation as a new 
therapeutic strategy in the chemotherapy of leukemia. 
Samenvatting 
De belangrijke rol van cobalamine ofwel vitamine B 12 in de folium-
zuurstofwisseling komt voort uit een functie als coenzym in het enzym 
methionine synthetase. Blootstelling aan het uit de anesthesie bekende gas 
lachgas veroorzaakt een oxidatie van het cobalamine coenzym, die leidt tot 
een vrijwel volledige inactivatie van dit enzym. De gevolgen van deze 
interactie zijn volledig vergelijkbaar met een emstige cobalaminedeficientie, 
met een verstoring van de foliumzuurstofwisseling die resulteert in een 
sterke remming van de hematopoese. 
Het onderwerp van dit proefschrift is het onderzoek van de toepas-
baarheid van deze specifieke bijwerking van lachgas in de chemotherapie 
van hematologische maligniteiten. In tegenstelling tot de bekende folium-
zuurantagonisten zijn er tot nu toe geen werkzame antagonisten van 
cobalamine beschikbaar. 
Het inleidende Hoofdstuk 1 bevat een overzicht van de biochemie van 
cobalamine en folaat en met name van hun onderlinge relatie, zoals die 
wordt beschreven door de methylfolaat-val ("trap") hypothese. Daamaast 
wordt samengevat wat bekend is over cobalamine-antagonisten in het 
algemeen, en over de interactie van lachgas en vitamine B 12 in het 
bijzonder. 
Hoofdstuk 2 behandelt de belangrijkste experimentele methoden zoals 
toegepast in het onderzoek beschreven in dit proefschrift. Dit betreft de 
myeloide leukemie in Brown Norway ratten (BNML), het systeem waarin 
deze ratten werden blootgesteld aan lachgas en de deoxyuridine suppres-
sietest. 
Hoofdstuk 3 beschrijft de resultaten van de blootstelling van ratten met 
leukemie aan lachgas. Daarbij werd een vertraging van de groei van de 
leukemie vastgesteld, gemeten door vermindering van de infiltratie van 
leukemie in lever en milt en een verminderd aantal leukemiecellen in het 
bloed. Tegelijk daalde het plasmagehalte van cobalamine, steeg het 
plasmafolaat en was de deoxyuridine suppressietest in de leukemiecellen 
verstoord. 
Hoofdstuk 4 is gewijd aan de eerste van een serie onderzoeken waarbij 
werd getracht de resultaten van lachgasblootstelling te versterken door ge-
richte combinaties met middelen die op dezelfde stofwisselingswegen 
aangrijpen. In dit hoofdstuk werd daarvoor cycloleucine toegepast, waar-
mee een synergistische remming van de leukemiegroei werd bereikt en ver-
dere verstoring van de deoxyuridine suppressietest. Een verdere verstoring 
van het foliumzuurmetabolisme door cycloleucine bleek op te treden, en het 
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mogelijke mechanisme daarvan wordt beschreven. 
Hoofdstuk 5 behandelt de resultaten van lachgasblootstelling gecom-
bineerd met methotrexaatbehandeling. Hierdoor werd de therapeutische 
activiteit ten opzichte van de ratteleukemie aanzienlijk verhoogd. Het intra-
cellulaire gehalte aan folaat en deoxythymidylaat bleek verder verlaagd dan 
bij iedere behandeling afzonderlijk, en er was een toegenomen verstoring 
van de deoxyuridine suppressietest. Uit deze experimenten bleek tevens dat 
een voorbehandeling met lachgas, voor het toedienen van methotrexaat, een 
vereiste was voor deze therapeutische interactie. 
Hoofdstuk 6 beschrijft de waarnemingen aan de behandeling met de 
combinatie van lachgas en 5-fluorouracil. 5-Fluorouracil bleek reeds zelf een 
effectief middel bij de behandeling van de ratteleukemie, doch de resultaten 
konden nog verbeterd worden door de toevoeging van lachgas. Omdat daar-
bij een verlaging van het intracellulair foliumzuur werd gevonden lijkt het 
effect van 5-fluorouracil in dit geval niet afhankelijk te zijn van het folaat-
gehalte, zoals bij andere tumoren wel is beschreven. 
Hoofdstuk 7 bespreekt de resultaten van experimenten gericht op een 
reductie van de synthese van polyamines, door middel van een gecom-
bineerde behandeling bestaande uit lachgas, cycloleucine en mitoguanozone 
(MGBG). Het bleek dat behandeling gericht op het verlagen van poly-
amines toxisch was en slechts weinig actief bij de ratteleukemie. In het gun-
stigste geval was er een additief effect van MGBG in de combinatie met 
lachgas en cycloleucine. Wel bleek het mogelijk om een verdere, selectieve, 
vermindering van spermine te veroorzaken door lachgas en cycloleucine. 
Dit kan betekenen dat cobalamine een rol speelt in de polyaminesynthese. 
Hoofdstuk 8 is gewijd aan in vitro experimenten waarbij lachgas werd 
toegepast op humane leukemiecellen, verkregen uit beenmerg en perifeer 
bloed van leukemiepatienten. Ter vergelijking werden ook cellen van con-
tinue humane leukemiecellijnen onderzocht (U937 en HL60). Uit deze 
experimenten bleek dat de resultaten verkregen door in vivo behandeling 
van ratten met leukemie ook opgaan voor humane leukemiecellen, zowel 
met betrekking tot de lachgasbehandeling als tot de combinatie met metho-
trexaat. 
Hoofdstuk 9 tenslotte bespreekt de resultaten van de verschillende 
hoofdstukken in samenhang, waarbij getracht wordt om meer algemene con-
clusies te trekken over de perspectieven van het inactiveren van cobalamine 
als een nieuwe behandelingsstrategie in de chemotherapie van leukemie. 
"I existed in a world of new connected and newly modified ideas, 
I theorized, I imagined that I made discoveries. When I was awakened 
from this semi-delirous trance by Dr Kinglake, who took the bag from 
my mouth, indignation and pride were the first feelings produced by 
the sight of persons about me .... I exclaimed to Dr Kinglake: Nothing 
exists but thoughts! The universe is composed of impressions, ideas, 
pleasure and pain" 
Humphry Davy, describing the effect of breathing nitrous oxide in 1799 
In: "Researches, chemical and philosophical, chiefly concerning nitrous oxide, or dephlo-
gisticated nitrous air, and its respiration", a volume of 580 pages, published in 1800. 

Nawoord 
Het schrijven van dit proefschrift is slechts mogelijk geweest door de 
steun van zeer velen. Graag wil ik al diegenen bedanken voor de prettige 
samenwerking in de afgelopen jaren. 
Professor Abels, mijn promotor, die mij de principes van weten-
schapsbeoefening bijbracht, het onderzoek krachtig en kritisch stimuleerde, 
en onvermoeibaar herhaalde revisies van de manuscripten bewerkte. 
Dr Jan Lindemans, mijn co-promotor, die vanaf het schuchtere begin 
van het project tot in de fase van afronding dagelijks direct betrokken was 
bij alle aspecten van het onderzoek, en wiens rol zodoende van doorslag-
gevende betekenis is geweest. 
De hoogleraren van Bekkum, Bruinvels en Willemze, die bereid waren 
zitting te nemen in de promotiecommissie. 
Dr Hagenbeek, die ons in de beginperiode van het werken met de BN 
leukemie belangrijke steun heeft geboden. 
Ir Ton Ermens, die de laatste jaren het lachgasonderzoek geleidelijk 
heeft overgenomen, met enthousiasme, kundigheid en bovenal een 
indrukwekkende collegialiteit. 
Martijn Schoester, wiens verbluffende werkkracht de uitvoering van alle 
experimenten in dit proefschrift mogelijk gemaakt heeft. 
Lidwien Spijkers, Jan van Kapel, Kirsten van Lorn, Nel Vink, die zoals 
nog vele andere analisten van het hematologisch laboratorium onontbeerlijke 
bijdragen leverden aan het onderzoek: 
Jack van Geel en Marjolein Melsen, die in hun stageperiode aan het 
onderzoek hebben meegedaan. 
Jeanne Vlasveld, die een onmisbare secretariele steun was. 
Ed Lansbergen van het CPB, die alles kon regelen met betrekking tot de 
proefdieren. 
Cor van Dijk en zijn medewerkers van het AVC, die alle illustraties 
hebben verzorgd. 
Drs Hans Tebra, die met grote deskundigheid op het gebied van de 
geautomatiseerde tekstverwerking de uitvoering van het proefschrift in deze 
vorm heeft mogelijk gemaakt. 
Tenslotte wil ik professor Schalekamp, mijn opleider na mijn indienst-
treding op de afdeling Inwendige Geneeskunde I, mw. Tan-Tjiong, mijn 
chef de clinique in het eerste jaar, andere stafleden en collega-assistenten 
bedanken voor de manier waarop zij mij ondersteunden bij de niet-
eenvoudige overgang naar het werken in de kliniek, juist in de periode 
waarin dit boekje moest verschijnen. 
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De schrijver van dit proefschrift werd geboren op 21 mei 1957 te Amster-
dam. Het Atheneum B-diploma werd behaald in 1975 aan het Waterlant 
College te Amsterdam, waarna de studie Geneeskunde werd begonnen aan 
de Universiteit van Amsterdam. Na het behalen van het kandidaatsexamen 
in 1978 (cum laude) was hij van 1978 tot 1980 werkzaam als kandidaats-
assistent op het Laboratorium voor Biochemie (B.C.P. Janseninstituut). In 
1980 werd het doctoraalexamen afgelegd (cum laude). Het basisartsexamen 
volgde in 1983, en aansluitend werd begonnen met het in dit proefschrift 
beschreven onderzoek op het Instituut Hematologie van de Erasmus Univer-
siteit Rotterdam onder leiding van prof.dr. J. Abels en dr. J. Lindemans. 
Sinds 1 september 1986 is hij in opleiding tot internist op de afdeling Inwen-
dige Geneeskunde I van het Academisch Ziekenhuis Rotterdam/Dijkzigt 
(hoofd: prof.dr. M.A.D.H. Schalekamp). 



